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Background: Falls are a serious cause of morbidity and cost to individuals and society. Evidence suggests
that foot problems and inappropriate footwear may increase the risk of falling. Podiatric interventions
could help reduce falls; however, there is limited evidence regarding their clinical effectiveness and
cost-effectiveness.
Objectives: To determine the clinical effectiveness and cost-effectiveness of a multifaceted podiatry
intervention for preventing falls in community-dwelling older people at risk of falling, relative to usual care.
Design: A pragmatic, multicentred, cohort randomised controlled trial with an economic evaluation and
qualitative study.
Setting: Nine NHS trusts in the UK and one site in Ireland.
Participants: In total, 1010 participants aged ≥ 65 years were randomised (intervention, n = 493;
usual care, n = 517) via a secure, remote service. Blinding was not possible.
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Interventions: All participants received a falls prevention leaflet and routine care from their podiatrist and
general practitioner. The intervention also consisted of footwear advice, footwear provision if required,
foot orthoses and foot- and ankle-strengthening exercises.
Main outcome measures: The primary outcome was the incidence rate of falls per participant in the
12 months following randomisation. The secondary outcomes included the proportion of fallers and
multiple fallers, time to first fall, fear of falling, fracture rate, health-related quality of life (HRQoL)
and cost-effectiveness.
Results: The primary analysis consisted of 484 (98.2%) intervention and 507 (98.1%) usual-care participants.
There was a non-statistically significant reduction in the incidence rate of falls in the intervention group
[adjusted incidence rate ratio 0.88, 95% confidence interval (CI) 0.73 to 1.05; p = 0.16]. The proportion of
participants experiencing a fall was lower (50% vs. 55%, adjusted odds ratio 0.78, 95% CI 0.60 to 1.00;
p = 0.05). No differences were observed in key secondary outcomes. No serious, unexpected and related
adverse events were reported. The intervention costs £252.17 more per participant (95% CI –£69.48 to
£589.38) than usual care, was marginally more beneficial in terms of HRQoL measured via the EuroQoL-5
Dimensions [mean quality-adjusted life-year (QALY) difference 0.0129, 95% CI –0.0050 to 0.0314 QALYs]
and had a 65% probability of being cost-effective at the National Institute for Health and Care Excellence
threshold of £30,000 per QALY gained. The intervention was generally acceptable to podiatrists and
trial participants.
Limitations: Owing to the difficulty in calculating a sample size for a count outcome, the sample size was
based on detecting a difference in the proportion of participants experiencing at least one fall, and not the
primary outcome. We are therefore unable to confirm if the trial was sufficiently powered for the primary
outcome. The findings are not generalisable to patients who are not receiving podiatry care.
Conclusions: The intervention was safe and potentially effective. Although the primary outcome measure
did not reach significance, a lower fall rate was observed in the intervention group. The reduction in the
proportion of older adults who experienced a fall was of borderline statistical significance. The economic
evaluation suggests that the intervention could be cost-effective.
Future work: Further research could examine whether or not the intervention could be delivered in group
sessions, by physiotherapists, or in high-risk patients.
Trial registration: Current Controlled Trials ISRCTN68240461.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 21, No. 24.
See the NIHR Journals Library website for further project information.
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Plain English summary
Each year, many older people suffer serious injuries from falling. Foot problems and unsuitable footwearincrease the risk of falling.
The REducing Falls with ORthoses and a Multifaceted podiatry intervention (REFORM) study aimed to find
out if a package of care provided by a podiatrist could reduce the number of falls experienced by people
≥ 65 years old. All 1010 participants were sent a leaflet about how to prevent falls, and 493 participants
were also offered the package of care, which consisted of three parts. Participants were given footwear
advice and new footwear if their current footwear was thought to be unsuitable. They were also given an
orthotic insole or, if they were already wearing an insole, their current insole was reviewed to ensure that
it met their clinical needs. Finally, they were given a programme of foot and ankle balance exercises to do
at home.
We found a small, but not statistically significant, reduction in the number of falls experienced by
participants offered the podiatry package. A lower proportion of participants suffered at least one fall over
12 months in the group offered the podiatry package. The podiatry package is relatively inexpensive and
we found that it was reasonable value for money. On the whole, participants liked the podiatry package
and the majority of podiatrists thought that it was acceptable and straightforward to deliver but also found
some of the programme elements to be time-consuming, such as explaining the foot and ankle exercises
and the provision of footwear.
DOI: 10.3310/hta21240 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 24
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Cockayne et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
xxiii

Scientific summary
Background
Falls and fall-related fractures are a serious cause of morbidity and cost to individuals and society.
Approximately 30% of people aged ≥ 65 years and 50% of those aged ≥ 80 years living in the community
fall each year. The financial cost of injurious falls has been estimated at £2B per annum, which is mainly
attributed to hip fractures.
It has been suggested that podiatry care could play a role in falls prevention, as cohort studies have
indicated a relationship between risk of falling and both foot and ankle problems and inappropriate
footwear. At the time of designing the REducing Falls with ORthoses and a Multifaceted podiatry
intervention (REFORM) study, two Cochrane reviews on falls prevention were identified; however, neither
included any randomised controlled trials (RCTs) of podiatry interventions. A subsequent update found one
Australian RCT that showed a statistically significant reduction in falls in community-dwelling older people
with foot pain who had received a multifaceted podiatry intervention (foot and ankle exercises, foot
orthoses, footwear advice, subsidy for new footwear and a falls prevention booklet with routine podiatry
care) compared with those who received routine podiatry care alone.
Objectives
1. Investigate the clinical effectiveness and cost-effectiveness of a multifaceted podiatry intervention for
falls prevention in a UK and Ireland setting.
2. Assess the participants’ and podiatrists’ views and experiences of the intervention and trial processes.
Methods
Study design
The REFORM study was a pragmatic multicentred cohort RCT with an economic evaluation and embedded
qualitative study. This design involved the recruitment of an observational cohort from which eligible,
consenting participants were randomised into a RCT. The cohort RCT design offered several possible
advantages over the traditional RCT. It was expected that trial recruitment rates would be enhanced, as
some participants would be eligible immediately and others could become eligible if they reported a
subsequent fall. Under this design, all participants were informed upon enrolment into the cohort that they
may at some point be offered a package of podiatry care. This was offered to participants subsequently
randomised to the intervention group; however, the usual-care group was not explicitly notified of their
allocation to minimise attrition and reporting bias by reducing cases of ‘resentful demoralisation’. We also
expected that the inclusion of a ‘run-in’ period in which participants had to return at least one falls
calendar before randomisation would reduce post-randomisation attrition rates.
Participant recruitment
Recruitment took place through 37 NHS podiatry clinics in primary or secondary care in nine NHS trusts
across the UK and at a university school of podiatry in Ireland. Potential participants were identified via a
search of electronic and/or paper medical records of registered patients and were posted a recruitment
pack inviting them to take part in the REFORM study.
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Exclusion criteria for the REFORM cohort
Participants who returned a background information form and valid consent form were screened for
eligibility. Participants were ineligible for the REFORM cohort if they:
1. were < 65 years of age
2. reported having neuropathy, dementia or another neurological condition such as Parkinson’s disease,
Alzheimer’s disease, multiple sclerosis, Lou Gehrig’s disease/amyotrophic lateral sclerosis or
Huntington’s disease
3. were unable to walk household distances (10 metres) without the help of a walking aid such as a
walking frame, a walker or a person to assist
4. had had a lower limb amputation
5. were unwilling to attend their podiatry clinic for a REFORM appointment.
Eligible participants were then sent a baseline questionnaire and pack of falls calendars to return each
month to indicate if and when they fell.
Inclusion criteria for the REFORM cohort
All eligible consenting participants who completed a baseline questionnaire and at least one monthly falls
calendar were included in the REFORM cohort.
While the cohort was being assembled, we invited a selection of participants eligible for the REFORM trial
from pilot sites to take part in the internal pilot trial.
REFORM pilot trial objectives
1. Develop and pilot the multifaceted podiatry intervention.
2. Develop the podiatry training package.
3. Pilot the falls calendar and other participant data collection questionnaires.
4. Pilot, review and refine if necessary the recruitment methodology for the main trial.
Inclusion criteria for the REFORM trial
Participants in the cohort were eligible for inclusion in the REFORM trial if they:
1. had had a fall in the past 12 months, or a fall in the past 24 months requiring hospital attention, or
reported worrying about falling at least some of the time in the 4 weeks prior to completing their
baseline questionnaire
2. were community dwelling
3. were able to read and speak English.
If participants did not report a recent fall on their screening form but later reported a fall on the baseline
questionnaire or monthly falls calendar, they became eligible to be randomised.
Sample size
Cohort
We aimed to recruit up to 2600 participants to the REFORM cohort.
Pilot trial
We considered a sample of 70 participants in the pilot trial (35 in each group) to be sufficient to test
the objectives.
REFORM trial
The primary outcome measure for the trial was the incidence rate of falls reported by participants over the
12 months post randomisation; however, because of the inherent difficulties of estimating the parameters
required to power a trial for a count outcome, the trial was instead powered for the binary outcome of whether
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or not the participants experienced at least one fall, which was one of our key secondary outcomes. We
retained rate of falls as the primary outcome, as we believed that the extra information contained in this
outcome would result in the sample size being conservative for this outcome.
The REFORM trial was therefore designed to detect a 10 percentage point reduction in the percentage of
people who fell over a 12-month period. We assumed that, among this high-risk group, 50% of participants
in the usual-care group would experience a fall in 12 months. To detect a reduction to 40% in the
intervention group, with 80% power, a two-sided 5% significance level and accounting for 10% loss to
follow-up, we required 890 participants (445 participants in each group) to be recruited and randomised.
REFORM trial
Randomisation
Clinics informed the York Trials Unit (YTU) of when they had capacity to see trial participants and the
number of participants who could be seen. The YTU then randomised a batch of participants in an
allocation ratio driven by treatment slot availability. In most instances, participants were allocated 1 : 1 to
the intervention or usual-care group; however, in some instances unequal randomisation was used if the
clinic had capacity to see more or less than half the batch size.
Trial interventions
All participants continued to receive usual care from their podiatrist and general practitioner and also
received a falls prevention advice leaflet.
Intervention group
The intervention group were offered a multifaceted podiatric intervention consisting of footwear advice,
footwear provision if required, an orthotic device, foot- and ankle-strengthening exercises and a falls
prevention leaflet.
Follow-up
All participants in the REFORM trial were followed up with questionnaires at 6 and 12 months post
randomisation and were asked to return monthly falls calendars to indicate if and when they fell.
The intervention participants were sent an exercise and orthosis compliance questionnaire at 3, 6 and
12 months.
Primary outcome
The primary end point for the trial was the incidence rate of falls per participant in the 12 months
following randomisation as indicated on the monthly falls calendars. A fall was defined as ‘an unexpected
event in which the participant comes to rest on the ground, floor or lower level’.
Secondary outcomes
Secondary outcomes included the proportion of fallers and those reporting multiple falls, time to first fall,
fear of falling, Short Falls Efficacy Scale – International, Frenchay Activities Index, Geriatric Depression Scale
(GDS), depression (as indicated by a score of ≥ 6 on the GDS), the two-item abbreviated version of the
Connor–Davidson Resilience Scale (CD-RISC2), foot pain, fracture rate, health-related quality of life
(HRQoL) and cost-effectiveness.
Other data collected
Details of the treatment received by intervention participants, and their adherence to the orthoses and
exercises, were collected. Any adverse events reported to the YTU were recorded.
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Statistical methods
Analyses were conducted using Stata® version 13 (StataCorp LP, College Station, TX, USA) on an available
case, modified intention-to-treat (ITT) basis using a two-sided statistical significance level of 0.05. All
regression models were adjusted for sex, age and history of falling, with centre as a random effect. The
rate of falls was analysed using a mixed-effects negative binomial regression, which took account of the
different observation periods for each individual. A complier average causal effect (CACE) analysis to assess
the impact of compliance with the intervention on the treatment estimate was undertaken for the primary
analysis. The proportion of fallers, and of multiple fallers, was analysed using mixed logistic regression.
Qualitative study
A qualitative study was undertaken via interviews to examine the views and experiences of the podiatrists
who delivered the intervention and of the trial participants. Topic guides were developed based on the
study’s research questions and provided the framework for the interviews.
Sampling strategy and recruitment
The principal investigator (PI) and the podiatrists who delivered the intervention at each site were invited
by e-mail to take part.
A purposive sample of 21 trial participants living in Yorkshire and Lincolnshire who indicated that they
would be willing to participate in the qualitative interview was sent a patient information sheet and
invitation letter in the post.
Interview design
The interviews lasted between 30 and 70 minutes, were semistructured and were conducted face to face,
or over the telephone if preferred.
Analysis
Following transcription, the interviews were analysed thematically.
Economic analysis
The economic analysis was conducted on an ITT basis from the NHS and Personal Social Services
perspective. Data on HRQoL, obtained from the EuroQoL-5 Dimensions (EQ-5D) instrument, were
converted into quality-adjusted life-years (QALYs) for each participant using the area under the curve
method. Costs were expressed in UK pounds sterling (£) at 2015 prices.
Differences in mean costs and QALYs at 12 months post randomisation, estimated by means of regression
methods, were used to assess the cost-effectiveness of the intervention compared with usual care. Multiple
imputation (MI) was used to impute missing cost and QALY data, and the base-case analysis was conducted
on this imputed data set. Sensitivity analyses were conducted to test assumptions regarding the missing
data mechanism, level of imputation on HRQoL, resource use and perspective of analysis. Cost-effectiveness
acceptability curves (CEACs) were used to express the probability of whether or not the intervention is
cost-effective at the willingness-to pay threshold used by the National Institute for Health and Care
Excellence (NICE).
In addition, HRQoL was extrapolated to 5 years in order to explore how the differences in HRQoL evolve
beyond the study follow-up. For this exploratory projection, we used a decision-modelling approach and
assumed that the difference in HRQoL and costs observed at 1 year would remain unchanged.
Results
A total of 37,389 recruitment packs were mailed out between October 2012 and August 2014; 3458
(9.2%) were returned with valid screening and consent forms. Eligible participants were sent a baseline
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questionnaire and a pack of falls calendars (n = 2536); 2301 participants returned a baseline questionnaire
and a falls calendar and joined the epidemiological cohort. In total, 1010 participants were randomised to
the trial: 493 to the intervention group and 517 to the usual-care group. The primary analysis comprised
991 participants [484/493 (98.2%) in the intervention group and 507/517 (98.1%) in the usual-care
group]. There was a non-statistically significant reduction in the incidence rate of falls in the intervention
group [adjusted incidence rate ratio (IRR) 0.88, 95% confidence interval (CI) 0.73 to 1.05; p = 0.16]. In the
CACE analysis, the intervention was seen to have a marginally greater benefit than in the ITT analysis
(IRR 0.86, 95% CI 0.69 to 1.06; p = 0.16). The proportion of participants experiencing a fall, or multiple
falls, was lower in the intervention group [50% vs. 55%, adjusted odds ratio (OR) 0.78, 95% CI 0.60 to
1.00; p = 0.05; and 28% vs. 35%, adjusted OR 0.69, 95% CI 0.52 to 0.90; p = 0.01, respectively]. No
statistically significant differences were observed in any of the other fall-related secondary outcomes.
No serious, unexpected and related adverse events were reported.
The base-case economic analysis showed that, over 12 months, the cost of the intervention was, on average,
£252.17 higher per participant (95% CI –£69.48 to £589.38) than the cost of usual care but that it was
marginally more beneficial in terms of QALYs. The net monetary benefit associated with the intervention is
positive, indicating that the resources to be displaced would be smaller than the benefit in QALYs gained if the
intervention were implemented in the NHS. The CEAC showed that the intervention has a 65% probability
of being cost-effective at the NICE threshold of £30,000 per QALY gained. These findings were robust to
sensitivity analyses. When we investigated the likely differences in HRQoL up to 5 years post randomisation,
the incremental cost per QALY for the base case ranged between £19,950 at 2 years and £21,406 at 5 years.
Qualitative interviews were conducted with 15 podiatrists and 21 intervention participants. Most podiatrists
found the intervention acceptable and straightforward to deliver; however, some raised concerns regarding
the implementation of the intervention into routine care. These concerns included the time to measure
footwear and deliver the exercise component of the intervention. It was suggested that footwear advice
and exercise instruction could be delivered in groups to avoid repetition. Footwear provision for falls
prevention is not currently part of routine care; podiatrists felt that adherence to footwear advice/orthotic
use would be much reduced given the lack of resources (financial and physical) available to many service
users to provide appropriate footwear. Adherence to the three components of the intervention varied across
trial participants. At 12-month follow-up, approximately one-quarter of the intervention group were not
performing the exercises or wore the orthotic a little or none of the time. Adherence was affected by the
comfort of the footwear/orthosis, whether or not the participants could incorporate the elements of the
intervention alongside current morbidity problems and whether or not participants perceived there to be a
benefit of carrying out the intervention components.
Conclusions
The multifaceted package of podiatry care was seen to be a safe, acceptable and potentially effective
intervention in reducing the proportion of older adults who experience a fall over 12 months. Although
the primary outcome (incidence rate of falls) did not reach statistical significance, the intervention
appeared to be cost-effective in terms of QALYs gained, based on the HRQoL measure, the EQ-5D.
Trial registration
This trial is registered as ISRCTN68240461.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Introduction
Burden of falls and falling in the UK
Falls and fall-related fractures are a serious cause of morbidity and cost to individuals and society.1 This
burden is likely to increase owing to an ageing population. Falls are associated with a loss of independence
and functional decline, and may result in the need for long-term care.2 Each year, approximately 30% of
people aged ≥ 65 years living in the community will have a fall, and among those aged ≥ 80 years this
increases to 50%.3,4 Older adults who fall once are two to three times more likely to fall again within
1 year. One-fifth of all falls require medical attention, with 5% of falls leading to a fracture.5 The financial
cost of injurious falls has been estimated at £2B per annum, a cost that is mainly attributed to resultant hip
fractures.6 The National Service Framework for Older People highlighted the importance of fall-related
injuries and called for health improvement plans to reduce this burden.7
Risk factors for falling
It is well recognised that falls occur for a variety of reasons. They may result from interactions between
environmental hazards, medical conditions and physiological risk factors.3 Foot problems, which affect one
in three community-dwelling people aged ≥ 65 years,8 have been associated with reduced walking speed
and difficulty in performing activities of daily living. Results from cohort studies have indicated that there is
a relationship between foot and ankle problems and risk of falling.9,10
In addition to causing foot problems, inappropriate footwear may contribute to poor balance and an
increased risk of falling.11 Footwear characteristics that are considered detrimental to balance include
higher heels, soft soles and inadequate slip resistance.11,12 Prospective studies have shown that walking
barefoot, wearing only stockings inside the home and wearing shoes with an increased heel height and
smaller contact area all increase the risk of falling.9,13,14
Podiatry interventions to improve balance
Given the emerging evidence that foot problems and inappropriate footwear increase the risk of falling,
it has been suggested that podiatry may have a role to play in falls prevention, with several guidelines
recommending that older people have their feet and footwear examined by a podiatrist.15,16 Previous studies
have looked at treatments that may improve balance in older adults, such as lesion debridement,17 foot
orthoses,18 foot and ankle exercises19,20 and footwear advice. Lesion debridement can improve function
during gait if pain is reduced, exercise programmes focus on internal strengthening and flexibility, and
appropriate footwear fitted with orthotic devices can provide external support, improved kinaesthesia and
improved function. Combining these therapies could, therefore, improve function and stability.
At the time of designing the current study there were two published Cochrane reviews on falls prevention.
One related to falls in community-dwelling older people21 and one focused on falls in hospitals and aged
care facilities.22 Neither identified any randomised controlled trials (RCTs) focusing on podiatry-related
interventions. A subsequent update identified one Australian trial of a podiatry-based intervention for the
prevention of falls.23 In this study of 305 community-dwelling older people who had foot pain, participants
allocated to receive a multifaceted podiatry intervention (n = 153) experienced 36% fewer falls than
participants in the control group [incidence rate ratio (IRR) 0.64, 95% confidence interval (CI) 0.45 to 0.91;
p = 0.01]. The intervention comprised foot and ankle exercises, foot orthoses, footwear advice, subsidy for
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1
new footwear and a falls prevention booklet combined with routine podiatry care and was compared with
those receiving only routine podiatry. This trial did not include an economic evaluation.
Aims and objectives of the podiatry intervention for podiatry
patients at increased risk of falling
The REducing Falls with ORthoses and a Multifaceted podiatry intervention (REFORM) study was funded by
the National Institute for Health Research (NIHR) Health Technology Assessment (HTA) programme in
response to a call to evaluate the clinical effectiveness and cost-effectiveness of foot orthoses. Its aim was
to establish the clinical effectiveness and cost-effectiveness of a package of podiatric care within a UK
health-care setting.
The main objectives of the REFORM study were to:
1. investigate the clinical effectiveness of a multifaceted podiatry intervention for falls prevention
2. investigate the cost-effectiveness of a multifaceted podiatry intervention for falls prevention
3. assess the participants’ and podiatrists’ views and experiences of the intervention and trial processes.
INTRODUCTION
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Chapter 2 Methods
Trial design
The REFORM study was a pragmatic multicentred cohort RCT.24 We chose this approach to test whether or not
the cohort RCT design could address some of the issues that other trial designs encounter with regard to
recruitment, attrition and participant preference. We expected that using this design would offer the following
advantages. First, trial recruitment rates would be enhanced. Some participants would be immediately eligible
for the study and could be randomised straight away and others who subsequently fell over time would
become eligible and could also then be randomised. If a traditional trial design had been used, then these
additional participants who were not immediately eligible would have been lost. In addition, as we were
undertaking an internal pilot, this could be undertaken while recruitment proceeded for the main study. Second,
we expected that this design would minimise the possibility of introducing attrition and reporting bias. As
participants were receiving routine podiatry care outside the study, the only incentive to take part in the study,
apart from altruistic reasons, was the possibility of receiving the intervention. Under this design, all participants
were informed upon enrolment into the cohort that they may at some point be offered a package of podiatry
care. This was offered to participants subsequently randomised into the intervention group of the RCT;
however, the usual-care group were not explicitly notified of their group allocation as they would have been in
the classic randomised design. We expected that this would reduce attrition caused by ‘resentful demoralisation’
and minimise the risk of participants in the usual-care group either knowingly or unknowingly biasing the trial
by reporting the number of falls they had experienced less conscientiously than those allocated to the
intervention group. Third, we also expected that that the inclusion of a ‘run-in’ period of falls data collection
before randomisation would reduce post-randomisation attrition rates and, therefore, the risk of selection bias.
Participants had to demonstrate engagement with the study by returning at least one falls calendar before they
were randomised, which enriched the sample with those participants most likely to keep responding.
The cohort RCT design allowed us to test the feasibility of this design and determine whether or not it
would enhance recruitment, minimise attrition and lower participant preference effects. It also enabled us
to establish a cohort of older adults who could be followed up, thereby helping to inform the knowledge
base around health and well-being in older adults. This approach also allowed the possibility for us to
invite participants, who had agreed to be contacted again, to take part in future studies.
Participants in the REFORM trial were randomised to receive one of either:
1. a multifaceted intervention consisting of footwear advice (and footwear provision if required), an
orthotic insole or review of an existing insole prescription, a programme of foot and ankle balance
exercises and a falls prevention leaflet
2. a falls prevention leaflet and usual care from their podiatrist and general practitioner (GP).
Approvals obtained
The study protocol was approved by the East of England – Cambridge East Research Ethics Committee (REC)
(multicentre REC) (and substantial amendments) on 9 November 2011 (REC reference number 11/EE/0379).
Galway REC approved the study (and substantial amendments) on 26 April 2013 (REC reference number
C.A 886). The University of York, Department of Health Sciences Research Governance Committee
approved the study (and substantial amendments) on 2 August 2011. Research management and
governance approval was obtained for each trust thereafter (see Appendix 1).
The trial was registered as ISRCTN68240461 on 1 July 2011.
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Study sites
Recruitment of all participants into the study took place through 37 NHS podiatry clinics based in either
primary or secondary care in nine NHS trusts across the UK, and at one international site in a university
school of podiatry in Ireland. Each participating podiatry clinic was associated with the trust under which it
operates, and each trust acted as a trial ‘centre’, except the Harrogate and District NHS Foundation Trust,
which cares for the population of North Yorkshire. As this is a particularly large and diverse area, the clinics
in this trust were split into four groups according to their geographical location: Scarborough, York,
Harrogate and Skipton. These four groups were also considered as trial ‘centres’, resulting in a total of 13.
The Ireland centre was set up to aid study recruitment. This site was chosen because some of the authors
had previously collaborated with this site on another NIHR HTA-funded podiatry study in which recruitment
had gone well. The NIHR HTA programme gave permission to include the site.
REFORM observational cohort
The REFORM study was initially designed to include people aged ≥ 70 years; however, following the pilot
phase, the age limit was reduced to include adults aged ≥ 65 years (see Chapter 3) to facilitate recruitment
and reflect the age range seen within the routine podiatry clinics. Participants were first recruited to the
REFORM observational cohort. While this cohort was being assembled, we invited a selection of eligible
participants from the pilot sites to take part in the internal REFORM pilot trial. After completion of the pilot
phase, the remaining eligible participants were invited to take part in the REFORM trial. Figure 1 reports
how participants were recruited to the observational cohort and when they were randomised to the trial.
Patient fulfils eligibility criteria 
for REFORM cohort, consents 
to the study and completes a 
baseline questionnaire
Ineligible patients
are not entered 
into the cohort
REFORM cohort
recruitment ongoing
Participant does not
fall and remains in the 
cohort for the duration 
of the study
Sample of 78 participants
fulfilling REFORM trial
inclusion criteria, including
the falls criteria
Pilot trial
Participant falls while
in the cohort and 
becomes eligible for 
the REFORM RCT
Participant randomised to
REFORM RCT
Participants who 
fulfilled REFORM trial 
inclusion criteria 
including the falls criteria
FIGURE 1 Recruitment of participants to the REFORM study.
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Participant recruitment
Recruitment of all participants into the study took place through NHS podiatry clinics based in either primary
or secondary care in the UK and at one international site in a university school of podiatry in Ireland. The
reasoning for recruiting only from podiatry clinics and not from general practices was because of the
requirement for all participants to be receiving routine podiatry care so that we could disentangle the effects
of the novel intervention from those of routine podiatry care. Recruitment directly from general practices
would most probably have identified many patients who were not receiving routine podiatry care. For these
patients to have been entered into the REFORM study, they would have to have been receiving routine
podiatry care. NHS podiatry service managers informed us that the burden of providing routine podiatry care
for all trial participants as well as delivering the intervention would have made the study unfeasible.
Potential participants were identified by either the REFORM research podiatrist or a podiatrist within the
clinic undertaking a search of either electronic or paper medical records of patients registered with the
service. Two search criteria were used: (1) age ≥ 65 years and (2) having attended routine podiatry services
within the past 6 months from the date of the search. People living in nursing homes were excluded, as
participants had to be community dwelling to be eligible for the study. At the time of undertaking the
search, it was not possible to easily identify those patients with neuropathy who would be ineligible for the
study. Therefore, to minimise the risk of approaching these patients, those who had attended high-risk
clinics, for example diabetes mellitus clinics, were excluded from the search. Potential participants were
invited to participate in the REFORM study by their podiatry clinic via a postal recruitment pack. This pack
comprised an invitation letter (see Appendix 2) electronically signed by the principal investigator (PI) at the
site, a consent form (see Appendix 3), a participant information sheet (see Appendix 4), a background
information form (see Appendix 5) and a prepaid return envelope addressed to the York Trials Unit (YTU).
During the pilot phase of the study, a decline form (see Appendix 6) was also included so that data could be
collected on people’s reasons for declining to participate. No identifiable data were available to the study
teams until a participant had returned their consent and background information forms.
To aid recruitment, the opportunistic screening of patients attending routine podiatry clinics was
undertaken when clinics had capacity to do so. Potential participants were given the recruitment pack and
verbal information about the study.
Potential participants who wished to take part in the REFORM study returned their completed consent and
background information forms by post to the YTU. The research team assessed the forms for eligibility.
Consenting participants
Participation in the REFORM study was voluntary. Participants who wished to take part were given written
information about the study and contact details for the research team should they have had any queries
about the study. The participants were asked to complete a consent form to indicate that they wished to
take part in the study. The qualitative researcher obtained consent for the qualitative study either face
to face or, for interviews conducted over the telephone, by post.
At the consent stage, participants were informed about the opportunity to participate in other related
studies. Participants were informed about the ‘possibility’ of being offered an additional podiatric
intervention for the prevention of falls and were asked to tick a box if they were interested in taking part
in such an intervention. If participants did not wish to be contacted about these studies, they were asked
to indicate this by ticking a box on the consent form.
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Baseline assessment
On receipt of written consent, researchers at the YTU assessed the participants’ responses on the
background information forms for eligibility. Participants assessed as being ineligible for the study were
notified in writing and no further correspondence was sent. Participants who were deemed eligible were
then sent a baseline questionnaire (see Appendix 7) and a pack of falls calendars (see Appendix 8).
Participant eligibility
Exclusion criteria for the REFORM cohort
Participants were ineligible for the REFORM cohort if they:
1. were > 65 years of age
2. reported having neuropathy, dementia or another neurological condition such as Parkinson’s disease,
Alzheimer’s disease, multiple sclerosis, Lou Gehrig’s disease/amyotrophic lateral sclerosis or
Huntington’s disease
3. were unable to walk household distances (10 metres) without the help of a walking aid, such as a
walking frame, a walker or a person to assist
4. had had a lower limb amputation
5. were unwilling to attend their podiatry clinic for a REFORM appointment.
Inclusion criteria for the REFORM cohort
All eligible consenting participants who completed a baseline questionnaire and at least one monthly falls
calendar were eligible for inclusion in the REFORM cohort.
Inclusion criteria for the REFORM trial
Participants in the cohort were eligible for inclusion in the REFORM trial if they:
1. had had a fall in the past 12 months, or a fall in the past 24 months requiring hospital attention, or
reported worrying about falling at least some of the time in the 4 weeks prior to completing their
baseline questionnaire
2. were community dwelling
3. were able to read and speak English.
If participants did not report a recent fall on their screening form but later reported a fall on the baseline
questionnaire or monthly falls calendar, they became eligible to be randomised.
REFORM internal pilot
An internal pilot was conducted at the start of the study. The objectives of the pilot trial were to:
1. develop and pilot the multifaceted podiatry intervention
2. develop the podiatry training package
3. pilot the falls calendar and other participant data collection questionnaires
4. pilot, review and refine if necessary the recruitment methodology for the main trial.
In order to progress to the main REFORM trial, the study team were asked by the NIHR HTA monitoring
team to fulfil the following progression criteria by the end of November 2013:
1. Recruit 580 participants to the REFORM cohort study.
2. Randomise 70 participants to the REFORM pilot trial.
3. Decide which orthotic insole would be used in the main trial.
METHODS
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Sample size
Pilot sample size
The pilot phase of the study ran from October 2012 until November 2013. No formal sample size
calculation was conducted but we aimed to randomise at least 70 participants into the pilot trial (35 in
each group), which we believed to be sufficient to test the objectives.
REFORM trial sample size
The primary outcome measure for the trial was the incidence rate of falls reported by the participants over
the 12 months post randomisation. This was analysed using a mixed-effects negative binomial regression
model. However, because of the inherent difficulties of estimating the parameters required to power a trial
for a count outcome, such as the IRR to detect and the measure of overdispersion, the trial was instead
powered for the binary outcome of whether or not the participants experienced at least one fall, which
was one of our key secondary outcomes. We retained incidence rate of falls as the primary outcome as we
believed the extra information contained in this outcome would result in the sample size being conservative
for this outcome.
A previous falls prevention trial conducted by some of the authors in community-dwelling older adults with
a history of recent falls found a 12% absolute reduction in the proportion of participants who fell among
those allocated to receive an environmental falls prevention intervention delivered by qualified occupational
therapists, relative to the control group.25 The REFORM trial was powered at 80% using a two-sided 5%
significance level to detect a more conservative absolute difference of 10 percentage points from 50% to
40% in the number of people experiencing at least one fall over the 12 months following randomisation.
The total sample size required, allowing for a 10% loss to follow-up, was 890 participants (445 in each group).
Randomisation
Participants who fulfilled the eligibility criteria for the REFORM trial and who had provided written
informed consent and indicated that they were interested in receiving the intervention were eligible for
randomisation. Randomisation was carried out by the YTU secure remote computer randomisation service.
Trial clinics informed the YTU when they had capacity to schedule baseline appointments for participants
and how many participants they felt that they could manage to schedule appointments for at that time. A
group of participants waiting to be randomised from the centre associated with that clinic were selected
and randomised in a single block (mainly) 1 : 1 to either the intervention or usual-care groups; however,
when clinics had the capacity to see more or less than half the group size, an appropriate alternative
allocation ratio was used. Prediction of allocated group by clinician was not possible because of the
dynamic nature of the randomisation and the use of a remote service; thus, allocation concealment was
maintained. Once intervention participants had been randomised, they were sent a letter informing them
of their group allocation and that the podiatry clinic would be in contact to arrange a trial appointment.
Participants who were allocated to the usual-care group were not informed of their group allocation in
order to minimise potential attrition and the possibility of resentful demoralisation.
Trial interventions
Intervention group
Participants in the intervention group were allocated to receive a multifaceted intervention comprising
footwear advice (and footwear provision if required), an orthotic insole or review of an existing
prescription, a programme of foot and ankle balance exercises and a falls prevention leaflet. The trial
protocol recommended that participants be invited to attend two appointments: the first as soon as
possible after randomisation and the second 2–4 weeks later. Further trial visits could be offered if
required, in addition to routine podiatry care appointments in accordance with usual practice.
DOI: 10.3310/hta21240 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 24
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Cockayne et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
7
Footwear advice and provision
Participants were asked to bring their indoor and outdoor footwear to their REFORM appointment. The
podiatrist assessed the following characteristics of the participant’s footwear that have been identified in
the literature as risk factors for falls in older people:12 correct size, method of fastening, height and width
of the heel, thickness of outsole, heel counter stiffness, longitudinal sole rigidity, sole flexion point and
tread pattern. Footwear was assessed as inappropriate if it had any of the following characteristics: (1) heel
height > 4.5 cm, (2) no adjustable fixation of the upper, (3) no heel counter or a heel counter that could
be depressed to > 45°, (4) a fully worn/smooth/thin sole, (5) heel width narrower than the participant’s
heel width by ≥ 20% or (6) incorrect shoe size. Participants were counselled about any hazardous
footwear features identified during the assessment and advised on safer footwear characteristics to select
when purchasing footwear in the future.
If a participant’s footwear was deemed inappropriate, and they did not own a suitable pair of shoes that
they could be advised to wear instead, new footwear was provided where possible. The podiatrists ordered
footwear directly from one of two companies participating in the Healthy Footwear Guide scheme:26 DB
shoes (DB Shoes Ltd, Rushden, UK) or Hotter company (Beaconsfield Footwear Limited, Skelmersdale, UK).
Not all of the footwear manufactured by these companies fulfil the characteristics of a ‘safe’ shoe; therefore,
participants chose footwear from a catalogue of preselected makes and models that the trial team had
previously assessed as being suitable. In order to avoid incentivising participants to take part in the study,
participants were told about footwear provision only if they were assessed as requiring new footwear.
Foot orthoses
Participants were considered for fitting with an X-Line standard orthotic insole (Healthystep, Mossley, UK).
If required, the insole was modified with prefabricated self-adhesive additions to improve the participant’s
foot posture. For those participants already wearing an orthotic insole, the treating podiatrist made a
clinical judgement on the suitability of replacing the insole with one used in the trial. If the participant’s
current insole was replaced, then any current prescription or modifications were repeated. If, however,
the podiatrist deemed it to be detrimental to replace their current insole with that of the trial insole, then
the participant continued to wear their own insole and this component of the intervention was considered
to be addressed. In cases in which the treating podiatrist felt that the participant required more or a
prescription that the trial insole could not provide, then a referral was made in line with routine practice.
Participants were advised to ‘wear-in’ the orthotic insole slowly. It was suggested that it should be worn
for 1 hour on the first day and wear time increased by a few hours each day, and that the insole could be
transferred from one pair of shoes to another.
Home-based foot and ankle exercise programme
When safe and appropriate, participants were prescribed a 30-minute home-based foot and ankle exercise
programme to be undertaken three times a week, indefinitely. The aim of the exercises was to stretch
and strengthen the muscles of the foot and ankle and improve balance. The exercises were based on the
programme developed by Spink et al.,23 which had been adapted for a UK and Irish setting during the
pilot phase of the study. A summary of the individual exercises is listed in Table 1. The podiatrist assessed
competence and safety at the baseline appointment through demonstration and participant repetition of
the exercises. These were supplemented by an explanatory illustrated booklet and a digital versatile disc
(DVD), which the participant took home along with the resistive bands and therapy ball that were required
to undertake the exercises. At subsequent appointments the podiatrists reviewed the participant’s exercise
techniques and, when required, advised the participant to ensure that the exercises were being conducted
safely and as intended.
Routine podiatry care
Participants continued to receive routine podiatry care as separate podiatry appointments in accordance
with usual practice. The aim of these appointments was to reduce painful conditions such as corns and
calluses that have been found to be associated with an increased risk of falls.
METHODS
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TABLE 1 Summary of the home-based foot and ankle exercises
Activity Description Dosage Increments
Ankle range of
motion/warm-up
Sitting, with the knee at 90°. Lift the
foot to clear the ground and then
rotate the foot slowly in a clockwise
direction and then an anticlockwise
direction
1 × 10 repetitions for
each foot in each
direction
None
Ankle inversion
strength
Sitting upright, with the hip, knee and
ankle at 90°. Invert foot against
resistive exercise band. The band should
be fixed at 90° to the foot from an
additional chair/table leg
3 × 10 repetitions for
each foot
Increase resistance
strength of resistive
exercise band
Ankle eversion
strength
Sitting upright, with hip, knee and
ankle at 90°. Evert foot against resistive
exercise band. The band should be
fixed at 90° to the foot from an
additional chair/table leg
3 × 10 repetitions for
each foot
Increase resistance
strength of resistive
exercise band
Ankle dorsiflexion
strength
Sitting, with hip, knee and ankle at 90°.
Dorsiflex both feet to end range of
motion and hold. Keep pulling feet up
towards the body during the hold
Hold feet in dorsiflexion
for 3 × 10 seconds
Increase repetitions up to
a maximum of 10
Intrinsic
strengthening, toe
plantarflexion
strength and toe
stretch
Sitting, with hip, knee and ankle at 90°.
(1) Use the therapy ball under the toes
to stretch the toes. The rest of the foot
should be plantigrade. Then curl and
point the toes up and over the ball.
(2) Use the therapy ball under the toes
to stretch the toes. The rest of the foot
should be plantigrade. With the heel
on/close to the floor, curl the toes over
the ball and attempt to pick up the ball
with the toes
3 × 10 repetitions for
each exercise for both
feet. Have a 30-second
break between each
repetition
Increase up to a maximum
of 50 repetitions
Ankle plantarflexion
strength
From standing position, rise up onto
toes of both feet and then slowly lower
back down. Just before the heels
contact the floor, rise back up onto the
toes
3 × 10 repetitions Increase repetitions up to
a maximum of 50
Calf stretch Facing a wall and using hands on the
wall for balance, step one foot in front
of the other keeping feet hip width
apart and hips, knees and feet facing
the wall. Bend the knee closest to the
wall and keep the back leg straight.
Keep both heels in contact with the
floor
Hold stretch for
3 × 20 seconds on each
leg
Increase the stride length
and forward lean to
increase the stretch
Proprioception/
balance training
From a standing position and holding
on to a work surface/chair/wall for
support, stand on one leg. Repeat on
the other side
Hold for 30 seconds,
repeat for three
repetitions
Increase slowly to hold for
1 minute per repetition.
If competent, rise up
on to toes on the one
supporting leg: 3 × 10
repetitions
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Podiatrist training to deliver the intervention
The podiatrists delivering the trial intervention attended a half-day face-to-face training session facilitated
by the research podiatrist (author LG). The training included instructions on the delivery of the individual
components of the intervention including footwear assessment and provision, prescribing and fitting trial
insoles and prescribing foot and ankle exercises. Podiatrists were given the opportunity to practice delivering
the intervention during role-play sessions. In addition, information about the day-to-day management of
podiatry tasks, for example booking appointments or ordering footwear, adverse event reporting and
completion of trial paperwork, was provided. When possible, the research podiatrist attended the first
participant appointment delivered by each podiatrist to give advice on the delivery of the intervention
when requested.
Falls prevention leaflet and trial newsletter
Participants were sent a falls prevention leaflet in the post along with their baseline questionnaire.
Participants living in the UK received the Age UK Staying Steady leaflet27 and those in Ireland received the
Irish Osteoporosis Society Fall Prevention leaflet.28
A postal group-specific trial newsletter was sent to participants at 3 months post randomisation, as well
as a generic trial newsletter at 12 months. The aim of the newsletters was to keep participants updated
with the progress of the trial in an attempt to minimise attrition and improve response rates to postal
questionnaires.29 The 3-month newsletter to the intervention group also included information about how
to undertake the foot and ankle exercises and wear the insoles and it aimed to aid compliance. It included
anonymised quotations reporting the benefit some participants had experienced after following the
package of care. The content of the newsletter was informed by issues raised by participants with the
research team during the course of the trial.
Usual-care group
Participants in the control group continued to receive usual care from their podiatrist and GP, which
may have included prescription of an orthosis and footwear advice. They also received the same falls
prevention advice leaflet sent to the intervention participants and a group-specific trial newsletter at the
same time points.
Participant follow-up
All participants in the REFORM trial were followed up with monthly falls calendars for 12 months post
randomisation. If a participant did not return their falls calendar after 10 days, a member of the study
team telephoned or wrote to them to collect the primary outcome data. The study team contacted
participants who had reported a fall to collect further information relating to the nature, cause and
location of the fall (see Appendix 9). Participants were also sent follow-up questionnaires at 6 (see
Appendix 10) and 12 months (see Appendix 11) post randomisation. Follow-up questionnaires were
posted to participants, along with a pre-addressed envelope, and reminder letters were sent after 2 and
4 weeks if unreturned. Participants also received an unconditional £5 in cash with their 12-month postal
questionnaire in recognition of their participation in the study and to offset any incidental expenses that
they may have incurred when completing postal questionnaires. Telephone follow-up by one of the study
team’s researchers was conducted 2 weeks after the second postal reminder for any participant who
had not returned a questionnaire to complete the primary outcome data as a minimum. In addition,
intervention participants were sent an exercise and orthosis compliance questionnaire at 3, 6 and
12 months (see Appendix 12). Any change in the participant’s trial status during the course of the study
was recorded by the study team (see Appendix 13). Data collection ceased in December 2015.
METHODS
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Trial completion and exit
Participants were deemed to have exited the trial when they:
1. had been in the trial for 12 months post randomisation
2. withdrew from the trial, that is, they wished to exit the trial with no further contact for follow-up
or treatment
3. were lost to follow-up
4. died.
Withdrawals
Withdrawals could occur at any point during the study at the request of the participant. The reason for
their withdrawal did not have to be declared; however, if a reason was provided, then it was recorded.
Participants could inform the trial team of their decision to withdraw from the study by contacting them
either by telephone or in writing. When possible, a researcher would clarify to what extent they wished
to withdraw: from the intervention only or from all aspects of the study. Treating podiatrists could also
withdraw participants from the intervention or from all aspects of the trial when they felt that this was
appropriate. When withdrawal was from the intervention only, follow-up data continued to be collected.
Data were retained for all participants, unless a participant specifically requested that their details
be removed.
Patient and public involvement in research
The REFORM trial was informed by the involvement of older people with a history of falls throughout
the research period. A patient reference group was established at the start of the study. The group
comprised four older people who provided valuable insights into the relevance and readability of the
study documentation and advice regarding recruitment methods. They provided input into the content
and layout of the patient information sheet, the exercise booklet, newsletters and recruitment posters.
They reviewed the exercise DVD and the package of care, and provided feedback on the selection of
footwear offered to participants. The patient reference group contributed to this HTA report by reviewing
the plain English summary and they will provide guidance about our dissemination strategies on how best
to share the study findings with trial participants.
Clinical effectiveness
Primary outcome
The primary end point for the trial was the incidence rate of falls per participant in the 12 months
following randomisation. A fall was defined as ‘an unexpected event in which the participant comes to
rest on the ground, floor, or lower level’.30 Data were collected via participant self-reported monthly falls
calendars. These took the form of A5 pieces of card with a calendar grid of individual months printed on
one side along with a definition of a fall and a freepost address to the YTU on the other. Participants were
asked to record the day of the month on which they fell or to record that they did not fall that month and
return the calendar to the YTU. Participants who did not return their monthly falls calendar were either
telephoned or written to by the YTU to obtain the missing data. Participants were also given a freephone
number to report any falls as soon as possible after they occurred, and these were recorded by research
staff on a falls telephone data collection sheet (see Appendix 9). The information collected included the
date and location of fall, the reason for the fall, any injuries sustained (e.g. a superficial wound or a broken
bone), hospital admissions, the footwear worn at the time of the fall and if the participant was wearing an
insole or using a walking aid.
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Secondary outcomes
All secondary outcomes were self-reported by the participant and collected by questionnaires at 6 and
12 months post randomisation or by monthly falls calendars. Secondary outcomes include:
1. proportion of fallers (at least one fall and multiple falls)
2. time to first fall from date of randomisation
3. incidence rate of falls in 12 months post randomisation as recorded on the 6- and 12-month
participant questionnaires
4. fear of falling as measured by the question ‘During the past 4 weeks have you worried about having a
fall?’ at 6 and 12 months
5. fear of falling as measured by the Short Falls Efficacy Scale – International (FES-I) at 6 and 12 months31
6. activities of daily living as measured by the Frenchay Activities Index (FAI) at 6 and 12 months32
7. depression as measured by the short form Geriatric Depression Scale (GDS) at 6 and 12 months33
8. proportion of participants with depression (score of ≥ 6 on GDS) at 12 months
9. adaptability and resilience as measured by the 2-item abbreviated version of the Connor-Davidson
Resilience Scale (CD-RISC2) at 6 months34
10. level of pain in the feet as measured on a visual analogue scale from 0 (no pain) to 10 (worst possible
pain) at 12 months
11. fracture rate (single and multiple)
12. health-related quality of life (HRQoL) as measured by the EuroQoL-5 Dimensions-3 Levels (EQ-5D-3L)35
13. health service utilisation.
Scoring of instruments
Fear of falling
Fear of falling was measured by the question ‘During the past 4 weeks have you worried about having a
fall?’ at screening and baseline and at 6 and 12 months. Response categories were all of the time, most of
the time, a good bit of the time, some of the time, a little of the time and none of the time. These were
scored from 1 to 6 and were treated as continuous data for analysis.
Short Falls Efficacy Scale – International
The Short FES-I asked participants at baseline and at 6 and 12 months to indicate how concerned they
were about falling when performing seven different activities: not at all concerned, somewhat concerned,
fairly concerned or very concerned. These were scored from 1 to 4, and a total score for the Short FES-I
was obtained by summing the seven item scores. When a participant selected two or more responses
to an item, this was treated as missing data. If data were missing on two or more items then the
questionnaire was considered invalid. If data were missing on no more than one of the seven items then
the total score was calculated for the six completed items, divided by six and multiplied by seven. The new
total score was then rounded up to the nearest whole number.31 A final total score of 7 or 8 indicates
no/low concern, 9–13 indicates moderate concern and 14–28 indicates a high degree of concern
about falling.
Frenchay Activities Index
This 15-item instrument was administered at baseline and at 6 and 12 months and assessed a broad
range of activities of daily living. The frequency with which each item or activity was undertaken over the
previous 3 or 6 months (depending on the nature of the activity) was assigned a score of 1–4, where a
score of 1 is indicative of the lowest level of activity (e.g. never performed). The scale provides a summed
total score from 15 to 60. When a participant selected two or more responses to an item, this was treated
as missing data. Only when there were no missing item responses was a total score computed for an
individual for this instrument.
METHODS
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Geriatric Depression Scale
The GDS is a 15-item scale used as a screening tool for geriatric depression and was administered at
baseline and at 6 and 12 months. Each item requires a ‘yes’ or ‘no’ response. A score of 1 is assigned
when the item response indicates a negative state of mind, for example responding ‘no’ to ‘Are you
basically satisfied with your life?’. A total score out of 15 can be calculated. When a participant selected
both ‘yes’ and ‘no’, the worst-case scenario was assumed and a score of 1 was assigned to the item. More
than five missing item responses invalidated the scale; otherwise, a total score when there were missing
data was calculated by summing the item scores, dividing by the total number of completed items and
multiplying by 15. The new total score was then rounded up to the nearest whole number to give the
score for an individual (https://web.stanford.edu/∼yesavage/GDS.html). A score of 0–5 is considered
normal, whereas a score of > 5 suggests depression. Any participant reporting a score of ≥ 10 on the
GDS,33,36 that is, more severe depression, was referred to their GP.
The two-item abbreviated version of the Connor-Davidson Resilience Scale
The CD-RISC2 is a two-item abbreviated version of the full 25-item Connor-Davidson Resilience Scale. It is
based on items 1 (‘I am able to adapt to change’) and 8 (‘I tend to bounce back after illness or hardship’)
of the original instrument. Each item is scored from 0 (‘not true at all’) to 4 (‘true nearly all the time’),
so the CD-RISC2 can be scored from 0 to 8. Higher scores reflect greater ‘bounce-back’ and adaptability.
This instrument was administered at baseline and at 6 months.
Other data collected
Non-consenting participants
Participants who did not wish to take part in the study were not required to return any forms to the YTU;
however, some chose to complete the screening form, thus providing us with some demographic
information. In addition, all participants in the pilot phase of the study were sent an invitation pack that
included a decline form, so that if they were willing they could provide a reason for declining. This provided
us with sufficient information to document the reasons why participants did not wish to take part in the
study, and allowed us to compare participants who declined with those who participated. The recruitment
pack in the main study did not contain a decline form.
Intervention: details and adherence
Treatment details were recorded by the podiatrist, including the number of podiatry visits, an eligibility checklist
with details on relevant health conditions and test results, characteristics of current indoor and outdoor shoes,
details relating to shoes ordered, details on the type and prescription of any current insole use, the type of
insole issued/retained with any modifications made, details of the size of any therapy ball and the strength of
any resistive band prescribed and any amendments or advice given on the intervention owing to safety reasons.
Information on adherence to the exercise, footwear advice and orthotic insole components of the
intervention was collected from participant self-reported questionnaires at 3, 6 and 12 months from
participants in the intervention group only. Participants were asked if, during the past month, they had
worn their insole all of the time, most of the time, some of the time, a little of the time or none of the
time. Participants were also asked, for the past month, typically how many times a week they had done
the exercises: not at all, once, twice, three times or more than three times. In addition, all participants
were asked on the 12-month follow-up questionnaire if they had been given footwear advice by the trial
podiatrist and whether or not they had followed the advice given.
Adverse events
Details of any adverse events reported to the YTU directly by the participant, a member of their family or
by a member of the research team at the recruiting site were recorded. Details of the event were recorded
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on a REFORM Adverse Event Form (see Appendix 14). Any serious adverse events (SAEs) judged to have
been related and unexpected were required to be reported to the REC under the current terms of the
standard operating procedures for RECs.
In this study, a SAE was defined as any untoward occurrence that:
1. resulted in death
2. was life-threatening
3. required hospitalisation or prolongation of existing hospitalisation
4. resulted in persistent or significant disability or incapacity
5. consisted of a congenital anomaly or birth defect
6. was otherwise considered medically significant by the investigator.
Expected events included aches and pains in the lower limb, new callus/corn formation, blisters or ulcers
and skin irritation/injury including pressure sores and soft tissue injury.
The occurrence of adverse events during the trial was monitored by an independent Data Monitoring
Ethics Committee and the Trial Steering Committee (TSC). The Data Monitoring and Ethics Committee/TSC
would have immediately seen all SAEs that were thought to be related to treatment.
Clinical effectiveness analysis
All analyses were conducted on a modified intention-to-treat (ITT) basis using available cases, using a
two-sided statistical significance level of 0.05 unless otherwise stated. The analyses were conducted using
Stata® version 13 (StataCorp LP, College Station, TX, USA).
Data collected at screening and on the baseline questionnaire are summarised for (1) consenting
individuals and those who assented to provide screening data but not to enter the trial, (2) the cohort and
(3) trial participants as randomised and as analysed in the primary outcome model by treatment group.
Comparisons between groups were made using chi-squared tests for categorical data, independent t-tests
for continuous variables and negative binomial regression for count data.
Primary analysis
The primary analysis model controlled, as fixed effects, for sex (coded 0 = female, 1 =male), age at
randomisation in years (integer) and history of falling. All participants had to have fallen at least once in
the previous 12 months, have had a fall in the last 24 months requiring hospitalisation or have a fear of
falling in order to be eligible for randomisation. Participants were classified into two groups for the history
of falling covariate: (1) one or no falls in the 12 months prior to completion of the background information
sheet; or (2) two or more falls reported in the 12 months prior to completion of the background
information sheet. These were coded as 0 and 1, respectively.
As there was evidence of overdispersion in the data, Poisson regression was not considered to be
appropriate, and so the incidence rate of falls was analysed using a mixed-effects negative binomial
regression model. Participants recruited from the same centre, and therefore residing in a particular
geographical area, are more likely to be similar to one another than to participants from other centres. This
can result in a correlation between participant outcomes within centres. Failure to account for this clustering
of outcomes in the analysis can lead to an increase in the type 1 error rate. Therefore, to account for the
potential correlation of participant outcomes from participants in the same centre, we included trial centre
(n = 13) as a random effect in the model. The model also took account of the different observation periods
for each individual by including a variable for the number of months for which the participant returned a
monthly falls calendar (using the exposure option within the Stata command).
METHODS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
14
The model equation is:
E(yij) = tijexp½β0 + β1(Sex =Male) + β2(History of falling = Yes) + β3(age at ramdomisation)
+β4(Allocation = Intervention),
(1)
where
l E(yij) is the expected number of falls for participant i in centre j in time tij
l tij is the length of exposure (follow-up) for participant i in centre j
l β is a vector of fixed-effect regression coefficients and
l exp(β) is a vector of the IRRs.
Coefficients are presented as IRRs with 95% CIs and p-values.
Sensitivity analyses
A sensitivity analysis of the primary outcome was conducted, adjusting for any pre-randomisation variables
found to be imbalanced by chance between the randomised groups.
Non-compliance
A complier average causal effect (CACE) analysis to assess the impact of compliance on the treatment
estimate was undertaken for the primary analysis. CACE analysis allows an unbiased treatment estimate
of, in this case, the podiatry intervention in the presence of non-compliance. It is less prone to biased
estimates than the more commonly used approaches of per protocol or ‘on treatment’ analysis, as it
preserves the original randomisation and uses the randomisation status as an instrumental variable to
account for the non-compliance. The CACE analysis employed a two-stage regression process: first,
compliance with the intervention was predicted using a linear mixed model adjusted for randomised
group, sex, age and history of falling, with centre as a random effect; and, second, the primary analysis
model was repeated but the variable for group allocation was replaced with the variable for compliance
and the predicted residuals from the first regression was added as a covariate.
Compliance was based on whether or not the participant was seen in clinic for a trial appointment;
therefore, all participants in the usual-care group and those in the intervention group who did not attend
an appointment were assigned a compliance value of 0 and those in the intervention group who attended
an appointment were assigned a value of 1. As this was a multifaceted intervention, it did not make sense
to try and measure the extent to which participants used the orthotic insole, performed their prescribed
exercises or wore their provided footwear. This would have been measured with too much error.
Excluding fear of falling participants
Over the course of the trial, it was observed that having a fear of falling was a strong predictor of having a
fall in the near future. A protocol amendment was submitted to, and approved by, the REC to include ‘fear
of falling’ as an inclusion criterion. Therefore, a small number of participants in the cohort were randomised
into the trial who reported a fear of falling on their baseline form but who had not reported a previous fall.
On advice from the TSC and the HTA programme, the trial over-recruited to make up for the number of
participants recruited using the fear of falling criterion. A sensitivity analysis was conducted excluding these
‘fear of falling’ participants from the primary analysis to determine their effect on the estimates.
Missing data
We compared data collected prior to randomisation for participants who are included in the primary analysis
to ensure that any attrition had not produced imbalance in the groups in important covariates. To account
for any possible selection bias, univariate logistic regressions were run to predict missing outcome data.
As the number of participants who did not return any falls calendars after randomisation was low, missing
outcome data were based on returning fewer than 6 months’ worth of data post randomisation. All
variables found to be predictive of missingness were then included in a single stepwise logistic regression
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model, which used a p-value of 0.1 to refine the covariates. The primary analysis was then repeated
including as covariates the variables found to be significantly predictive of non-response to determine if this
affected the parameter estimates.
Podiatrist effects
In 6 of the 13 sites, only one podiatrist delivered the intervention; therefore, podiatrist effects are to some
extent captured by centre effects that are being accounted for in the primary analysis. However, in other
sites, more than one podiatrist delivered the intervention to the participants. We therefore have potential
clustering by podiatrist in the intervention group that is not completely captured by centre. The success
of the intervention may depend on the skill/experience of the podiatrist and their relationship with the
participant. To account for this variation between podiatrists, a sensitivity analysis was conducted in
which every participant, whether allocated to the intervention or usual-care group, was associated with a
podiatrist. For intervention participants, this podiatrist was the podiatrist who delivered their intervention
appointments. For usual care participants or intervention participants who did not attend an appointment,
we assigned them a counterfactual podiatrist, that is, one that they could have seen had they received
the intervention. All participants at sites with only one trial podiatrist were assigned this podiatrist.
In sites with more than one trial podiatrist, the participants were randomly assigned one of the podiatrists
who saw participants who were randomised in the same month as them, in the proportion that they
saw intervention participants. Each podiatrist then had their own cluster of usual care and intervention
participants. The primary analysis was then repeated with podiatrist, rather than centre, as a random effect.
Secondary analyses
The incidence rate of falls over the 12 months following randomisation (as reported for the previous
6 months on the 6- and 12-month participant questionnaires) was analysed in the same way as the
primary outcome.
The proportion of fallers versus non-fallers, and of multiple fallers versus single or non-fallers, in each
group was compared using a mixed logistic regression model adjusting for sex, age and history of falling,
with centre included as a random effect.37
The time from randomisation to first fall in days was derived. Participants who did not have a fall were
censored at their date of death or, if alive, their withdrawal from the trial, the date of the last available
assessment or 365 days after randomisation, whichever was latest. Kaplan–Meier survival curves were
produced for each group. The time to first fall was analysed by a Cox proportional hazard regression with
shared centre frailty effects adjusting for sex, age and history of falling.38
Fear of falling in the past 4 weeks, and the total scores for the Short Falls Efficacy Scale – International, GDS
and FAI were compared between the two groups using a covariance pattern mixed model incorporating all
post-randomisation time points (6 and 12 months) adjusting for baseline score, sex, age, history of falling,
treatment group, time and a treatment group-by-time interaction term, with centre as a random effect.
Such an approach models the correlation of observations within participants over time. Different covariance
structures for the repeated measurements, which are available as part of Stata version 13 (unstructured,
exchangeable, independent and banded), were explored and the most appropriate pattern used for the
final model based on the Akaike’s information criterion (smaller values are preferred).39 Participants were
included in the model if they had full data for the baseline covariates and outcome data for at least one
post-randomisation time point (6 or 12 months). An estimate of the difference between treatment groups in
the outcome was extracted for each time point with a 95% CI and p-value.
The assumptions of the covariance pattern mixed model were checked visually. The normality of the
standardised residuals was assessed via a histogram and Q–Q plot, and the homoscedasticity of the errors
was checked by plotting the residuals against the fitted values.
METHODS
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The CD-RISC2 score at 6 months was compared between the two groups using a linear mixed model
adjusting for baseline CD-RISC2 score, sex, age and history of falling, with centre as a random effect.
Participants with a score of ≥ 6 on the GDS were categorised as having depression; the proportion of
people with depression in each group was compared at 12 months using a mixed logistic regression model
adjusting for sex, age and history of falling, with centre as a random effect.
The proportion of participants obtaining at least one fracture over the 12-month follow-up period was
compared using a mixed logistic regression adjusting for sex, age and history of falling, with centre as a
random effect.
At 12 months, participants were asked to indicate their level of pain or discomfort in their feet on a visual
analogue scale from 0 (no pain) to 10 (worst possible pain). This was analysed using a linear mixed model
adjusting for sex, age and history of falling, with centre as a random effect in an ITT analysis, and also
in a CACE analysis. We based compliance on whether or not the participant was seen in clinic for a trial
appointment. The CACE analysis employed a two-stage regression process: first, compliance with the
intervention was predicted using a linear mixed model adjusting for randomised group allocation, sex, age
and history of falling, with centre as a random effect; and second, foot pain score was predicted using a
linear mixed model adjusting for compliance, sex, age, history of falling and the predicted residuals from
the first regression, with centre as a random effect.
Economic analysis
The economic analysis was conducted on an ITT basis from the NHS and Personal Social Services
perspective. Data on HRQoL, obtained from the EuroQoL-5 Dimensions (EQ-5D) instrument collected from
self-reported questionnaires, were converted into quality-adjusted life-years (QALYs) for each participant
using the area under the curve method. Costs were expressed in UK pounds sterling (£) at 2015 prices.
Differences in mean costs and QALYs at 12 months post randomisation, estimated by means of regression
methods, were used to assess the cost-effectiveness of the intervention compared with usual care. Multiple
imputation (MI) was used to impute missing cost and QALY data, and the base-case analysis was conducted
on this imputed data set. Sensitivity analyses were conducted to test assumptions regarding the missing
data mechanism, level of imputation on HRQoL, resource use and perspective of analysis. Cost-effectiveness
acceptability curves (CEACs) were used to express the probability of whether or not the intervention is
cost-effective at the willingness-to-pay (WTP) threshold used by the National Institute for Health and Care
Excellence (NICE).
In addition, HRQoL was extrapolated to 5 years in order to explore how the differences in HRQoL evolve
beyond the study follow-up. For this exploratory projection, we used a decision-modelling approach and
assumed that the difference in HRQoL and costs observed at 1 year would remain unchanged.
Qualitative study
A qualitative study was undertaken to explore the views, experiences and acceptability of the REFORM
package of care from the perspective of both service users and service providers. In particular, this
qualitative study considered the barriers to and facilitators of delivering and receiving the intervention, in
the context of podiatry care. An in-depth appreciation of these issues is useful for the future successful
implementation of complex podiatry interventions in this population group.
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Design
A semistructured interview study was used to gather in-depth information on the trial participants’
experiences of receiving the podiatry intervention, alongside the podiatrists’ experiences of delivering the
intervention. The interviews were conducted either face to face or over the telephone with participants
and podiatrists in the trial (at the end of the intervention period).
Sampling
A purposive sampling strategy was used to achieve a hetergeneous sample of trial participants from the
intervention group to ensure maximum variation40 according to age, sex and history of falls. Previous
studies have indicated that a sample of approximately 20–30 trial participants is sufficient to address the
aforementioned aims from the point of view of the service users.
As podiatrists delivering the intervention were based in a wide variety of clinics, it was expected that their
views and experiences may differ. For example, some podiatrists worked in biomechanics and others
worked in routine podiatry clinics. All 28 podiatrists who delivered the REFORM intervention were invited
for interviews through the PI at each site.
Recruitment and consent
All REFORM trial participants living in the Yorkshire or Lincolnshire areas who expressed an interest in
undertaking other associated REFORM research studies on the consent form and who had received the
intervention were eligible for participation in the qualitative study. Following sampling, study participants
were approached by letter, which contained an information sheet (see Appendix 15) and two consent forms
(see Appendix 16). The letter also informed trial participants that a qualitative researcher (authors AC and
SC) would contact them via telephone to find out if they would be willing to take part and, if so, to arrange
a time for the interview to take place. In accordance with ethics guidelines, informed consent was gained
by the researcher before the commencement of the interview. The aim of the interview was explained
to the participant, and this was followed by an opportunity for them to ask questions about the study.
The anonymity and confidentiality of participants’ personal information were assured by the researcher.
Podiatrists were also invited to take part in the qualitative interviews. The PI at each site was sent an e-mail
asking if he or she and the podiatrists who delivered the intervention would like to be interviewed. The PI
was asked to forward the e-mail on to podiatrists at their site who delivered the intervention. Podiatrists
were asked to contact the research team directly if they wished to take part. The recruitment e-mail
included an invitation, information sheet (see Appendix 17) and consent form (see Appendix 18). This was
followed up by a telephone call or an e-mail. Prior to the interviews, podiatrists were assured anonymity
and confidentiality and were given the opportunity to ask questions. For podiatrists interviewed face to
face, a similar process to that used to obtain consent for trial participants was used. For interviews
conducted over the telephone, verbal consent was obtained prior to the start of the interview and a copy
of the consent form was sent to the qualitative researcher either in the post or via e-mail.
Data collection
The semistructured interviews with trial participants were carried out in participants’ homes or at the University
of York between November 2013 and March 2016 and on average lasted 40 minutes using a topic guide
(see Appendix 19). All interviews were audio-recorded, transcribed and anonymised before data analysis.
The semistructured interviews with podiatrists were carried out between July 2015 and January 2016 in a
private room on premises where the podiatrist was based or over the telephone. The interviews lasted
between 30 and 70 minutes and were conducted using a topic guide (see Appendix 20).
The topic guides provided a framework for the semistructured interviews and ensured that all podiatrists
and trial participants were asked the same questions, allowing comparisons to be made during the
analysis. However, the wording of questions was not fixed to allow interviews to flow and to allow for
probing when more detail was required.
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Data analysis
An initial thematic analysis was carried out using the stages as outlined by Braun and Clarke:41 (1) familiarisation,
(2) generating initial codes, (3) searching for themes, (4) reviewing themes, (5) defining and naming themes
and (6) data reporting. An initial coding framework was developed based on a priori themes relating to
issues included in the topic guide while allowing for emergent themes. Descriptive coding was conducted,
following familiarisation with the data, by the main qualitative researcher on the project (author SC),
informed by regular discussion with the qualitative team (authors JA and AC). Subsequently, initial codes
were refined in order to address the aims of the qualitative study outlined above, following the analysis of
the main trial. A constant comparison method42 was used to check and compare across the data set and to
establish appropriate analytical categories. This also ensured that any additional codes were added to reflect
as many of the nuances or outlier views in the data as possible, taking into consideration the participants’
wider contexts. Anonymised participant identifiers are used for the reporting of results.
To promote quality, the following strategies were used: description of the participants to provide context
(credibility and transferability), transparency of the research process (transferability), evidence of consistency
using multiple examples from data (dependability) and engagement of the wider research team with
interim findings (confirmability). In addition, a reflexive approach was taken to data analysis. The main
interviewers (authors SC and AC) were academic research fellows with no podiatry training. SC was the
main REFORM trial co-ordinator and AC had no prior knowledge or experience of podiatry interventions,
orthotic insoles or RCTs. The other member of the qualitative team (author JA) had an academic research
background and also did not have previous knowledge or experience of podiatry care. This placed the
qualitative research team in a very neutral position relating to any prior expectations relating to the
study intervention.
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Chapter 3 Protocol changes
Clarification to trial documentation and collection of data
Following review of the trial documentation in March 2012, we decided to simplify the participant
self-report question regarding neuropathy status. Participants were asked to report if they had any
numbness or tingling in their feet or lower limbs as opposed to being asked if they had neuropathy. This
was because it was felt that participants may not have known that they had neuropathy but would be able
to report if they had numbness or tingling in their lower limbs. Baseline data regarding referrals to a falls
service were also collected.
Following completion of the pilot study, it was felt that sufficient data had been collected about the
reasons why potential participants did not wish to take part in the study. To reduce the postage costs for
the study and on advice of the patient representative, who expressed concerns about this additional
data collection, it was agreed that data on reasons for declining participation in the study would not be
collected in the main study.
To minimise participant burden and to improve data collection, it was agreed that qualitative data from
participants could be collected over the telephone and that information regarding exercise and orthosis
compliance would be collected via postal questionnaire at 3, 6 and 12 months post randomisation rather
than by the completion of an exercise diary.
Amendments were made to the participant information sheet and consent form in August 2012 to clarify
that not all participants would be offered an additional podiatry visit.
Recruitment
The original protocol stated that we planned to recruit 1700 participants to the REFORM cohort, of whom
we would randomise 890 to the REFORM trial over a 24-month period from three NHS trusts (Harrogate,
Sheffield and Leeds). However, the study commencement was delayed by approximately 5 months
because of contractual issues and delays in obtaining service support costs for the study and research and
development approval. As the trial progressed, recruitment fell below the expected level because, in the
main, a lower than expected uptake rate to the study by participants and a lower than expected number
of eligible participants expressing an interest in taking part. Approval was obtained from the funder to
extend the study by 10 months to a total of 52 months (December 2011 to March 2016). This permitted
the recruitment of seven additional sites. The details of the recruiting sites and date on which research
governance approval was received can be found in Appendix 1.
With the number of eligible participants lower than expected, the number of participants in the REFORM
cohort had to be increased from 1700. It was decided to aim to recruit 2600 participants into the cohort.
To assist with recruitment, approval was obtained to implement the opportunistic screening of participants
by podiatrists in clinics, falls practitioners, physiotherapists and the research podiatrist.
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Inclusion criteria
The following changes were made to the eligibility criteria during the study.
1. Responses on the ‘decline forms’ received from participants who did not wish to take part in the study
during the pilot phase indicated that participants declined because they assumed that they would not
be eligible as they considered themselves either too old or too ill. The participant information sheet was
modified to try and address this concern stating that, in effect, no one was ‘too old’ to take part and
having a chronic illness did not necessarily exclude people from participation. In addition, the TSC
reviewed the age limit and agreed to a change from ≥ 70 years to ≥ 65 years, as it was felt that
younger participants may also potentially benefit from the intervention. It was hoped that this change
would increase the size of the eligible population and improve recruitment. An amendment to reduce
the age limit of participants in the study was approved by the multicentre REC in February 2013.
2. Responses from the screening forms sent out during the pilot phase indicated that participants were
being excluded as they were already wearing an insole. In order to aid recruitment the TSC agreed that
as the trial was evaluating a multifaceted intervention and not insoles on their own, from February
2013 patients could be included if they were currently wearing a full or three-quarter length insole for
the purpose of altering or modifying foot function. For participants allocated to the intervention group
who were already wearing an orthotic insole, the treating podiatrist made a clinical judgement on the
suitability of replacing the insole with one used in the trial. Usual care participants continued to wear
their insole but may have had a new insole prescribed by their podiatrist as part of their routine care.
3. To minimise post-randomisation attrition rates, participants had to demonstrate their commitment to
the study by returning three falls calendars before they could be randomised. This was thought to
cause considerable delay in participants being randomised at new sites. Therefore, to aid recruitment, in
April 2013 the need to return a minimum of three falls calendars was reduced to a minimum of one.
4. We undertook an analysis of the predictors of falling in those participants who had been recruited to
the study but were in the 3-month ‘run-in’ phase, so were yet to be randomised. As expected, those
who reported having had a previous fall were at a higher risk of falling during the run-in period than
those who had not [odds ratio (OR) 2.4]. We also observed that those who reported having a fear of
falling on their baseline questionnaire were at an elevated risk (OR 2.1). In a previous trial of fracture
prevention, a similar relationship was found: fear of falling is a risk factor nearly as strong as a history of
falls.43 Following advice from our TSC and the funders, it was agreed that from June 2014 an additional
inclusion criterion (i.e. fear of falling) could be used at clinics that had the capacity to see participants
but did not currently have any participants eligible under the current criteria. We felt that this would
improve the generalisability of the study and aid recruitment.
To enhance participant safety, it was agreed that, from February 2015, participants should be excluded
from the study if they:
1. Had a lower limb amputation.
2. Were unable to walk household distances without the help of a walking aid such as a walking frame,
a walker or a person to assist. Participants who used one walking stick, however, were still eligible for
the study.
Orthoses
In the original protocol, we intended to use the same orthotic insole (Formthotics™, Foot Science
International, Sockburn, New Zealand) used by one of the authors (HBM) in an Australian study,23 as it
was found to be acceptable to participants and had been associated with a reduction in falls. However,
during the setup of the pilot phase of the study, podiatrists at the recruiting sites reported difficulties
using Formthotics, particularly in relation to fitting and modifying. Feedback from a group of podiatrists
at recruiting sites indicated that they frequently used an alternative range of orthotic insoles called the
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‘X-Line range’, as they were reportedly easier to fit in participant’s current shoes and easily modifiable.
In addition to basic functional foot support and control, cushioning properties were also identified as
desirable. Therefore, during the pilot phase of the study, 31 participants were given both a Formthotics
and an X-Line insole to take home and wear; they were then questioned about their insole preference.
As the majority of participants (84%, 26/31) preferred the X-Line range, it was decided to use it in the
main trial instead of the Formthotics insole.
Exercises
The exercises developed by one of the authors (HBM) for his Australian trial were reviewed and adapted to
take on board lessons learned from the study and to make them more suitable for a UK population.
Owing to cost and safety reasons the use of the Archxerciser™ device (Elgin Archxerciser Foot Exercisers,
Elgin Division, IL, USA) and marbles were replaced with a therapy ball, which simplified the toe exercises
using one device, reflecting current UK practice. Standing calf stretch exercises were adapted for an older
UK population by providing an option to use a firm belt/band to stretch while in a sitting position. A
further proprioception/balance training exercise was also added.
Additional criteria to expected adverse events
Following discussion with the Trial Management Group it was decided to include some additional expected
adverse events relating to wearing an orthotic insole or undertaking foot- and ankle-strengthening
exercises to the protocol. These included aches and pains in the lower limb for longer than 48 hours, new
callus/corn formation, blisters or ulcers, skin irritation/injury including pressure sores and soft tissue injury.
Provision of footwear
In the original protocol participants were to be provided with a voucher allowing them to purchase their
new footwear from participating designated shoe shops. However, this system became unworkable as the
number of sites increased and sites became more geographically dispersed. Participants therefore chose
their footwear from a catalogue of footwear reviewed and compiled by the research team for suitability.
These were then ordered directly from the company by the podiatrist. Footwear that did not fit the
participant could be returned to the supplier and exchanged for a different size.
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Chapter 4 Clinical effectiveness results
Participant flow
Participants were enrolled into the REFORM study from nine NHS trusts based in either primary or secondary
care in the UK (Harrogate and District NHS Foundation Trust; Sheffield Teaching Hospitals NHS Foundation
Trust; Leeds Community Healthcare NHS Trust; Solent NHS Trust; Kent Community Health NHS Foundation
Trust; Humber NHS Foundation Trust; Northern Lincolnshire and Goole NHS Foundation Trust; South Tyneside
NHS Foundation Trust; and North Tees and Hartlepool Hospitals NHS Foundation Trust) and one international
site in a university school of podiatry in Galway, Ireland. Harrogate and District NHS Foundation Trust was
split into four geographical locations, which were considered to serve distinct populations (Scarborough,
York, Harrogate and Skipton), thus forming 13 trial centres. A total of 42 podiatry clinics consented to screen
their practice lists and identify participants who met the initial inclusion criteria: those aged ≥ 65 years who
were registered with the service and had attended routine podiatry services within the past 6 months.
Patients who had attended high-risk clinics (e.g. a diabetes clinic) or who lived in a nursing home were
excluded from the invitation mail-out. In addition, sites were requested to screen out, when possible, patients
in the following groups: patients with a life expectancy of < 6 months, patients known to have dementia, a
neurodegenerative disorder, neuropathy or a lower limb amputation, and patients who were chair or
bed bound.
A total of 37,389 recruitment packs were mailed out to potential participants between October 2012 and
August 2014: 4428 background information forms (screening forms) were returned to the YTU, of which
3458 (78.1%) were also sent back with a valid consent form. Consenting participants were screened for
eligibility to the cohort and potentially eligible participants were sent a baseline questionnaire and a pack
of falls calendars (n = 2536). Of the 2389 participants who returned a baseline questionnaire, 88 did not
ever return a falls calendar; the remaining 2301 participants joined the epidemiological cohort. Within the
cohort, 990 participants were immediately eligible to be randomised, as they reported that they had had at
least one fall in the previous 12 months, or one fall in the previous 24 months requiring hospitalisation;
750 of these went on to be randomised into the main trial (participants could be randomised only as and
when there was capacity at the clinic to schedule them a baseline appointment). A further 234 participants
were randomised after a subsequent fall, and 26 participants were randomised when the eligibility criteria
were widened to include participants who had not had a fall but reported a fear of falling. A median of
47 participants were recruited from each centre (range 20–323).
Patents were mostly randomised 1 : 1, although at some sites the ratio was fixed depending on the number
of participants the clinic had capacity to see and the number of participants available to be randomised.
Of the 1010 participants randomised, 493 were allocated to the intervention group and 517 to the usual-
care group. The randomised number of 1010 participants exceeded that of the planned sample size of
890 participants. The flow of participants is illustrated in a Consolidated Standards of Reporting Trials
(CONSORT) diagram in Figure 2.
Pilot trial
During the pilot phase of the study, the following quantitative progression criteria were imposed to permit
continuation to the main trial: (1) recruit 580 participants to the REFORM cohort study and (2) randomise
70 participants to the REFORM pilot trial. By the end of November 2013, 972 participants had been
recruited to the REFORM cohort, and 78 had been randomised (39 participants per group) from York and
Scarborough podiatry clinics.
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Allocated to receive intervention
(n = 493)
• Received allocated intervention, n = 413
• Did not receive allocated intervention, n = 80
   • Declined to attend podiatry clinic, n = 47
   • Were not scheduled appointment, n = 31
   • Died before intervention received, n = 2
Allocated to usual care
(n = 517)
Invitation mail-outs 
(n = 37,389)
• Did not respond, n = 32,961
• Returned screening form but declined to 
   participate, n = 970
Excluded
 (n = 33,931)
Assessed for eligibility 
(n = 3458)
Enrolment
• Did not return baseline questionnaire, n = 147
• Did not return a falls calendar, n = 88
• Did not report a fall on screening or
   subsequent falls calendar, n = 914
• Not randomised for other reason (e.g. no 
   capacity at clinic), n = 377
Ineligible
(n = 922)
Randomised 
(n = 1010)
Allocation
Followed up with 6-month participant 
questionnaire
(n = 448)
• Died, n = 4
• Withdrew from trial, n = 28
• Did not return questionnaire, n = 13
   • Withdrew from treatment, n = 35
Followed up with 6-month participant 
questionnaire
(n = 480)
• Died, n = 7
• Withdrew from trial, n = 12
• Did not return questionnaire, n = 18
Followed up with 12-month participant 
questionnaire 
(n = 425)
• Died, n = 5
• Withdrew from trial, n = 16
• Did not return questionnaire, n = 15
   • Withdrew from treatment, n = 10
Followed up with 12-month participant
questionnaire 
(n = 460)
• Died, n = 8
• Withdrew from trial, n = 13
• Did not return questionnaire, n = 17
Follow-up
Analysed
(n = 484)
• Excluded from analysis, n = 9
   • Did not return a falls calendar post
      randomisation, n = 9
Analysed
(n = 507)
• Excluded from analysis, n = 10
   • Did not return a falls calendar post 
      randomisation, n = 9
   • Age covariate data missing, n = 1
Analysis
FIGURE 2 Consolidated Standards of Reporting Trials (CONSORT) flow diagram of participants in the REFORM
study. Reproduced from Cockayne et al.44 This is an open access article distributed under the terms of the Creative
Commons Attribution Licence (CC BY 4.0), which permits unrestricted use, distribution and reproduction in any
medium, provided the original author and source are credited (https://creativecommons.org/licenses/by/4.0/).
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Reasons for non-participation
In total, 567 potential participants provided a reason on a decline form for their decision not to participate
in the study (Table 2). The most commonly cited reason was not having an interest in the study (n = 330,
58.2%). Many of the ‘other’ reasons stated by participants could potentially fall into one of the other three
broad categories and included the participant feeling too old/unwell to take part, having too many other
commitments (e.g. being a carer to a partner) or feeling they would be unsuitable for the study as they do
not fall. Collection of this form ceased after the pilot phase of the study.
Trial completion and trial exit
Participants were able to withdraw from the study at any point. They were offered the options of
withdrawing from the intervention only or from all aspects of the study. Data were retained for all
participants who withdrew, as no participant specifically requested that their details be removed. Of the 493
(9.1%) participants in the intervention group, 45 (9.1%) formally withdrew from treatment, 38 (7.7%)
withdrew fully from the trial, 17 (3.5%) were withdrawn by the podiatrist, and there were 9 (1.8%) reported
deaths (including one participant who died shortly before they were randomised but whose death was only
reported later). These withdrawals were not necessarily mutually exclusive: six participants who withdrew
from treatment later went on to fully withdraw from the trial and one of the participants who died had
previously withdrawn from treatment. In the usual-care group, 28 out of 517 (5.4%) participants withdrew
from the trial and 15 out of 517 (2.9%) participants died (mutually exclusive participants). When reasons for
withdrawal were provided, these were grouped into common categories, which are listed in Table 3.
Timing of follow-up and response
The median time between completion of the screening form and baseline questionnaire for participants in
the entire cohort was 38 days. Owing to the study design, there was often a delay between completion
of the baseline questionnaire and randomisation (median 152 days, range 2–584 days). The timing of the
6- and 12-month participant questionnaires was based on the date of randomisation. Time between
randomisation and completion of the 6- and 12-month participant questionnaires and the time between
when the questionnaires were sent and returned is presented by randomised group in Table 4.
Questionnaire return rates by randomised group
The return rates for participant questionnaires administered at 6 and 12 months post randomisation and
exercise and orthosis diaries administered to intervention participants only at 3, 6 and 12 months are
presented in Table 5. The ‘expected’ columns take into account participants who withdrew or died before
the questionnaire was due to be completed. Response rates were consistently high in this trial; overall,
885 participants (87.6% of randomised participants) returned the 12-month participant questionnaire.
TABLE 2 Reasons for non-participation from the decline form (pilot phase only)
Reason for non-participationa Frequency (%)
I am not interested in taking part in this study 330 (58.2)
I feel too unwell to take part in this study 167 (29.5)
I do not have time to take part in this study 137 (24.2)
Other reason 107 (18.9)
a Participants could select more than one reason.
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TABLE 3 Details of full withdrawal from the trial by participant, full withdrawal by podiatrist (intervention group
only) and withdrawal from treatment (intervention group only)
Participation in the trial
Treatment group, n (%)
Total
(N= 1010), n (%)
Intervention
(N= 493)
Usual care
(N= 517)
Full participation 438 (88.8) 489 (94.6) 927 (91.8)
Withdrew from trial 38 (7.7) 28 (5.4) 66 (6.5)
Ill health 15 (3.0) 11 (2.1) 26 (2.6)
Relative is ill 3 (0.6) 0 (0.0) 3 (0.3)
Too busy 1 (0.2) 2 (0.4) 3 (0.3)
Feels cannot contribute/study is not relevant to them 2 (0.4) 3 (0.6) 5 (0.5)
Other 4 (0.8) 0 (0.0) 4 (0.4)
No reason given 13 (2.6) 12 (2.3) 25 (2.5)
Podiatrist withdrew participant from trial 17 (3.5) – –
Neuropathy in feet or poor mobility 9 (1.8) – –
Ill health 3 (0.6) – –
No reason given 5 (1.0) – –
Withdrawal from treatment 45 (9.1) – –
Ill health/mobility issues 12 (2.4) – –
Problem with interventiona 7 (1.4) – –
Declined to attend baseline appointment 5 (1.0) – –
Does not attend routine podiatry care 3 (0.6) – –
Too busy 3 (0.6) – –
Moved out of area 2 (0.4) – –
Clinic too far away 2 (0.4) – –
No reason given 11 (2.2) – –
a Prefers other exercises; shoes gave participant cellulitis; participant received insole and footwear from another podiatrist;
caused increased pain (n = 2); shoes too large and hurt feet; and participant not suitable for exercise.
TABLE 4 Timing of follow-up and time to response to participant questionnaires by randomised group
Time in days between time points
Treatment group
Total (N= 1010)Intervention (N= 493) Usual care (N= 517)
Mean
(SD)
Median
(minimum,
maximum)
Mean
(SD)
Median
(minimum,
maximum)
Mean
(SD)
Median
(minimum,
maximum)
Completion of baseline questionnaire
and randomisation
175.0
(133.3)
149
(2, 544)
183.1
(135.5)
161
(5, 584)
179.1
(134.4)
152
(2, 584)
Randomisation and completion of
6-month participant questionnaire
198.0
(13.8)
194
(180, 294)
196.5
(14.3)
193
(174, 279)
197.2
(14.0)
193
(174, 294)
Sent and returned dates for 6-month
participant questionnaire
16.4
(13.0)
13
(5, 111)
14.9
(14.4)
12
(4, 126)
15.6
(13.7)
12
(4, 126)
Randomisation and completion of
12-month participant questionnaire
376.9
(13.0)
373
(359, 467)
375.9
(13.0)
372
(337, 465)
376.4
(13.0)
373
(337, 467)
Sent and returned dates for 12-month
participant questionnaire
13.6
(10.0)
11
(4, 101)
12.1
(10.0)
10
(1, 147)
12.8
(10.0)
11
(1, 147)
SD, standard deviation.
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The intervention: package of podiatry care
Of the 493 participants allocated to receive the podiatry intervention, 412 (83.6%) attended at least one
podiatry appointment and one further participant had a telephone baseline appointment, as the podiatrist was
ill on both occasions on which appointments were booked. The trial protocol stated that participants were to
be invited to attend two podiatry visits, one as soon as possible after randomisation and another 2–4 weeks
later. Further appointments could be offered if required in addition to the participant’s routine podiatry care. In
total, 38 participants attended only one appointment and 375 had more than one contact with the podiatrist
(occasionally follow-up appointments were conducted over the telephone rather than in person). Participants
received a median of two podiatry appointments each (range 1–7 appointments). The first appointment
occurred a median of 22 days after randomisation (range 3–275 days) and the second appointment occurred a
median of 20 days after the first (range 6–184 days, with one outlier at 343 days for one participant who failed
to attend several follow-up appointments booked for them because of conflicting hospital appointments).
The reasons why the remaining 80 participants did not receive the intervention are detailed in Table 6.
The intervention was delivered by 28 podiatrists across the 13 centres. Podiatrists saw a median of
10 participants each (range 2–83 participants).
TABLE 5 Questionnaire return rates for randomised participants by treatment group
Questionnaire
Treatment group, n (%)
Total (N= 1010), n (%)aIntervention (N= 493)a Usual care (N= 517)a
Expected Received Expected Received Expected Received
Questionnaire
6 months 461 (93.5) 448 (97.2) 498 (96.3) 480 (96.4) 959 (95.0) 928 (96.8)
12 months 440 (89.2) 425 (96.6) 477 (92.3) 460 (96.4) 917 (91.8) 885 (96.5)
Intervention diary
3 months 476 (96.6) 457 (96.0) – – – –
6 months 461 (93.5) 427 (92.6) – – – –
12 months 440 (89.2) 408 (92.7) – – – –
a Percentages given out of number randomised for expected column and number expected for received column.
TABLE 6 Compliance with the intervention
Intervention received, or reason participant did not receive intervention Intervention (N= 493), n (%)
Attended at least one podiatry appointment 413 (83.8)
Was offered but declined baseline appointmenta 47 (9.5)
Was not made an appointmentb 31 (5.3)
Died shortly before or after randomisation 2 (0.4)
a Declined appointment when contacted (e.g. did not want to take part, too busy, unknown reason), n= 18; declined
appointment because of ill health, n= 7; cancelled or did not attend scheduled appointment, n= 22.
b No capacity to be seen, n= 9; participant not receiving routine podiatry care, n= 8; podiatrist felt participant not suitable
for intervention because of ill health, n= 5; participant moved out of area, n= 2; unknown reason, n= 7.
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Package of podiatry care
A baseline appointment form completed by the treating podiatrist was received for 380 participants. From this,
we can summarise details of the intervention delivered, when this was provided. Twenty of 351 participants
(5.7%) were reported as currently wearing custom-made shoes. Of the 364 participants who had their usual
outdoor footwear assessed by the podiatrist at this visit, 249 (68.4%) were deemed to be wearing appropriate
footwear; therefore, 115 (31.6%) exhibited a feature that made the shoes a risk for falling. The most common
reason was inappropriate fixation/fastening (n= 81, 70.4%), followed by an inappropriate heel counter
(n= 57, 49.5%), incorrect size (n= 43, 37.4%), unsuitable sole (n = 42, 36.5%), inappropriate heel width
(n= 17, 14.8%) and excessive heel height (n = 15, 13.0%). New footwear was provided to 260 (52.7% of
493, 63.0% of 413) intervention participants throughout the course of the trial.
At the baseline appointment, 115 out of 363 (31.7%) participants were currently wearing an insole.
The type of current insole being used was not recorded for six participants, and two participants reported
wearing two different types of insole in different shoes or for different occasions. The most common type
of insole being used was a simple flat-bed insole (n = 37, 32.2%), followed by a contoured prefabricated
insole with simple modification (n = 25, 21.7%), a bespoke total contact insole (n = 23, 20.0%), a simple
contoured prefabricated insole (n = 21, 18.2%) and a contoured prefabricated insole with complex
modifications (n = 5, 4.4%).
An orthotic insole was fitted for 241 of the 413 (58.4%) participants who received the intervention (X-Line
blue, n = 209; X-Line red, n = 23; Formthotics, n = 9). A therapy ball and theraband were prescribed for
355 (93.4%) and 358 (94.2%) participants, respectively, of the 380 for whom we have this information.
Screening and baseline characteristics
Data collected on the screening form are summarised for consenting participants and those who declined
to participate but completed a screening form in Tables 7–9. Consenting participants appear to be more
TABLE 7 Demographic information for individuals who returned a screening form stratified by whether or not
they consented to take part in the study (N= 4428)
Characteristic
Consent
(N= 3458)
Did not consent
(N= 970)
Total
(N= 4428)
Age (years)*
Mean (SD) 76.7 (7.1) 78.8 (7.5) 77.1 (7.2)
Median (minimum, maximum) 77 (64, 99) 79 (64, 99) 77 (64, 99)
Sex, n (%)*
Male 1621 (47.1) 381 (40.5) 2002 (45.7)
Female 1819 (52.9) 559 (59.5) 2378 (54.3)
Ethnic group, n (%)
White 3386 (98.8) 905 (97.6) 4291 (98.5)
Asian or Asian British 18 (0.5) 11 (1.2) 29 (0.7)
Black or Black British 19 (0.6) 8 (0.9) 27 (0.6)
Other 6 (0.2) 3 (0.3) 9 (0.2)
Willing to attend local podiatry clinic if required, n (%)* 1800 (52.1) 298 (30.7) 2098 (47.4)
*p< 0.05.
SD, standard deviation.
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physically able than those who chose not to participate (e.g. tended to be slightly younger, more likely to
be willing to attend their local podiatry clinic if required and more likely to be able to walk 10 metres
unaided); however, they also appeared to be at a higher risk of falling (e.g. more likely to require a
modification to shoes or wear an insole, to have had a previous fall or have concern about falling).
Characteristics for all participants in the cohort (eligible, consenting participants who returned a baseline
questionnaire and at least one falls calendar, n = 2301) at screening and baseline are presented in
Tables 10–12. The average age of participants in the cohort was 76 years (range 64–99 years), and 44.3%
were male (n = 1015). One-third of participants reported experiencing at least one fall in the 12 months
prior to completing the screening questionnaire (n = 784, 34.1%). The median number of falls reported in
this time was two; however, participants reported up to 60 falls in this time.
TABLE 8 Clinical information for individuals who returned a screening form stratified by whether or not they
consented to take part in the study (N= 4428)
Characteristic
Consent
(N= 3458), n (%)
Did not consent
(N= 970), n (%)
Total
(N= 4428), n (%)
Able to walk for 10 metres unaided* 2987 (86.4) 711 (73.3) 3698 (83.5)
Had lower limb surgery in the previous 3 months 109 (3.2) 23 (2.4) 132 (3.0)
Lower limb surgery planned in the next 6 months* 94 (2.7) 13 (1.3) 107 (2.4)
Has had any toe or lower limb amputations 98 (2.8) 18 (1.9) 116 (2.6)
Requires modifications to shoes* 556 (16.1) 122 (12.6) 678 (15.3)
Currently wearing an insole or orthosis* 1156 (33.4) 201 (20.7) 1357 (30.7)
Comorbiditiesa
ALS/Lou Gehrig’s disease 21 (0.6) 5 (0.5) 26 (0.6)
Alzheimer’s disease* 38 (1.1) 27 (2.8) 65 (1.5)
Arthritis* 1945 (56.3) 472 (48.7) 2417 (54.6)
Dementia* 52 (1.5) 43 (4.4) 95 (2.2)
Depression* 345 (10.0) 76 (7.8) 421 (9.5)
Diabetes 1339 (38.7) 374 (38.6) 1713 (38.7)
Dizziness/vertigo* 642 (18.6) 152 (15.7) 794 (17.9)
Huntington’s disease 22 (0.6) 7 (0.7) 29 (0.7)
Ménière’s disease/conditions affecting balance 142 (4.1) 29 (3.0) 171 (3.9)
Multiple sclerosis 25 (0.7) 9 (0.9) 34 (0.8)
Numbness or tingling in feet or lower limbs* 1067 (30.9) 222 (22.9) 1289 (29.1)
Osteoporosis 466 (13.5) 122 (12.6) 588 (13.3)
Parkinson’s disease 61 (1.8) 15 (1.6) 76 (1.7)
*p < 0.05.
ALS, amyotrophic lateral sclerosis.
a Participant could select more than one option.
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TABLE 10 Demographic and clinical information for participants in the cohort (N= 2301)
Characteristic Cohort (N= 2301)
Age (years)
Mean (SD) 76.7 (7.0)
Median (minimum, maximum) 77 (64,a 99)
Sex, n (%)
Male 1015 (44.3)
Female 1279 (55.8)
BMI (kg/m2)
Mean (SD) 27.6 (5.2)
Median (IQR) 27.0 (24.0–30.5)
Ethnic group, n (%)
White 2267 (99.1)
Asian or Asian British 8 (0.4)
Other 9 (0.4)
Missing 4 (0.2)
TABLE 9 Data collected on falls, fear of falling and injuries for individuals who returned a screening form stratified
by whether or not they consented to take part in the study (N= 4428)
Characteristic
Consent
(N= 3458)
Did not consent
(N= 970)
Total
(N= 4428)
Experienced at least one fall in previous 12 months, n (%)* 1342 (38.8) 283 (29.2) 1625 (36.7)
If yes, number of falls,* median (minimum, maximum) 2 (1, 90) 2 (1, 24) 2 (1, 90)
Experienced at least one fall in previous 24 months, n (%)* 1581 (45.7) 323 (33.3) 1904 (43.0)
If yes, did any require hospitalisation?, n (%)* 518/1581 (32.8) 137/323 (42.4) 655/1904 (34.4)
Worried about falling during previous 4 weeks, n (%)*
All of the time 199 (5.8) 48 (5.3) 247 (5.7)
Most of the time 193 (5.6) 51 (5.6) 244 (5.6)
A good bit of the time 242 (7.1) 35 (3.9) 277 (6.4)
Some of the time 619 (18.0) 144 (15.9) 763 (17.6)
A little of the time 894 (26.0) 162 (17.9) 1056 (24.3)
None of the time 1288 (37.5) 465 (51.4) 1753 (40.4)
Broken a bone in the previous 12 months, n (%)a 146 (4.2) 44 (4.5) 190 (4.3)
*p< 0.05.
a Participants reported one broken bone (consent, n = 128; did not consent, n= 37), two broken bones (consent, n = 16;
did not consent, n= 7) or three broken bones (consent, n= 2; did not consent, n = 0).
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TABLE 10 Demographic and clinical information for participants in the cohort (N= 2301) (continued )
Characteristic Cohort (N= 2301)
Living arrangements, n (%)b
Lives alone 925 (40.2)
Lives with a partner or spouse 1257 (54.6)
Lives with a friend or relative 97 (4.2)
Lives in sheltered accommodation 69 (3.0)
Education continued after minimum school leaving age, n (%) 1227 (53.3)
Has degree or equivalent professional qualification, n (%) 758 (32.9)
Comorbidities, n (%)b
ALS/Lou Gehrig’s disease 4 (0.2)
Alzheimer’s disease 6 (0.3)
Arthritis 1234 (53.6)
Dementia 4 (0.2)
Depression 185 (8.0)
Diabetes 834 (36.3)
Dizziness/vertigo 368 (16.0)
Huntington’s disease 5 (0.2)
Ménière’s disease/conditions affecting balance 67 (2.9)
Multiple sclerosis 4 (0.2)
Numbness or tingling in feet or lower limbs 373 (16.2)
Osteoporosis 289 (12.6)
Parkinson’s disease 5 (0.2)
Taking more than four medications prescribed by a doctor, n (%) 1347 (58.5)
Able to walk for 10 metres unaided, n (%)a 2144 (93.2)
Had lower limb surgery in the previous 3 months, n (%) 56 (2.4)
Lower limb surgery planned in the next 6 months, n (%)a 35 (1.5)
Has had any toe or lower limb amputations, n (%) 8 (0.4)
Requires modifications to shoes, n (%) 301 (13.1)
Currently wearing an insole or orthosis, n (%) 739 (32.1)
ALS, amyotrophic lateral sclerosis; BMI, body mass index; IQR, interquartile range; SD, standard deviation.
a A small (n= 7) number of participants were aged 64 years when they returned their baseline questionnaire. As they
were all less than 6 months from turning 65 years old, the decision was made to retain these participants in the cohort
but randomise them only when they had turned 65 years.
b The participant could select more than one option.
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Data collected at screening and baseline are presented for all 1010 randomised participants (intervention,
n = 493; usual care, n = 517) in Tables 13–16. The average age of the trial participants was 77 years
(range 65–99 years) and 39.6% were male (n = 400). The proportion of participants currently wearing an
orthotic insole was slightly higher in the intervention group than in the usual-care group (38.7% vs.
31.5%), as was the proportion who reported at least one fall in the 6 months prior to baseline (51.5% vs.
47.6%); otherwise, the randomised groups appear comparable.
TABLE 11 Data collected at screening on falls, fear of falling and injuries for participants in the cohort (N= 2301)
Characteristic Cohort (N= 2301)
Experienced at least one fall in previous 12 months, n (%) 784 (34.1)
If yes, number of falls, median (minimum, maximum) 2 (1, 60)
Experienced at least one fall in previous 24 months, n (%) 955 (42.0)
If yes, did any require hospitalisation?, n (%) 292/955 (30.6)
Worried about falling during previous 4 weeks, n (%)
All of the time 72 (3.1)
Most of the time 90 (3.9)
A good bit of the time 125 (5.5)
Some of the time 379 (16.5)
A little of the time 651 (28.4)
None of the time 976 (42.6)
Broken a bone in the previous 12 months, n (%)a 87 (3.8)
a Participants reported one broken bone (n= 76), two broken bones (n= 10) or three broken bones (n= 1).
TABLE 12 Data collected at baseline on falls and fear of falling for participants in the cohort (N= 2301)
Characteristic Cohort (N= 2301)
Experienced at least one fall in previous 6 months, n (%) 647 (28.1)
If yes, number of falls, median (minimum, maximum) 1 (1, 30)
Worried about falling during previous 4 weeks, n (%)
All of the time 72 (3.2)
Most of the time 98 (4.3)
A good bit of the time 130 (5.7)
Some of the time 396 (17.4)
A little of the time 732 (32.1)
None of the time 851 (37.3)
Referred to a falls clinic/service, n (%) 103 (4.5)
CLINICAL EFFECTIVENESS RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
34
TABLE 13 Demographic information for randomised participants by randomised group (N = 1010)
Characteristic
Treatment group
Total (N= 1010)
Intervention
(N= 493)
Usual care
(N= 517)
Age (years)
Mean (SD) 78.1 (7.2) 77.7 (7.0) 77.9 (7.1)
Median (minimum, maximum) 78 (65, 96) 78 (65, 99) 78 (65, 99)
Sex, n (%)
Male 190 (38.5) 210 (40.6) 400 (39.6)
Female 303 (61.5) 307 (59.4) 610 (60.4)
BMI (kg/m2)
Mean (SD) 27.6 (5.3) 27.7 (5.4) 27.6 (5.4)
Median (IQR) 26.9 (23.9–30.6) 27.1 (24.1–30.6) 27.0 (24.0–30.6)
Ethnic group, n (%)
White 492 (99.8) 510 (98.7) 1002 (99.2)
Asian or Asian British 0 (0.0) 2 (0.4) 2 (0.2)
Other 0 (0.0) 2 (0.4) 2 (0.2)
Missing 1 (0.2) 3 (0.6) 4 (0.4)
Living arrangements, n (%)a
Lives alone 236 (47.9) 220 (42.6) 456 (45.2)
Lives with a partner or spouse 230 (46.7) 266 (51.5) 496 (49.1)
Lives with a friend or relative 22 (4.5) 27 (5.2) 49 (4.9)
Lives in sheltered accommodation 19 (3.9) 14 (2.7) 33 (3.3)
Education continued after minimum school leaving age, n (%) 269 (54.6) 296 (57.3) 565 (55.9)
Has degree or equivalent professional qualification, n (%) 170 (34.5) 194 (37.5) 364 (36.0)
BMI, body mass index; IQR, interquartile range; SD, standard deviation.
a Participant could select more than one option.
TABLE 14 Clinical information for randomised participants by randomised group (N= 1010)
Characteristic
Treatment group, n (%)
Total (N= 1010),
n (%)
Intervention
(N= 493)
Usual care
(N= 517)
Comorbiditiesa
Arthritis 292 (59.2) 300 (58.0) 592 (58.6)
Depression 49 (9.9) 48 (9.3) 97 (9.6)
Diabetes 158 (32.1) 175 (33.9) 333 (33.0)
Dizziness/vertigo 107 (21.7) 95 (18.4) 202 (20.0)
Ménière’s disease/conditions affecting balance 21 (4.3) 15 (2.9) 36 (3.6)
Numbness or tingling in feet or lower limbs 76 (15.4) 85 (16.4) 161 (15.9)
Osteoporosis 86 (17.4) 65 (12.6) 151 (15.0)
Taking more than four medications prescribed by a doctor 313 (63.5) 304 (58.8) 617 (61.1)
Requires modifications to shoes 67 (13.6) 69 (13.4) 136 (13.5)
Currently wearing an insole or orthosis 191 (38.7) 163 (31.5) 354 (35.1)
a Participant could select more than one option. One participant (in the usual-care group) with dementia was randomised
even though this was an exclusion criteria.
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Primary outcome
Raw data
In total, 992 (98.2%) trial participants returned at least one falls calendar following randomisation
[intervention, n = 484, 98.2%; usual care, n = 508, 98.3%], with 762 (75.5%) returning a complete
12 months’ worth of calendars post randomisation (intervention, n = 360, 73.0%; usual care, n = 402,
77.8%). In total, 1423 falls were reported: 661 in the intervention group (median 1 fall, range 0–23 falls)
over a median of 365 days (range 6–365 days), and 762 in the usual-care group (median 1 fall, range
0–28 falls) over a median of 365 days (range 27–365 days) (Figures 3 and 4).
TABLE 15 Data collected at screening on falls, fear of falling and injuries for randomised participants by randomised
group (N = 1010)
Characteristic
Treatment group
Total
(N= 1010)
Intervention
(N= 493)
Usual care
(N= 517)
Experienced at least one fall in previous 12 months, n (%) 325 (65.9) 332 (64.2) 657 (65.0)
If yes, number of falls, median (minimum, maximum) 2 (1, 25) 2 (1, 20) 2 (1, 25)
Experienced at least one fall in previous 24 months, n (%) 329 (66.7) 330 (63.8) 659 (65.2)
If yes, did any require hospitalisation?, n (%) 113/329 (34.4) 99/330 (30.0) 212/659 (32.2)
Worried about falling during previous 4 weeks, n (%)
All of the time 23 (4.7) 22 (4.3) 45 (4.5)
Most of the time 30 (6.1) 25 (4.9) 55 (5.5)
A good bit of the time 42 (8.5) 43 (8.4) 85 (8.4)
Some of the time 100 (20.3) 129 (25.1) 229 (22.7)
A little of the time 168 (34.1) 154 (29.9) 322 (31.9)
None of the time 130 (26.4) 142 (27.6) 272 (27.0)
Broken a bone in the previous 12 months, n (%) 38 (7.7) 27 (5.2) 65 (6.4)
Bones broken, n (%)a
Crown or facial bone 1 (2.6) 0 (0.0) 1 (1.5)
Breast or collar bone 1 (2.6) 0 (0.0) 1 (1.5)
Rib 4 (10.5) 2 (7.4) 1 (1.5)
Back or spine 1 (2.6) 2 (7.4) 3 (4.6)
Shoulder 5 (13.2) 2 (7.4) 7 (10.8)
Arm 3 (7.9) 3 (11.1) 6 (9.2)
Wrist 8 (21.1) 6 (22.2) 14 (21.5)
Hand or finger 1 (2.6) 4 (14.8) 5 (7.7)
Hip or pelvis 2 (5.3) 2 (7.4) 4 (6.2)
Leg 4 (10.5) 4 (14.8) 8 (12.3)
Ankle 3 (7.9) 2 (7.4) 5 (7.7)
Foot or toe 11 (29.0) 3 (11.1) 14 (21.5)
a Percentage of participants reporting at least one broken bone in previous 12 months; participants reported one broken
bone (intervention, n= 33; usual care, n= 24), two broken bones (intervention, n= 4; usual care, n= 3) or three broken
bones (intervention, n = 1; usual care, n= 0).
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TABLE 16 Data collected at baseline on falls and fear of falling for randomised participants by randomised group
(N= 1010)
Characteristic
Treatment group
Total
(N= 1010)
Intervention
(N= 493)
Usual care
(N= 517)
Experienced at least one fall in previous 6 months, n (%) 254 (51.5) 246 (47.6) 500 (49.5)
If yes, number of falls, median (minimum, maximum) 1 (1, 20) 1 (1, 8) 1 (1, 20)
Worried about falling during previous 4 weeks, n (%)
All of the time 24 (4.9) 18 (3.5) 42 (4.2)
Most of the time 40 (8.2) 27 (5.3) 67 (6.7)
A good bit of the time 47 (9.6) 42 (8.2) 89 (8.9)
Some of the time 109 (22.2) 138 (27.0) 247 (24.6)
A little of the time 165 (33.6) 178 (34.8) 343 (34.2)
None of the time 106 (21.6) 109 (21.3) 215 (21.4)
Referred to a falls clinic/service, n (%) 32 (6.5) 35 (6.8) 67 (6.6)
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FIGURE 3 Histogram displaying the distribution of the number of falls by treatment group. (a) Intervention; and
(b) usual care.
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Information, such as the cause and location, was available for 1172 (82.7%) falls (intervention, n = 549,
83.3%; usual care, n = 623, 82.1%; Table 17). Over one-third of the falls were reportedly caused by a trip
(n = 457, 39%), and an injury was sustained in over half of the falls (n = 655, 55.9%). These injuries
include 31 broken bones (from 17 falls in the intervention group and 14 in usual care). The most common
bones broken in a fall were the hip or bones in the hand (n = 5 each).
Covariates
The primary analysis model controlled for sex, age at randomisation and history of falling. The age of one
participant in the usual-care group was not available so the primary model was based on 991 participants
(484 in the intervention group and 507 in the usual-care group).
Screening and baseline data for participants analysed in the primary model
Data collected on the screening form and baseline questionnaire are presented by randomised group for the
991 participants included in the primary analysis (‘as analysed’ population; Tables 18–21). The composition
of the analysis groups is virtually identical to that at randomisation, indicating that the loss of the 19
participants from the primary analysis has not introduced any selection bias.
Number of falls by centre
A summary of the number of falls for participants contributing to the primary analysis is presented by
centre in Table 22, in order of largest to smallest contributing centre.
Primary analysis
The adjusted negative binomial model indicated a non-statistically significant reduction in the fall rate in
the intervention group relative to usual care (IRR 0.88, 95% CI 0.73 to 1.05; p = 0.16). History of falling
was seen to be a significant predictor in the model (IRR 2.10, 95% CI 1.74 to 2.54; p < 0.001; Table 23).
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FIGURE 4 Histogram displaying the distribution of the length of follow-up for falls data by treatment group.
(a) Intervention; and (b) usual care.
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TABLE 17 Details relating to the cause and location of the falls reported
Information about fall
Treatment group, n (%)
Total
(N= 1172), n (%)
Intervention
(N= 549)
Usual care
(N= 623)
Cause of/reason for fall
Trip 205 (37.3) 252 (40.5) 457 (39.0)
Slip 55 (10.0) 76 (12.2) 131 (11.2)
Turning 51 (9.3) 42 (6.7) 93 (7.9)
Legs gave way 50 (9.1) 67 (10.8) 117 (10.0)
Dizzy 23 (4.2) 34 (5.5) 57 (4.9)
Lost balance 60 (10.9) 48 (7.7) 108 (9.2)
Unknown/cannot remember 48 (8.7) 42 (6.7) 90 (7.7)
Other 70 (12.8) 77 (12.4) 147 (12.5)
Location of fall
Inside own home 221 (40.3) 263 (42.2) 484 (41.3)
Inside, but not in own home 40 (7.3) 54 (8.7) 94 (8.0)
Outside 259 (47.2) 280 (44.9) 539 (46.0)
Missing 29 (5.3) 26 (4.2) 55 (4.7)
If fall was inside, was it . . ?
On one level 169 (64.5) 195 (61.5) 364 (62.9)
Accessing shower/bath 6 (2.3) 23 (7.3) 29 (5.0)
Getting out of bed 17 (6.5) 23 (7.3) 40 (6.9)
Getting out of a chair 22 (8.4) 19 (6.0) 41 (7.1)
Walking up or down stairs 42 (16.0) 52 (16.4) 94 (16.2)
Accessing the toilet 6 (2.3) 5 (1.6) 11 (1.9)
If fall was outside, was it. . ?
Car park/driveway 16 (6.2) 13 (4.6) 29 (5.4)
Crossing a street 4 (1.5) 8 (2.9) 12 (2.2)
Garden/grassed area 73 (28.2) 76 (27.1) 149 (27.6)
Getting in or out of a vehicle 5 (1.9) 5 (1.8) 10 (1.9)
On a bus or train 3 (1.2) 1 (0.4) 4 (0.7)
On a footpath 77 (29.7) 86 (30.7) 163 (30.2)
On a kerb 13 (5.0) 13 (4.6) 26 (4.8)
On a step/escalator 18 (7.0) 29 (10.4) 47 (8.7)
On one level 8 (3.1) 11 (3.9) 19 (3.5)
Other 27 (10.4) 21 (7.5) 48 (8.9)
Missing 15 (5.8) 17 (6.1) 32 (5.9)
Footwear worn
Barefoot 45 (8.2) 66 (10.6) 111 (9.5)
Slippers 126 (23.0) 121 (19.4) 247 (21.1)
Shoes/boots 292 (53.2) 332 (53.3) 624 (53.4)
continued
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TABLE 17 Details relating to the cause and location of the falls reported (continued )
Information about fall
Treatment group, n (%)
Total
(N= 1172), n (%)
Intervention
(N= 549)
Usual care
(N= 623)
Wellington boots 11 (2.0) 4 (0.6) 15 (1.3)
Flip-flops/sandals 22 (4.0) 36 (5.8) 58 (5.0)
Cannot remember 24 (4.4) 34 (5.5) 58 (5.0)
Missing 29 (5.3) 30 (4.8) 59 (5.0)
Using a walking aid
Yes 83 (15.1) 91 (14.6) 174 (14.9)
No 414 (75.4) 483 (77.5) 897 (76.5)
Missing 52 (9.5) 49 (7.9) 101 (8.6)
Wearing an insole or orthosis
Yes 200 (36.4) 135 (21.7) 335 (28.6)
No 289 (52.6) 410 (65.8) 699 (59.6)
Missing 60 (10.9) 78 (12.5) 138 (11.8)
Injuries suffered
None 195 (35.5) 259 (41.6) 454 (38.7)
Superficial 305 (55.6) 319 (51.2) 624 (53.2)
Broken bone 17 (3.1) 14 (2.3) 31 (2.7)
Missing 32 (5.8) 31 (5.0) 63 (5.4)
Bones broken
Crown or facial bone 1 (5.9) 0 (0.0) 1 (3.2)
Breast or collar bone 0 (0.0) 0 (0.0) 0 (0.0)
Rib 2 (11.8) 1 (7.1) 3 (9.7)
Back or spine 1 (5.9) 0 (0.0) 1 (3.2)
Shoulder 2 (11.8) 0 (0.0) 2 (6.5)
Arm 0 (0.0) 1 (7.1) 1 (3.2)
Wrist 1 (5.9) 14 (14.3) 3 (9.7)
Hand or finger 2 (11.8) 3 (21.4) 5 (16.1)
Hip or pelvis 3 (17.7) 14 (14.3) 5 (16.1)
Leg 1 (5.9) 1 (7.1) 2 (6.5)
Ankle 1 (5.9) 0 (0.0) 1 (3.2)
Foot or toe 2 (11.8) 14 (14.3) 4 (12.9)
Other/unknown 1 (5.9) 14 (14.3) 3 (9.7)
Overnight stay in hospital required
Yes 15 (2.7) 16 (2.6) 31 (2.7)
No 473 (86.2) 527 (84.6) 1000 (85.3)
Missing 61 (11.1) 80 (12.8) 141 (12.0)
If yes, how many nights?
Median (minimum, maximum) 7 (1, 21) 5 (1, 21) 6 (1, 21)
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TABLE 18 Demographic information for ‘as analysed’ participants by randomised group (N= 991)
Characteristic
Treatment group
Total (N= 991)
Intervention
(N= 484)
Usual care
(N= 507)
Age (years)
Mean (SD) 78.1 (7.2) 77.6 (7.0) 77.8 (7.1)
Median (minimum, maximum) 78 (65, 96) 78 (65, 99) 78 (65, 99)
Sex, n (%)
Male 189 (39.1) 207 (40.8) 396 (40.0)
Female 295 (61.0) 300 (59.2) 595 (60.0)
BMI (kg/m2)
Mean (SD) 27.6 (5.3) 27.7 (5.4) 27.6 (5.4)
Median (IQR) 27.0 (23.9–30.6) 27.1 (24.1–30.6) 27.1 (24.0–30.6)
Ethnic group, n (%)
White 483 (99.8) 500 (98.6) 983 (99.2)
Asian or Asian British 0 (0.0) 2 (0.4) 2 (0.2)
Other 0 (0.0) 2 (0.4) 2 (0.2)
Missing 1 (0.2) 3 (0.6) 4 (0.4)
Living arrangements, n (%)a
Lives alone 230 (47.5) 214 (42.2) 444 (44.8)
Lives with a partner or spouse 227 (46.9) 262 (51.7) 489 (49.3)
Lives with a friend or relative 22 (4.6) 27 (5.3) 49 (4.9)
Lives in sheltered accommodation 18 (3.7) 14 (2.8) 32 (3.2)
Education continued after minimum school leaving age, n (%) 263 (54.3) 289 (57.0) 552 (55.7)
Has degree or equivalent professional qualification, n (%) 167 (34.5) 191 (37.7) 358 (36.1)
BMI, body mass index; IQR, interquartile range; SD, standard deviation.
a Participant could select more than one option.
TABLE 19 Clinical information for ‘as analysed’ participants by randomised group (N= 991)
Characteristic
Treatment group, n (%)
Total (N= 991),
n (%)
Intervention
(N= 484)
Usual care
(N= 507)
Comorbiditiesa
Arthritis 286 (59.1) 290 (57.2) 576 (58.1)
Depression 46 (9.5) 48 (9.5) 94 (9.5)
Diabetes 155 (32.0) 168 (33.1) 323 (32.6)
Dizziness/vertigo 102 (21.1) 91 (18.0) 193 (19.5)
Ménière’s disease/conditions affecting balance 20 (4.1) 15 (3.0) 35 (3.5)
Numbness or tingling in feet or lower limbs 76 (15.7) 83 (16.4) 159 (16.0)
Osteoporosis 83 (17.2) 65 (12.8) 148 (14.9)
Taking more than four medications prescribed by a doctor 305 (63.0) 297 (58.6) 602 (60.8)
Requires modifications to shoes 67 (13.8) 68 (13.4) 135 (13.6)
Currently wearing an insole or orthosis 189 (39.1) 161 (31.8) 350 (35.3)
a Participant could select more than one option.
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TABLE 20 Data collected at screening on falls, fear of falling and injuries for ‘as analysed’ participants by
randomised group (N= 991)
Characteristic
Treatment group
Total
(N= 991)
Intervention
(N= 484)
Usual care
(N= 507)
Experienced at least one fall in previous 12 months, n (%) 319 (65.9) 323 (63.7) 642 (64.8)
If yes, number of falls, median (minimum, maximum) 2 (1, 25) 1 (1, 20) 2 (1, 25)
Experienced at least one fall in previous 24 months, n (%) 323 (66.7) 321 (63.3) 644 (65.0)
If yes, did any require hospitalisation?, n (%) 110/323 (34.1) 96/321 (29.9) 206/644 (32.0)
Worried about falling during previous 4 weeks, n (%)
All of the time 22 (4.6) 21 (4.2) 43 (4.4)
Most of the time 27 (5.6) 24 (4.8) 51 (5.2)
A good bit of the time 42 (8.7) 41 (8.1) 83 (8.4)
Some of the time 100 (20.7) 128 (25.4) 228 (23.1)
A little of the time 163 (33.7) 151 (29.9) 314 (31.8)
None of the time 130 (26.9) 140 (27.7) 270 (27.3)
Broken a bone in the previous 12 months, n (%)a 36 (7.4) 27 (5.3) 63 (6.4)
a Percentage of participants reporting at least one broken bone in previous 12 months; participants reported one broken
bone (intervention, n= 31; usual care, n= 24), two broken bones (intervention, n= 4; usual care, n= 3) or three broken
bones (intervention, n = 1; usual care, n= 0).
TABLE 21 Data collected at baseline on falls and fear of falling for ‘as analysed’ participants by randomised
group (N= 991)
Characteristic
Treatment group
Total
(N= 991)
Intervention
(N= 484)
Usual care
(N= 507)
Experienced at least one fall in previous 6 months, n (%) 248 (51.2) 246 (47.6) 500 (49.5)
If yes, number of falls, median (minimum, maximum) 1 (1, 20) 1 (1, 8) 1 (1, 20)
Worried about falling during previous 4 weeks, n (%)
All of the time 22 (4.6) 18 (3.6) 40 (4.1)
Most of the time 40 (8.3) 26 (5.2) 66 (6.7)
A good bit of the time 44 (9.1) 40 (8.0) 84 (8.5)
Some of the time 106 (22.0) 137 (27.3) 243 (24.7)
A little of the time 165 (34.2) 173 (34.5) 338 (34.4)
None of the time 105 (21.8) 108 (21.5) 213 (21.7)
Referred to a falls clinic/service, n (%) 30 (6.2) 35 (6.9) 65 (6.6)
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Little difference in the estimate of the treatment effect was observed when centre was included as a fixed,
as opposed to a random, effect in the primary analysis model in a sensitivity analysis (IRR 0.88, 95% CI
0.73 to 1.07; p = 0.20).
Sensitivity analyses
Non-compliance
When non-compliance with the intervention was accounted for using an instrumental variable CACE
analysis approach, the intervention was seen to have a marginally greater benefit than in the ITT analysis
but the conclusions were otherwise consistent (IRR 0.86, 95% CI 0.69 to 1.06; p = 0.16).
TABLE 22 Summary of the number of falls by centre
Centre
Number of participants contributing
to primary analysis
Number of falls
Mean (SD) Median (minimum, maximum)
1 320 1.4 (2.2) 1 (0, 15)
2 131 1.6 (3.0) 1 (0, 23)
3 102 1.3 (2.0) 1 (0, 10)
4 91 1.5 (2.4) 0.5 (0, 10)
5 63 0.8 (1.4) 0 (0, 6)
6 56 1.9 (3.2) 1 (0, 18)
7 46 1.5 (2.3) 1 (0, 13)
8 41 1.6 (2.7) 1 (0, 15)
9 38 1.6 (2.9) 1 (0, 17)
10 31 2.2 (5.1) 1 (0, 28)
11 27 1.1 (1.3) 1 (0, 5)
12 26 1.2 (1.6) 0.5 (0, 6)
13 19 1.1 (1.7) 0 (0, 6)
SD, standard deviation.
TABLE 23 Model parameters from the primary analysis for incidence rate of falls
Variable IRR (standard error) 95% CI (p-value)
Allocation (0, usual care; 1, intervention) 0.88 (0.08) 0.73 to 1.05 (p= 0.16)
Sex (0, female; 1, male) 1.10 (0.10) 0.91 to 1.32 (p= 0.33)
Age at randomisation (years) 1.01 (0.01) 0.99 to 1.02 (p= 0.31)
History of falling (0, fewer than two falls in 12 months
before screening; 1, more than two falls)
2.10 (0.20) 1.74 to 2.54 (p< 0.001)
Constant 0.002 (0.001) < 0.001 to 0.005 (p< 0.001)
DOI: 10.3310/hta21240 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 24
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Cockayne et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
43
Podiatrist effects
A single podiatrist appeared to deliver the intervention to all participants in 6 of the 13 centres. In the
other seven centres, two, three, four (two centres each) or six (one centre) podiatrists held intervention
appointments. Counterfactual podiatrists were assigned to the 80 participants in the intervention group
who did not receive the intervention and the 517 usual care participants. Repeating the primary analysis
with podiatrist as a random effect in the place of centre had a negligible effect on the treatment estimate
(IRR 0.88, 95% CI 0.73 to 1.05; p = 0.16).
Baseline imbalance by chance
A sensitivity analysis of the primary outcome was planned, which adjusted the model for any
pre-randomisation variables found to be imbalanced by chance between the randomised groups, namely
proportion of participants wearing an insole, number of falls in 6 months prior to completion of baseline
questionnaire and total FAI score. However, owing to concerns that this model could be overparameterised
by including two variables relating to past falls history (a dichotomous variable indicating two or more falls in
the 12 months prior to screening and a continuous variable of the number of falls recalled in the 6 months
before baseline), the number of falls variable was not included.
The resultant model was based on 912 participants (intervention, n = 448, 90.9%; usual care, n = 464,
89.7%). Of those included in the primary model, 77 did not have a valid baseline FAI score and three did
not provide a response to whether or not they were wearing an orthotic insole at screening; 79 participants
were missing at least one of these additional covariates.
When these variables were added to the primary model, the predicted IRR was 0.88 (95% CI 0.72 to 1.06;
p = 0.18), which is virtually unchanged from the primary model.
Fear of falling participants
Excluding the 26 fear of falling participants from the primary model had a negligible effect on the
treatment estimate (IRR 0.88, 95% CI 0.73 to 1.05; p = 0.16).
Missing data
Not living with a partner or spouse, not having a degree or equivalent professional qualification, reporting
dizziness or vertigo at screening and number of falls in the 6 months prior to completion of the baseline
questionnaire were observed to predict returning less than 6 months’ worth of falls calendar data post
randomisation. When these variables were included in the primary analysis model (excluding the number
of falls variable for the same reasons as cited above), the parameter estimate for the treatment effect
was IRR 0.86 (95% CI 0.72 to 1.04; p = 0.11). This model was based on 976 participants (intervention,
n = 477, 96.8%; usual care, n = 499, 96.5%).
Post hoc analysis
Prior to the analysis of this study, a trial of structured physical activity for the prevention of serious fall
injuries in adults aged 70–89 years [Lifestyle Interventions and Independence for Elders (LIFE) study] was
published.45 In subgroup analyses the authors observed that the hazard ratio for time to first serious fall
injury did not differ significantly according to sex (interaction p = 0.14); however, a clinically meaningful
qualitative difference was observed with a hazard ratio of 0.62 (95% CI 0.34 to 1.12) in men and of 1.05
(95% CI 0.72 to 1.52) in women. In an analysis that was not prespecified, we repeated the primary analysis
in the subgroups of males and females and found similar treatment effects in each (men: IRR 0.87, 95% CI
0.64 to 1.17; women: 0.86, 95% CI 0.68 to 1.09). When an interaction between sex and treatment
allocation was included in the primary model, the interaction was not observed to be statistically
significant (p = 0.93).
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Secondary analyses
Number of falls as reported for the previous 6 months on the 6- and 12-month
participant questionnaires
This outcome was computed for 450 (91.3%) participants in the intervention group and 484 (93.6%) in
the usual-care group. In the intervention group, 423 (85.8%) participants responded to this question at both
6 and 12 months and 27 (5.5%) responded at either 6 or 12 months only; the average number of falls
reported in this group was 1.5 (median 1 fall, range 0–20 falls). In the usual-care group, 457 (88.4%)
participants responded to this question at both 6 and 12 months and 27 (5.2%) responded at either 6 or
12 months only; the average number of falls reported in this group was 1.7 (median 1 fall, range 0–29 falls).
The adjusted IRR obtained from the negative regression model was 0.87 (95% CI 0.72 to 1.06; p = 0.17).
Proportion of fallers and multiple fallers
In total, 245 out of 493 (49.7%) intervention participants and 284 out of 517 (54.9%) usual care participants
reported at least one fall on their monthly falls calendars (adjusted OR 0.78, 95% CI 0.60 to 1.00; p = 0.05).
An OR of 0.6 (lower confidence limit) approximately relates to a decrease in the percentage of fallers from
55% in the usual-care group to 42% in the intervention group, which exceeds the 10 percentage point
difference for which the trial was powered.
To calculate the percentage of the intervention group, let us say that the 2 × 2 table for falls by allocation
is as given in Table 24.
In this case, we know that a + b = 493, c = 284, d = 233, c + d = 517 and N = 1010. The calculation for
the OR is:
OR = (a/b)/(c/d). (2)
We want to know the values of a and b if c and d are as observed in the trial and the OR is 0.6.
Rearranging (2), we get:
(a/b) = 0:6(284/233) = 0:73: (3)
We know that a + b = 493, so if we rearrange and solve these equations, we conclude that a = 208 and
b = 285. Therefore, if there were 208 fallers, this would equate to a percentage of 208/493 × 100 = 42%.
The analysis of fallers assumes that the 18 participants who did not return any falls calendars following
randomisation into the trial did not fall. To test the sensitivity of the results to this assumption we repeated
the logistic regression (1) dropping these participants and (2) assuming, conversely, that they did fall
at least once. Estimates were robust: adjusted OR 0.77 (95% CI 0.59 to 0.99; p = 0.04); and OR 0.77
(95% CI 0.60 to 0.99; p = 0.05), respectively. In addition, if participants did not report a fall, it is implicitly
assumed that these participants did not fall in the months for which they did not return a falls calendar.
To test this, we assumed that a random 50% of the 185 participants [99/493 (20.1%) participants in the
intervention group and 86/517 (16.6%) participants in the usual-care group] who did not report a fall and
did not complete a falls calendar for all 12 months post randomisation fell at least once in a month for
which data were missing. This increased the effect (adjusted OR 0.72, 95% CI 0.55 to 0.93; p = 0.01).
TABLE 24 Falls by allocation
Treatment group Fall No fall Total
Intervention a b a + b
Usual care c d c + d
Total a+ c b+ d N
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The proportion of participants who reported two or more falls on their falls calendars following randomisation
was also lower in the intervention group than in the usual-care group [27.6% (n = 136/493) vs. 34.6%
(n = 179/517); adjusted OR 0.69, 95% CI 0.52 to 0.90; p = 0.01].
Time to first fall
The median time to the first fall and its associated 95% CIs were estimated at 314 days (95% CI 267 days,
upper limit not calculable) in the intervention group and 257 days in the usual-care group (95% CI 209 to
319 days). Kaplan–Meier survival curves are presented for each group in Figure 5. The adjusted hazard
ratio from the Cox proportional hazards model for the treatment effect was 0.88 (95% CI 0.74 to 1.04;
p = 0.13), indicating that the hazard or chance of falling at any particular time is lower in the intervention
group than in the usual-care group, but this ratio is not statistically significant. Log-log plots of the
categorical covariates indicated slight violation of the proportional hazard assumption for sex and
allocation (and indeed we observe that the survival curves cross one another on the Kaplan–Meier curve
but this occurs relatively early on); however, the Grambsch and Therneau test did not provide evidence
that the assumptions did not hold.
Participant-reported outcome measures
No statistically significant differences between the two groups were observed at 6 or 12 months in the fear of
falling question, the Short FES-I, the FAI or the GDS (Tables 25–28). For the Short FES-I and the GDS, the
residuals from the model showed slight violation from normality, so the models were repeated using a
log-transformed outcome, but this did not change the conclusions. The results presented in the main body
of the table are for the untransformed analysis, with the results from the transformed analysis included in the
footer. The Short FES-I total score was categorised and is presented in Table 29. At 12 months, a similar
proportion of participants in each group reported no, or low, concern about falling (intervention, 21.2%;
usual care, 22.2%), but, of those who were concerned, the proportion reporting high concern about falling
was slightly higher in the intervention group (32.2% vs. 30.0%). No difference in CD-RISC2 score at 6 months
was observed between the groups (adjusted means: intervention 6.4, usual care 6.3; adjusted mean
difference: 0.10, 95% CI –0.08 to 0.28; p = 0.26). Higher scores reflect greater resilience and adaptability.
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Proportion of participants with depression
The proportion of participants who were depressed was higher in the intervention group than in the usual-
care group (as measured by a score of ≥ 6 on the GDS) at all three assessment time points (12 months:
23.2% vs. 19.1%; Table 30). The adjusted OR at 12 months was 1.26 but this effect was not statistically
significant (95% CI 0.91 to 1.75; p = 0.16).
Proportion of participants obtaining a fracture or multiple fractures
Over the 12-month follow-up, 31 participants (intervention, n = 17; usual care, n = 14) reported breaking
or fracturing a bone as a result of a fall (adjusted OR 1.21, 95% CI 0.59 to 2.49; p = 0.60). Two
participants, both in the intervention group, reported fractures from two distinct events. The types of
fractures reported are presented in Table 31.
TABLE 30 Summary of depression indicator by time point and randomised group
GDS score of ≥ 6
Treatment group
Total (N= 1010)Intervention (N= 493) Usual care (N= 517)
Baseline
n 484 510 994
Depressed, n (%) 120 (24.8) 104 (20.4) 224 (22.5)
Not depressed, n (%) 364 (75.2) 406 (79.6) 770 (77.5)
Month 6
n 439 467 906
Depressed, n (%) 113 (25.7) 101 (21.6) 214 (23.6)
Not depressed, n (%) 326 (74.3) 366 (78.4) 692 (76.4)
Month 12
n 418 450 868
Depressed, n (%) 97 (23.2) 86 (19.1) 183 (21.1)
Not depressed, n (%) 321 (76.8) 364 (80.9) 685 (78.9)
TABLE 31 Types of fractures reported as a result of a fall by randomised group
Type of fracture
Treatment group, n (%)
Total (N= 33), n (%)Intervention (N= 19) Usual care (N= 14)
Hip 5 (26.3) 2 (14.3) 7 (21.2)
Hand/finger 2 (10.5) 3 (21.4) 5 (15.2)
Toe/foot 2 (10.5) 2 (14.3) 4 (12.1)
Wrist 2 (10.5) 2 (14.3) 4 (12.1)
Leg 2 (10.5) 1 (7.1) 3 (9.1)
Rib 1 (5.3) 1 (7.1) 2 (6.1)
Shoulder 2 (10.5) 0 (0.0) 2 (6.1)
Ankle 1 (5.3) 0 (0.0) 1 (3.0)
Arm 0 (0.0) 1 (7.1) 1 (3.0)
Spine/back 1 (5.3) 0 (0.0) 1 (3.0)
Unknown 1 (5.3) 2 (14.3) 3 (9.1)
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Foot pain
Participants in the intervention group reported greater foot pain at 12 months (adjusted mean 3.1 vs. 2.6;
adjusted mean difference 0.43, 95% CI 0.06 to 0.80; p = 0.02). When non-compliance with the intervention
was accounted for through CACE analysis, the predicted mean pain score among compliers in the intervention
group was 3.1, and among the counterfactual group of compliers in the usual-care group was 2.6 (adjusted
mean difference 0.50, 95% CI 0.08 to 0.92; p = 0.02).
Adverse events
Serious adverse events
A total of 95 SAEs were reported in the period between randomisation and 1 month following the trial
end (12 months after randomisation), by 49 (9.9%) participants in the intervention group and 37 (7.2%)
participants in the usual-care group (Table 32). The majority of participants (90.7%) reported only one
event. During the reporting period, there were 23 reported deaths (eight in the intervention group and
15 in usual care); all deaths were considered expected. For seven deaths, the relationship to research
procedures could not be assessed owing to a lack of information, but, for those that could, none was
deemed to be related. Nearly two-thirds of all SAEs were hospitalisations (n = 62, 65.3%). The two events
considered to be life- or limb-threatening were in the intervention group, and one of these was related to
the intervention. Details of the SAEs deemed to be at least possibly related to the research are presented in
Table 33. None of these events was attributable to the exercise programme but tended to relate to the
trial shoes or orthosis.
TABLE 32 Serious adverse events by randomised group
SAEs
Treatment group
Total (N= 1010)Intervention (N= 493) Usual care (N= 517)
Total number of SAEs 53 42 95
Number of participants with one or more SAEs 49 37 86
Number of events per participant, n (%)
1 45 (91.8) 33 (89.2) 78 (90.7)
2 4 (8.2) 3 (8.1) 7 (8.1)
3 0 (0.0) 1 (2.7) 1 (1.2)
Event details, n (%)
Death 8 (15.1) 15 (35.7) 23 (24.2)
Hospital required/prolonged 36 (67.9) 26 (61.9) 62 (65.3)
Life-/limb-threatening 2 (3.8) 0 (0.0) 2 (2.1)
Disability 0 (0.0) 0 (0.0) 0 (0.0)
Other 7 (13.2) 1 (2.4) 8 (8.4)
Intensity, n (%)
Mild 0 (0.0) 0 (0.0) 0 (0.0)
Moderate 5 (9.4) 2 (4.8) 7 (7.4)
Severe 47 (88.7) 40 (95.2) 87 (91.6)
Missinga 1 (1.9) 0 (0.0) 1 (1.1)
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TABLE 32 Serious adverse events by randomised group (continued )
SAEs
Treatment group
Total (N= 1010)Intervention (N= 493) Usual care (N= 517)
Outcome, n (%)
Recovered fully 22 (41.5) 12 (28.6) 34 (35.8)
Recovered partially 6 (11.3) 2 (4.8) 8 (8.4)
Ongoing 16 (30.2) 13 (31.0) 29 (30.5)
Died 8 (15.1) 15 (35.7) 23 (24.2)
Missing 1 (1.9) 0 (0.0) 1 (1.1)
Relationship to any of the research procedures, n (%)
Unrelated 35 (66.0) 31 (73.8) 66 (69.5)
Unlikely 8 (15.1) 6 (14.3) 14 (14.7)
Possibly 3 (5.7) 0 (0.0) 3 (3.2)
Probably 0 (0.0) 0 (0.0) 0 (0.0)
Definitely 2 (3.8) 0 (0.0) 2 (2.1)
Not able to assess 4 (7.6) 5 (11.9) 9 (9.5)
Missing 1 (1.9) 0 (0.0) 1 (1.1)
Expectedness, n (%)
Expected 48 (90.6) 37 (88.1) 85 (89.5)
Unexpected 4 (7.6) 5 (11.9) 9 (9.5)
Missing 1 (1.9) 0 (0.0) 1 (1.1)
a Event with missing outcome, relationship and expectedness was initially reported on participant’s 12-month questionnaire
and followed up by a member of the research team. Participant reported breaking their leg and developing tendinopathy
following a fall 8 months earlier. Event was not reported at the time and limited information was available when this
event was followed up.
TABLE 33 Details of the SAEs deemed to be at least possibly related to the research (all in intervention group)
Event type Description Intensity Outcome Relationship Expectedness
Hospitalisation Participant tripped while wearing trial
shoes, fell and was hospitalised (found
to have elevated blood pressure and
low blood glucose)
Severe Recovered
partially
Possible
related
Yes
Hospitalisation Participant fell and fractured wrist and
skull; they were not wearing trial shoes
Severe Recovered
partially
Possible
related
Yes
Hospitalisation Participant fell while wearing trial shoes
with insoles. Laces were correctly
fastened. Injured elbow and shoulder,
and was hospitalised
Severe Ongoing Possible
related
Yes
Hospitalisation Participant fell while wearing trial shoes
and broke hip
Severe Recovered
partially
Definitely Yes
Life-/limb-
threatening
Participant’s shoes with an insole
caused pressure ulceration at the toes
and subsequent cellulitis, which
required antibiotics
Severe Recovered
fully
Definitely Yes
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Non-serious adverse events
Non-SAEs that occurred within the reporting period and were deemed to be at least possibly related to
any of the research procedures are summarised in Table 34. These were all in the intervention group.
Participant self-reported occurrences of pain or cramp possibly resulting from the exercises were forwarded
to the treating podiatrist for review. If these events lasted for > 48 hours, then an adverse event was
recorded. Pain and cramp lasting for < 48 hours was considered an expected occurrence within this
population and for this component of the intervention, and so was not recorded.
TABLE 34 Non-SAEs that occurred within the reporting period and were deemed to be at least possibly related to
any of the research procedures
Non-SAEs Intervention (N= 493)
Total number of non-SAEs 58
Number of participants with one or more non-SAEs 49
Number of events per participant, n (%)
1 42 (85.7)
2 5 (10.2)
3 2 (4.1)
Event details, n (%)
Aches/pains in lower limbs lasting for ≥ 48 hours 26 (44.8)
Injury attributable to exercise equipment 1 (1.7)
Soft tissue injury 5 (8.6)
Skin irritation/injury (e.g. pressure sore, callus/corn) 9 (15.5)
Other 22 (37.9)
Intensity, n (%)
Mild 36 (62.1)
Moderate 22 (37.9)
Severe 0 (0.0)
Outcome, n (%)
Recovered fully 28 (48.3)
Recovered partially 15 (25.9)
Ongoing 15 (25.9)
Relationship to any of the research procedures, n (%)
Possibly 11 (19.0)
Probably 29 (50.0)
Definitely 18 (31.0)
Expectedness, n (%)
Expected 46 (79.3)
Unexpected 12 (20.7)
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Chapter 5 Economic evaluation
Introduction
As stated in earlier chapters, the aim of the REFORM trial is to provide rigorous trial evidence for the role
of a complex podiatry care intervention that combines foot and ankle exercise with footwear advice and
orthotic inserts for falls prevention within a UK setting.
Economic evaluation supports decision-making in prioritising the allocation of limited health-care
resources.46 Economic evaluation alongside clinical trials, as in the REFORM trial, can therefore be a
valuable tool to help decide what interventions should be implemented, based not only on clinical
effectiveness but also on cost-effectiveness. Moreover, RCTs are often the best means for providing
unbiased estimates of both health effects and costs.47
This chapter reports on the economic evaluation that was conducted alongside the REFORM trial. The aim
of this economic analysis is to help decision-making in determining whether or not the multifaceted
intervention represents a cost-effective alternative within the UK NHS for falls prevention compared with
usual care provided by the podiatrist or GP and a falls prevention leaflet.
Methods
Overview
Individual participant data collected in the REFORM trial were used to perform a within-trial economic analysis
that comprised (1) a cost–utility analysis, in terms of the cost per QALY, and (2) a cost-effectiveness analysis
(CEA), in terms of the cost per fall averted (i.e. using the primary effectiveness outcome of the trial). Costs
are presented in UK pounds sterling (£) at 2015 prices, and the analysis has been undertaken in Stata
version 13.1. The NICE guidelines were applied to all methods used for this economic analysis.48
Base-case analysis
The base-case analysis was conducted on an ITT basis using multiple imputed data and from the perspective
of the UK NHS and Personal Social Services, which included resource use related to falls only. The ITT aspect
compares participants in the two groups (intervention vs. usual care) on the basis of their initial random
allocation, irrespective of protocol deviations or withdrawal. A secondary analysis was undertaken from the
societal perspective. Costs and outcome data are compared for the two groups over 12 months and, hence,
discounting was not required.
Owing to the impact of missing data for the within-trial CEA, our economic analysis plan indicated that the
base-case analysis would be conducted as an imputed analysis by means of MI at the utility level. This has
been recommended as the appropriate method to reflect the uncertainty in the results of the economic
evaluation attributable to missing data.49
Sensitivity analysis
Additional sensitivity analyses were conducted to explore the extent to which the results change with
different assumptions. Sensitivity analyses were conducted in order to test (1) complete case as an
alternative method to MI for handling missing data, (2) the impact of imputing HRQoL at aggregated level
(e.g. QALY level), (3) the impact of including both fall- and non-fall-related visits and hospitalisations in the
calculation of total costs and (4) the societal perspective (e.g. cost of the shoes as a personal expense for
the patient). Finally, we used a probabilistic sensitivity analysis to explore the uncertainty associated with
the mean difference in costs and health outcomes using both the imputed and the complete data sets.
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Economic data collection
Data for outcomes and resource use for the economic analysis were collected prospectively. Health service
usage was measured using participant-reported questionnaires at baseline and at 6 and 12 months during
the 12 months’ follow-up.
Health-related quality of life
Health-related quality of life is expressed in terms of utilities, which were assessed at baseline and at
6 months and 12 months using the EQ-5D-3L.50 The EQ-5D is a standardised and validated generic
instrument for the measurement of HRQoL that allows the translation of patient utilities into QALYs,
which is the primary outcome for the base-case analysis.
The QALY is a measure of health that simultaneously incorporates changes in both morbidity (related to
quality of life) and mortality (related to the quantity of years lived). As well as being one of the most widely
used generic health status measures, the EQ-5D is the instrument recommended by the NICE appraisal
guidance.48 The EQ-5D considers health (functioning) in terms of five dimensions: mobility, self-care, usual
activities, pain/discomfort and anxiety/depression. Each dimension has three possible levels: no problems,
moderate problems and severe problems. This five-domain and three-level system generates 245 mutually
exclusive health states, including unconscious and dead. To estimate HRQoL weights (known as utilities)
and to reflect the preferences of the UK population, each of these health states has been validated in a
large UK population sample30 using the time trade-off method, ranging from 1 for perfect health (thus,
the maximum value possible) to –0.594 for severe problems; 0 corresponds to death. Utility values were
generated by valuing health status (using a social tariff) as measured using the EQ-5D system. Mean utility
values were reported for each trial group, and differences in utilities between the two treatment groups
were estimated using ordinary least squares (OLS) regression.
The EQ-5D has been recommended by The Prevention of Falls Network Europe Consensus as the measure
of HRQoL to be used in fall prevention trials.32 The rationale behind this is that the EQ-5D is simple and
responsive to changes in health and, more importantly, it has been used widely in older populations.51
Similarly, the EQ-5D has been used before in a UK setting to assess HRQoL and costs implications of falls in
elderly people.1 We converted the utilities derived from the EQ-5D into QALYs for each participant using
the area under the curve method, following the trapezium rule, which assumes linear interpolation
between follow-up points.52 Despite the randomisation process, which should ensure that, on average,
baseline variables are balanced between the groups of the trial, in practice (regardless of sample size)
it is not unusual to find imbalance in mean baseline utility. As baseline utility is likely to be correlated
with participants’ QALY gains over time, there are robust reasons to control for baseline utility when
estimating QALYs;53 therefore, incremental mean QALYs between treatment groups were estimated with
and without adjustment for baseline utility, using regression methods according to ITT allocation. In
addition, incremental mean QALYs were adjusted for the same set of covariates as in the primary clinical
effectiveness analysis model: age at randomisation, sex and history of falling. Centre was treated as a fixed
effect in all models.
Health benefits in terms of falls
The primary outcome of the trial was the incidence rate of falls per participant during the 12 months
following randomisation. The primary clinical effectiveness analysis used a mixed negative binomial
regression model to analyse the number of falls per person per year controlling, as fixed effects, for sex,
age at randomisation and history of falling, with centre as a random effect.
In order to interpret the cost-effectiveness results, the health outcome was reported as ‘falls averted’. The
number of falls averted was estimated as the difference in mean reduction in the fall rate between the two
groups in the trial estimated as per the adjusted negative binomial model used for the primary clinical
effectiveness analysis.
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Health-care resource use
Health-care resource use data were collected via participant-reported questionnaires. Participants were
asked to complete information on their number of visits to primary care facilities (e.g. contacts with a GP
and general practice nurse), use of community care (e.g. contacts with occupational therapist) and their
number of hospital visits [inpatient, day case, outpatient, and accident and emergency (A&E) department]
at baseline and at 6 and 12 months. Patients were also asked about the number of times they made an
emergency service call or the used the Patient Transportation Service. All resource use (except inpatient
hospital stay) was split into ‘fall-related’ and ‘non-fall-related’. The base-case analysis was based on
fall-related resource use, except for inpatient hospital stay, given the format of the questionnaire.
A sensitivity analysis explored the impact of including both fall- and non-fall-related resource use in
the analysis.
Participants were asked to record the total number of times they stayed in hospital as an inpatient as well
as the number of nights for each visit and the reason for attendance. The number of inpatient visits did
not differentiate fall- from non-fall-related incidents and, hence, the base-case analysis included all
inpatient stays reported by participants during the trial. Following a reported fall, participants were
contacted to obtain information about the nature, location and cause of the fall. They were asked whether
or not they sustained any injuries from the fall and, if so, whether or not they required an overnight stay in
hospital. Only 28 participants (intervention, n = 14; usual care, n = 14) reported that they had to spend a
night in hospital as a result of their fall. We assumed that missing answers (boxes left blank) to the second
question (i.e. number of nights in hospital) when participants reported no hospital stay indicated no use
of services and, thus, no overnight stays. There were participants with missing responses to number of
nights but who reported the reason for their stay; for these cases the length of stay (nights in hospital)
was assumed to be one night. Similarly, there were participants who reported not being in hospital but
who gave information on the reason for their attendance; it was assumed that these participants stayed in
hospital for one night. Finally, there were participants who reported that they stayed overnight in hospital
but left blank the remaining information regarding number of occasions, number of nights and reason for
stay. As a conservative assumption, we assumed that these participants stayed in hospital for one night on
one occasion.
The number of visits made by the participant to their podiatry clinic in the previous 12 months was
collected on the 12-month participant questionnaire. This information was available for participants in both
treatment groups. In the case of participants in the intervention group, the number of visits made to the
podiatry clinic as part of the intervention was collected via a trial-specific podiatrist database. Therefore,
for participants in the intervention group, the number of podiatry appointments self-reported at 12 months
was assumed to consist of trial appointments and unrelated routine care appointments. We knew the
number of appointments received as part of the intervention and, therefore, assumed that all other
reported visits were unrelated; hence, these were not included as part of the cost of the intervention.
We also asked about the use of Meals on Wheels and paid care; however, few participants reported using
either Meals on Wheels (96.14% did not use this service) or paid-for help (92.87% did not pay for care).
Therefore, it was decided not to incorporate these into the societal perspective analysis. Resource use was
valued in monetary terms and unit costs were reported in UK pounds sterling (£) for the financial year 2014/15.
The cost for each participant in the REFORM trial was calculated by multiplying health-care resource use by
associated unit costs. Table 35 details the unit costs for the estimation of costs related to patient care that were
used in the analysis.
Costing the intervention
The cost of the podiatry intervention was assessed based on the data collected as part of a baseline
appointment questionnaire and the podiatrist database, which included information directly related to the
podiatrist assessments and the intervention package received by the participant (e.g. orthosis prescription,
exercise programme and exercise equipment).
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Unit costs, together with their sources, for the podiatry intervention are provided in Table 36. Aside from
manufacturer prices, the unit costs used in the analysis were obtained from published national sources:
Unit Costs of Health and Social Care (Personal Social Services Research Unit)54 and NHS Reference Costs.55
The base-case analysis includes only costs falling within the NHS and, hence, the cost of the shoe was not
included in the primary analysis. This issue was discussed at length within the trial team and with the trial
podiatrists; all were in strong agreement that, if the intervention were implemented, the NHS would not
cover the cost of the shoes. We therefore considered the price of the shoes as a personal expense for the
patient (e.g. as part of the societal perspective). A secondary analysis from the societal perspective that
included the cost for the shoe was conducted.
We calculated the cost for each participant in the trial by multiplying their use of health-care resources by
the associated unit costs. The total costs for the base-case analysis included only fall-related resource use
(except for inpatient stay, which included both fall- and non-fall-related resource use). The total cost
comprises five main components: (1) podiatrist visits, (2) hospital visits (inpatient, outpatient and day
cases), (3) visits to primary and community health-care professionals (GP, practice nurse and occupational
therapist), (4) patient transportation and (5) the cost of the podiatrist intervention. Other scenarios were
TABLE 35 Unit costs (and sources) of health-care services used to estimate total cost for each individual participant:
primary and community care, secondary care and podiatry care
Resource use Unit cost (£) Source
Cost component: primary care
Visit to GP 44.00 Unit Costs of Health and Social Care 201554
Visit to general practice nurse 25.00 Unit Costs of Health and Social Care 201554
Occupational therapist 44.00 Unit Costs of Health and Social Care 201554
Cost component: secondary care
Hospital stay 3106.00 aNHS Reference Costs 2014–1555
Excess hospital stay 303.00 bNHS Reference Costs 2014–1555
Outpatient visit 114.50 cNHS Reference Costs 2014–1555
Day case 720.00 dNHS Reference Costs 2014–1555
A&E 140.60 eNHS Reference Costs 2014–1555
Emergency service call 154.00 fUnit Costs of Health and Social Care 201554
Patient transportation service 99.00 Unit Costs of Health and Social Care 201554
Cost component: podiatrist
Podiatrist first visit (assessment) 46.00 gNHS Reference Costs 2014–1555
Podiatrist second visit 44.00
gNHS Reference Costs 2014–1555
Podiatrist follow-up visit 39.00
gNHS Reference Costs 2014–1555
a Averaged (elective and non-elective), weighted by activity levels across all NHS trusts and NHS foundation trusts.
b Excess bed-day averaged (elective and non-elective) per activity across all NHS trusts and NHS foundation trusts.
c Averaged total outpatient attendances, weighted by activity levels across all trusts and specialties.
d Day cases averaged per activity across all trusts and specialties.
e A&E averaged per activity across all NHS trusts and NHS foundation trusts.
f Ambulance services weighted average of attendances by activity level (‘see and treat and refer’; ‘see and treat
and convey’).
g The podiatrist visits for the intervention group were classified as first assessment visit (podiatrist Tier 3, management of
at-risk complex foot); second visit (podiatrist specialist care 1) and the rest as follow-up visits (general podiatry). For the
usual-care group, podiatrist visits were costed as follow-up (podiatrist specialist care 2).
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tested as part of the sensitivity analysis, in which we explored the impact of incorporating both types of
resource use (fall- and non-fall-related) into the analysis.
Multiple imputation
Missing data occur frequently in RCTs, irrespective of how well designed the data collection is. This is a
major concern for within-trial CEA, as costs and QALYs, the main outcomes in CEAs, are cumulative
measures collected over the trial follow-up. Therefore, missing data at one follow-up time point (e.g. one
dimension response missing to the EQ-5D at one time point) result in missing aggregate data (e.g. total
QALYs over the trial) for that participant. This problem is common in economic evaluations, as the analysis
has to draw on all aspects of the study, including resource use and health outcomes. Non-response to
questionnaires and returned but incomplete questionnaires reduce, often considerably, the number of
data on resource use that are available for analysis. The problem is amplified when there are frequent
assessments, as in the REFORM trial.
Complete-case assessment and available case analysis are proposed as useful preliminary estimations for
economic evaluation but should not constitute the base case for within-trial economic evaluation.56
An alternative method to address missing data in CEAs alongside clinical trials is MI,57 which has been
recommended as the appropriate method to reflect the uncertainty in the results of the economic
evaluation attributable to missing data.49 As already stated, our economic analysis plan indicated that the
TABLE 36 Unit costs and sources of the multifaceted podiatry intervention
Resource use Unit cost (£) Source
Cost component: podiatry intervention
Shoes provided, per pair 64.00 Manufacturer price 2015
Therapy ball (large) 0.95 Manufacturer price 2013a
Therapy ball (small) 0.90 Manufacturer price 2013a
Resistive exercise band (band 1) 1.11 Manufacturer price 2013a
Resistive exercise band (band 2) 1.21 Manufacturer price 2013a
Resistive exercise band (band 3) 1.28 Manufacturer price 2013a
Resistive exercise band (band 4) 1.45 Manufacturer price 2013a
Resistive exercise band (band 5) 1.72 Manufacturer price 2013a
Resistive exercise band (band 6) 1.50 Manufacturer price 2013a
Resistive exercise band (band 7) 1.74 Manufacturer price 2013a
Resistive exercise band (band 8) 1.89 Manufacturer price 2013a
Resistive exercise band (band 9) 1.97 Manufacturer price 2013a
Resistive exercise band (band 10) 2.09 Manufacturer price 2013a
X-Line Extra insoles 5.95 Manufacturer price 2015
X-Line Pressure Perfect insoles 4.75 Manufacturer price 2015
Formthotics Dual insoles 14.99 Manufacturer price 2015
DVD and booklet 3.82 Manufacturer price 2013a
Podiatrist first visit (assessment) 46.00 NHS Reference Costs 2014–1555
Podiatrist second visit 44.00 NHS Reference Costs 2014–1555
Podiatrist follow-up visit 39.00 NHS Reference Costs 2014–1555
a Price inflated to 2014/15 prices using Personal Social Services Research Unit 201554 (Hospital and Community
Service Index).
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base case would be conducted as an imputed analysis using MI with chained equations. Given the extent
of missing data in the REFORM trial, this initial decision is justified; therefore, the base-case analysis was
conducted on the imputed data set. A descriptive analysis of missing data was conducted in order to help
inform the base-case assumption regarding the missing data mechanism. We described the number of
missing data by treatment group at each follow-up point. We also examined the missing data pattern to
find out whether or not participants with missing data were lost to follow-up throughout the duration of
the trial.
Multiple imputation comprises three steps. First, the imputed data set is created through the use of regression
models to predict plausible values for the missing observations from the observed values. The process
includes all the variables that might be associated with the missingness mechanism (here, sex, age, history
of falls, centre, baseline costs, primary care and hospital costs) and QALY utilities (at baseline and at
6 and 12 months). Costs and utilities were imputed simultaneously rather than separately in the model.
Therefore, the covariates registered in the model were used for both costs and utilities, when a regression
model was fitted for each variable with missing values, with the previous variables as covariates. Based on the
resulting model, a new regression model is then estimated and used to impute the missing values for each
variable. A random component is included to reflect the uncertainty around the predictions. Thus, MI reflects
the uncertainty in the prediction of missing values while preserving the distribution and correlations in the
data.58 These values are then used to fill in the gaps in the data set. This process is repeated m times, creating
m imputed data sets. It is suggested that, if missing values account for 20% of the total number of data,
three imputations are sufficient.59 Given the extent of missing data in REFORM, five imputations were
performed. In the second stage, each data set is analysed independently using complete-case methods.
Finally, the estimates obtained from each imputed data set are combined to generate mean estimates of
costs and QALYs, variances and CIs using Rubin’s rules.60
The correct specification of the regression model is vital to ensure that the distribution of imputed values
does not differ from the observed values and, thus, that unbiased estimates are obtained. The specification
of the regression models depends on the type and distribution of the variable to be imputed. Costs and
QALYs are both continuous and non-normally distributed. Two alternative methods are proposed to deal
with this difficulty when using MI with chained equations: (1) data transformation and (2) predictive mean
matching.61 Predictive mean matching was used for the imputation of REFORM data. This method ensures
that observed data were used to estimate a predictive model (using the specified covariates) but, instead of
replacing missing values with the model predicted values, the nearest observed value is used to fill the
missing one. This guarantees that the imputed values are sampled from values in the original data set,
and, therefore, that no imputed values will lie outside the bounds of the original data distribution. In
addition to the description of the missing data mechanism, we used graphical plots to visualise whether or
not the distribution of imputed data resembles the distribution of original data.
The main assumption that drives the MI mechanism is that the data are missing at random (MAR).
Additional sensitivity analyses were conducted to test the robustness of the results to deviations from this
assumption. In that sense we explored (1) the use of the complete data set [e.g. assume that the data are
missing completely at random (MCAR)] and (2) imputation at various levels of aggregation (e.g. at utility
level rather than QALY level).
Incremental analysis
Total health-care expenditure must be covered from a limited budget and, therefore, the most informative
estimate for CEA is based on the difference of arithmetic mean effect from both budgetary and social
perspectives.62 Therefore, the focus of this economic evaluation was to estimate the mean costs and mean
health outcomes. The cost-effectiveness of the podiatry intervention was evaluated by comparing the
mean costs and outcomes (QALYs and falls) incurred in the intervention group with the mean costs and
outcomes (QALYs and falls) in the usual-care group at 12 months’ follow-up, using conventional decision
rules and estimating incremental cost-effectiveness ratios (ICERs) when appropriate.
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As expected, costs in the REFORM trial were right-skewed, and we found that some participants had costs
that far exceeded the mean value. In order to deal with skewness and heteroscedasticity, non-parametric
bootstrap procedures62–64 are usually implemented as the primary statistical test for making inferences
about arithmetic means for moderately sized samples of skewed cost data (such as the REFORM sample).
Bootstrap methods assume that the empirical distribution of the data is an adequate representation of the
true distribution of the data; the analysis is based on repeatedly sampling (with replacement) from the
observed data. For the REFORM analysis we repeatedly randomly drew a sample of 1000 for each of the
imputed five data sets. Each bootstrap repetition is the equivalent of a repetition of the trial. To obtain
reliable results in practice it has been recommended to use at least 1000 resamples to estimate a bootstrap
CI.63 For the REFORM analysis we used 5000 resamples (bias corrected and accelerated). The mean
difference in costs and QALYs for the base-case analysis was estimated using seemingly unrelated
regression (SUR) equations for data on costs and QALYs. The SUR model used the same set of covariates
as the mixed-effect regression model used for the clinical effectiveness analysis (sex, age at randomisation,
fall history) as well as total number of falls and baseline utility. Incremental costs were also adjusted for
baseline costs. SUR is used to address the correlation of standard errors between costs and QALYs.65 This
brings efficiency gains over unrelated OLS regression for three reasons: (1) it allows for explicit modelling
of both costs and effects while allowing the inclusion of a set of different covariates in the two equations;
(2) it exploits the existence of correlation between costs and effects; and (3) SUR does not require a new
regression for every value of the cost-effectiveness threshold.66 Again, the same set of covariates as used in
the clinical effectiveness analysis was used. The baseline EQ-5D utility was also included in the utility
regression to adjust for possible baseline imbalance and to reduce the standard errors of post-test EQ-5D.
Incremental costs were also adjusted for baseline costs.
The ICER was estimated as the difference in mean total costs divided by the difference in mean total
QALYs from baseline to 12 months. The ICER is estimated to inform decision-makers about the optimal
use of NHS resources. According to standard cost-effectiveness decision rules, four different eventualities
are plausible when comparing incremental costs and QALYs. If the new intervention provides better
outcomes (positive incremental QALYs) at lower costs (negative incremental costs) it is considered a
dominant intervention and, hence, cost-effective. If the new intervention achieves poorer outcomes
(negative incremental QALYs) at higher costs (positive incremental costs) it is considered a dominated
option and, hence, not cost-effective. Thus, the ICER is considered only if either intervention does not
dominate, that is, both incremental costs and incremental QALYs are positive (or negative). In these last
two situations, to determine whether or not the incremental health gain is worth the incremental cost, the
ICER needs to be compared against a threshold value. For positive incremental costs and QALYs (the most
frequent situation in HTA), an intervention will be considered cost-effective only if the ICER is lower than
the threshold. According to NICE, the WTP threshold for an additional QALY ranges from £20,000 to
£30,000.48 This threshold has been used by NICE for more than a decade; however, it has recently been
suggested that the threshold should be decreased to £13,000 per QALY gained.67 According to the current
established decision rules, if the result of this cost–utility analysis, namely the estimated cost per QALY, is
below the £30,000 threshold, the podiatry intervention would be considered cost-effective in terms of
QALYs gained.
The ICER can be rearranged in terms of net benefit, which is a more intuitive way of expressing whether or
not the health benefits of the podiatry intervention are worth the additional costs.68 The net benefit can
be estimated on the cost scale as the incremental health gain, expressed in terms of money, minus the
incremental cost of the intervention. The health benefits are translated into monetary value using the
cost-effectiveness threshold, that is, incremental QALYs are multiplied by the WTP threshold. Therefore,
the net monetary benefit (NMB) provides an estimation of the gain (or loss) in resources of investing
in a particular intervention when those resources might be used elsewhere.69 Current NICE guidance
recommends presenting the NMB using values of £20,000 and £30,000 per QALY for the WTP threshold.
The podiatry intervention would be considered cost-effective only if the NMB were positive.
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Analysis of uncertainty
Uncertainty in economic evaluation is related to the expected values of model inputs but not to patient
variability. The uncertainty around the cost-effectiveness estimates was explored by means of sensitivity
analyses in order to test the robustness of the results under different scenarios. These scenarios captured
variability in the estimates of costs and outcomes, which resulted from either different methods (e.g.
imputation methods), from the costs included in the analysis or from the perspective for the analysis.
The extent of missing data in the REFORM trial justified the use of the imputed data set as the base-case
analysis. Nevertheless, a complete-case analysis was explored as part of a sensitivity analysis. Similarly, we
also conducted sensitivity analyses to test different levels of aggregation when imputing costs and QALYs.
The base case was based on the imputed data set and included only fall-related visits and hospitalisations.
One-way sensitivity analyses were conducted to test the impact of including all visits and hospitalisations
regardless of them having being classified as fall- or non-fall-related.
Finally, we used probabilistic sensitivity analysis to investigate the uncertainty associated with the mean
difference in costs and QALYs between the two treatment groups using both the imputed and the
complete-case data sets. Non-parametric bootstrapping was used to plot the joint distribution of costs and
effects (QALYs) on the cost-effectiveness plane and to derive the CEAC to express the (Bayesian)
probability that the podiatry intervention is cost-effective as a function of the WTP threshold.70
Exploration of the need for a long-term model
An exploratory model was developed to explore how the differences in HRQoL observed during the
trial (e.g. at 1 year) evolve beyond the study (up to 5 years). For this exploratory projection, we used a
decision-modelling approach and assumed that the difference in HRQoL and costs observed at 1 year
would remain unchanged.
Validation of results
In order to validate the results of the analysis, two statistical codes (written in Stata) were independently
developed and their results compared. The codes were developed by one analyst and checked independently
by another. The distributions of the observed and imputed values were compared graphically.
Results
Patient population and missing data mechanism
Twenty-four participants died during the trial: 9 out of 493 (1.8%) in the intervention group and 15 out of
517 (2.9%) in the usual-care group. When there were missing data before these participants’ deaths, the
imputation process was applied in the same way as for the rest of the patients in the trial. The questionnaires
that should have been received at any other assessment after their deaths were considered as part of the
complete-case analysis with zero resource use and zero utilities. The complete-case analysis comprised those
participants for whom data were available for the whole trial duration for utilities and all cost categories.
The proportion of participants with complete data decreased with the duration of follow-up but remained
similar in both groups (Table 37): from 72.0% (baseline) to 54.4% (12 months) for the intervention group
and from 71.8% (baseline) to 61.3% (12 months) for the usual-care group. In the usual-care group,
more individuals are observed at 12 months than at 6 months; therefore, the missing data follow not a
monotonic pattern but an intermittent one (i.e. there are participants with missing 6-month data but
complete data at 12 months). A complete-case assessment would be, as a minimum, inefficient because it
would discard observed data from individuals with some missing outcomes.
Table 38 presents the ORs from a logistic regression of indicators of missing QALY data on treatment
group allocation and the covariates used for the main statistical model. Lower EQ-5D at baseline is
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associated with missing QALY data but is not statistically significant at the 5% level. This suggests that
the data are unlikely to be MCAR. It was found that older and frailer (lower utility) participants with a
history of falling were more likely to have missing QALY data. This information would support the MAR
assumption (e.g. MI assumed missing data mechanism).
Multiple imputation and likelihood-based methods can handle non-monotonic missing data under the
MAR assumption while incorporating the uncertainty around the unobserved data and maintaining the
correlation structure.56 Therefore, the base case for the REFORM analysis uses MI. A complete-case
analysis, which is not valid under MAR, is presented only for comparison.
The MI model was validated by comparing the distributions of the observed and the imputed data
(Figures 6 and 7). The distributions of imputed data are similar to the distribution of the observed data.
The MI data sets were analysed with the same SUR model used for the complete-case analysis.
Health-related quality of life
The complete-case analysis for utilities consisted of the participants who returned all questionnaires and
completed the EQ-5D questions. The EQ-5D is classified as complete only if its five dimensions contain
a response. Table 39 shows the number of questionnaires returned (including those with missing
dimensions) and the number of completed EQ-5D questions for each time point. The number of
questionnaires returned decreases with time.
Table 40 describes the number and proportion of participants in the REFORM trial reporting each of the
levels on each EQ-5D dimension.
At baseline, participants reported problems in mobility and pain more than in the other dimensions.
These domains are worse for the participants in the intervention group: mobility (56.9% usual care vs.
59.7% intervention) and pain (56.6% usual care vs. 78.4% intervention). As expected, the intervention
improved mobility as data showed an 11% reduction in the number of participants reporting problems
from baseline to 12 months in the intervention group (compared with 1% change in the usual-care group).
TABLE 37 Number and proportion of participants with complete-case data by treatment group
Time point Intervention (N= 493), n (%) Usual care (N= 517), n (%)
Baseline 355 (72.0) 371 (71.8)
6 months 285 (57.8) 305 (59.0)
12 months 268 (54.4) 317 (61.3)
Total trial duration 129 (26.2) 157 (30.4)
TABLE 38 Logistic regression to predict missing QALYs on baseline variables
Missing data on QALYs OR (95% CI)
Treatment group 1.13 (0.82 to 1.55)
Sex 1.27 (0.92 to 1.77)
Age 1.04a (1.02 to 1.06)
History of fall 1.26 (0.89 to 1.77)
EQ-5D at baseline 0.68 (0.35 to 1.32)
a Statistically significant at 5% level.
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FIGURE 7 Comparison of the distribution of imputed values (imputations 1–5) with the observed data (imputation 0)
for total QALYs.
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FIGURE 6 Comparison of the distribution of imputed values (imputations 1–5) with the observed data (imputation 0)
for total costs.
TABLE 39 Health-related quality of life: number of questionnaires returned, completed EQ-5D scores and
corresponding proportion of missing data by treatment group and follow-up time point
Time point
Treatment group, n (%)
Intervention (N= 493) Usual care (N= 517)
Completed EQ-5D Missing EQ-5D Completed EQ-5D Missing EQ-5D
Baseline 468 (94.9) 25 (5.1) 497 (96.1) 20 (3.9)
6 months 422 (85.6) 71 (14.4) 448 (86.7) 69 (13.4)
12 months 405 (82.2) 88 (17.9) 440 (85.1) 77 (14.9)
Total trial duration 369 (74.9) 113 (21.9) 404 (78.1) 113 (21.9)
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Similarly, the intervention improved pain (15% reduction in participants reporting problems in the
intervention group compared with 10% change in the usual-care group).
The likelihood of remaining in perfect health decreased with time (Tables 41 and 42). However, the
reduction in the number of participants in perfect health is lower in the intervention group (7.4%) than in
the usual-care group (17.7%). The data also suggested that improvement in anxiety/depression is
proportionally even greater than the improvement in other dimensions, especially among participants in the
intervention group (19% reduction in numbers reporting anxiety problems).
Utility values were generated by valuing health status (using a social tariff) as measured using the EQ-5D
system. The analysis of utilities (Table 43) shows that participants in the intervention group start from a
lower baseline utility, on average (0.67 for the intervention group vs. 0.69 for usual care). The data also
TABLE 41 Proportion of participants reporting perfect health or problems (level 2+ level 3) by time point
Description
Treatment group
Usual care (%) Intervention (%)
Baseline
Perfect health 15.3 13.6
Problems 84.7 86.4
6 months
Perfect health 12.8 11.6
Problems 87.2 88.4
12 months
Perfect health 12.6 12.6
Problems 87.4 87.4
TABLE 42 Variation in proportion of participants reporting perfect health or problems (level 2 + level 3) from
baseline to 12 months per treatment group
Description
Treatment group
Usual care (%) Intervention (%)
Variation in perfect health –17.7 –7.4
Variation in problems 3.2 1.2
TABLE 43 Health-related quality of life: EQ-5D mean (SD) scores and unadjusted and adjusted mean difference
(95% CI) at baseline and follow-up assessments up to 12 months according to ITT
Time point
Treatment group, EQ-5D score
Unadjusted mean
difference
(intervention – usual
care) (95% CI)a
Mean difference
adjusted for
baseline utility
(intervention – usual
care) (95% CI)a
Intervention Usual care
n
Mean score
(SD) n
Mean score
(SD)
Baseline 468 0.67 (0.24) 467 0.70 (0.23) –0.023 (–0.053 to 0.008) –0.023 (–0.053 to 0.008)
6 months 426 0.65 (0.27) 455 0.65 (0.27) –0.005 (–0.041 to 0.031) 0.013 (–0.016 to 0.041)
12 months 414 0.66 (0.27) 455 0.66 (0.26) –0.005 (–0.041 to 0.031) 0.015 (–0.013 to 0.043)
a CIs estimated using OLS regression.
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showed that participants in the intervention group had, on average, 0.14 [standard deviation (SD) 0.38]
admissions to the hospital during the 6 months before randomisation, whereas participants in the usual-
care group had, on average, 0.12 (SD 0.45) admissions. This emphasises the need to adjust the utilities
gained for baseline utility level. When considering this baseline imbalance, the data show that by the end
of the trial participants allocated to intervention obtained, on average, a marginally higher HRQoL gain
than participants allocated to usual care.
The overall distribution of EQ-5D scores (utilities) for the different follow-up time points is illustrated by
treatment group in Figure 8. Utilities at baseline ranged from –0.181 to 1 for both groups; at the end of
the trial, utilities ranged from –0.239 to 1 for both groups.
The distribution of mean utilities across the 12-month follow-up for the two groups is shown in Figure 9.
The usual care participants reported higher HRQoL at baseline and at 6 and 12 months. All of the
differences were small, and the 95% CIs overlap at each time point.
The mean QALYs were estimated based on individual participants’ utilities. Table 44 summarises the mean
QALYs and the difference between treatment groups for all available cases. At the end of the trial,
participants allocated to the intervention obtained, on average, a marginally higher QALY gain than
participants allocated to usual care (Figure 10) when adjusted for baseline utility (0.010 QALY gain).
The difference is 0.083 when adjusted for all covariates.
Health-care resource use and costs
The mean levels of resource use over the trial based on all available data are shown for the two treatment
groups in Table 45. Although participants in the intervention group had, on average, fewer hospital day
cases and used the patient transportation service fewer times, they had, on average, more hospital
admissions, more outpatient visits and more A&E attendances than usual care participants over the
trial duration.
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intervention.
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FIGURE 9 Mean EQ-5D scores at baseline and follow-up time points by treatment group.
TABLE 44 Health-related quality of life: total QALYs for all available cases by treatment group over trial duration
(12 months) and difference in mean QALYs (95% CI) (estimated using OLS)
Treatment group Total Mean (SD) QALYs
Difference (intervention –
usual care) (95% CI)a
Difference (intervention –
usual care) (95% CI)b
Intervention 377 0.67 (0.24) 0.010 (–0.010 to 0.031) 0.008 (–0.009 to 0.026)
Usual care 415 0.68 (0.23)
a Adjusted for baseline utility.
b Adjusted for all covariates (baseline utility, total falls, sex, age, fall history and centre).
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FIGURE 10 Mean total QALYs for the intervention and usual-care groups.
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TABLE 45 Average hospital resource use per treatment group (all fall-related resource use except hospital
admissions, which includes both fall- and non-fall-related stays)
Type of resource use
Treatment group
Intervention (N= 493) Usual care (N= 517)
Hospital admissions
At 6 months
n 444 475
Mean (SD) 0.20 (0.50) 0.16 (0.46)
Median (minimum, maximum) 0 (0, 3) 0 (0, 3)
Missing (%) 49 (9.94) 42 (8.12)
At 12 months
n 425 467
Mean (SD) 0.14 (0.45) 0.13 (0.41)
Median (minimum, maximum) 0 (0, 4) 0 (0, 3)
Missing (%) 68 (13.79) 50 (9.67)
Over the trial
n 418 452
Mean (SD) 0.34 (0.81) 0.30 (0.71)
Median (minimum, maximum) 0 (0, 7) 0 (0, 6)
Missing (%) 75 (15.21) 65 (12.57)
Hospital outpatient visits
At 6 months
n 341 359
Mean (SD) 0.17 (0.92) 0.12 (0.52)
Median (minimum, maximum) 0 (0, 13) 0 (0, 5)
Missing (%) 152 (30.83) 158 (30.56)
At 12 months
n 315 362
Mean (SD) 0.15 (1.11) 0.12 (0.50)
Median (minimum, maximum) 0 (0, 18) 0 (0, 4)
Missing (%) 178 (36.11) 155 (29.88)
Over the trial
n 259 292
Mean (SD) 0.32 (1.66) 0.23 (0.73)
Median (minimum, maximum) 0 (0, 20) 0 (0, 4)
Missing (%) 234 (47.46) 225 (43.52)
continued
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TABLE 45 Average hospital resource use per treatment group (all fall-related resource use except hospital
admissions, which includes both fall- and non-fall-related stays) (continued )
Type of resource use
Treatment group
Intervention (N= 493) Usual care (N= 517)
Hospital day case
At 6 months
n 331 354
Mean (SD) 0.04 (0.26) 0.07 (0.43)
Median (minimum, maximum) 0 (0, 3) 0 (0, 5)
Missing (%) 162 (32.86) 163 (31.53)
At 12 months
n 313 363
Mean (SD) 0.07 (0.57) 0.11 (1.10)
Median (minimum, maximum) 0 (0, 7) 0 (0, 20)
Missing (%) 180 (36.51) 154 (29.79)
Over the trial
n 245 287
Mean (SD) 0.11 (0.80) 0.12 (1.33)
Median (minimum, maximum) 0 (0, 10) 0 (0, 22)
Missing (%) 248 (50.30) 230 (44.49)
Hospital A&E
At 6 months
n 346 375
Mean (SD) 0.13 (0.56) 0.10 (0.38)
Median (minimum, maximum) 0 (0, 6) 0 (0, 3)
Missing (%) 147 (29.82) 142 (27.47)
At 12 months
n 328 373
Mean (SD) 0.07 (0.32) 0.09 (0.37)
Median (minimum, maximum) 0 (0, 3) 0 (0, 4)
Missing (%) 165 (33.47) 144 (27.85)
Over the trial
N 268 309
Mean (SD) 0.22 (0.73) 0.19 (0.58)
Median (minimum, maximum) 0 (0, 6) 0 (0, 4)
Missing (%) 225 (45.64) 208 (40.23)
Emergency service call
At 6 months
n 365 384
Mean (SD) 0.06 (0.30) 0.05 (0.39)
Median (minimum, maximum) 0 (0, 3) 0 (0, 6)
Missing (%) 128 (25.96) 133 (25.73)
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Participants in the intervention group had, on average, fewer visits to the GP than the usual-care group
(Table 46); however, they had, on average, more visits to the practice nurse and the occupational
therapist. Participants in the intervention group undertook more podiatrist visits in total than the usual-care
group, as this group received this service as part of the intervention.
Table 47 summarises the mean cost by item of resource use based on all available cases and according to
treatment group. Costs associated with hospital inpatient stay and the intervention itself were the major
cost drivers for the participants in the intervention group.
Twenty-eight participants (intervention, n = 14; usual care, n = 14) reported that they had to spend a night
in hospital as a result of a fall. The average cost per inpatient stay was £7121.00 (SD £1535.83) in the
intervention group and £6666.50 (SD £1156.84) in the usual-care group. Therefore, inpatient stay based
on fall calendars was £454.50 more expensive for participants in the intervention group (95% CI –£601.80
TABLE 45 Average hospital resource use per treatment group (all fall-related resource use except hospital
admissions, which includes both fall- and non-fall-related stays) (continued )
Type of resource use
Treatment group
Intervention (N= 493) Usual care (N= 517)
At 12 months
n 338 381
Mean (SD) 0.02 (0.26) 0.03 (0.19)
Median (minimum, maximum) 0 (0, 4) 0 (0, 2)
Missing (%) 156 (31.64) 136 (26.31)
Over the trial
n 287 321
Mean (SD) 0.08 (0.43) 0.09 (0.48)
Median (minimum, maximum) 0 (0, 6) 0 (0, 6)
Missing (%) 206 (41.78) 196 (37.91)
Patient transportation
At 6 months
n 360 382
Mean (SD) 0.013 (0.13) 0.031 (0.30)
Median (minimum, maximum) 0 (0, 2) 0 (0, 5)
Missing (%) 133 (26.98%) 136 (26.31%)
At 12 months
n 337 381
Mean (SD) 0.053 (0.58) 0.015 (0.21)
Median (minimum, maximum) 0 (0, 10) 0 (0, 4)
Missing (%) 156 (31.64) 136 (26.31)
Over the trial
Patient transportation (N) 283 319
Mean (SD) 0.021 (0.20) 0.015 (0.14)
Median (minimum, maximum) 0 (0, 3) 0 (0, 2)
Missing (%) 210 (42.60) 198 (38.30)
DOI: 10.3310/hta21240 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 24
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Cockayne et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
71
TABLE 46 Average primary and community care resource use by treatment group over the 12-month follow-up
(fall-related resource use only)
Type of resource use
Treatment group
Intervention (N= 493) Usual care (N= 517)
GP visit at GP practice
At 6 months
n 328 364
Mean (SD) 0.17 (1.17) 0.15 (0.55)
Median (minimum, maximum) 0 (0, 20) 0 (0, 5)
Missing (%) 165 (33.47%) 153 (29.59%)
At 12 months
n 323 364
Mean (SD) 0.11 (0.47) 0.14 (0.57)
Median (minimum, maximum) 0 (0, 4) 0 (0, 5)
Missing (%) 170 (34.48) 153 (29.59)
Over the trial
n 250 295
Mean (SD) 0.25 (1.53) 0.30 (0.95)
Median (minimum, maximum) 0 (0, 23) 0 (0, 10)
Missing (%) 243 (49.29) 222 (42.94)
Nurse visit at GP practice
At 6 months
n 324 360
Mean (SD) 0.12 (0.62) 0.25 (1.48)
Median (minimum, maximum) 0 (0, 6) 0 (0, 20)
Missing (%) 169 (34.28) 157 (30.37%)
At 12 months
n 309 359
Mean (SD) 0.23 (2.89) 0.13 (0.86)
Median (minimum, maximum) 0 (0, 50) 0 (0, 10)
Missing (%) 184 (32.32) 158 (30.56)
Over the trial
n 241 287
Mean (SD) 0.37 (3.54) 0.35 (1.88)
Median (minimum, maximum) 0 (0, 54) 0 (0, 20)
Missing (%) 252 (51.12) 230 (44.49)
Occupational therapist visit
At 6 months
n 342 376
Mean (SD) 0.10 (0.71) 0.04 (0.46)
Median (minimum, maximum) 0 (0, 10) 0 (0, 6)
Missing (%) 151 (30.63) 141 (27.27)
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to £1510.80). Given the small sample size, it was decided to estimate inpatient stay based on data from
the participant questionnaires. The only limitation of this is that the participant questionnaire did not
differentiate inpatient stay as fall- and non-fall-related, although the rest of hospital stay (outpatient, day
case and A&E) did differentiate between these.
Costing the intervention
The protocol stated that participants allocated to the intervention would receive at least one baseline visit
to the podiatrist plus at least one follow-up appointment. In total, 413 out of 493 (83.8%) participants
allocated to the intervention had at least one visit to the podiatry clinic and 183 (37.1%) had at least two.
The first appointment was assumed to last for 1 hour, the second appointment for 30 minutes and all the
rest were assumed to be the same duration as a GP clinic consultation (11.7 minutes). The cost for the
visits was estimated according to NHS pay scales on the Agenda for Change (https://healthcareers.nhs.uk/
glossary#Agenda_for_Change) for NHS podiatrist staff in England, Wales, Scotland and Northern Ireland
from 1 April 2015. Podiatrists delivering the intervention ranged from band 6 to band 8. The annual
and unit costs per podiatry visit were estimated, excluding qualifications but including overheads on a
community basis.
TABLE 46 Average primary and community care resource use by treatment group over the 12-month follow-up
(fall-related resource use only) (continued )
Type of resource use
Treatment group
Intervention (N= 493) Usual care (N= 517)
At 12 months
n 334 370
Mean (SD) 0.04 (0.31) 0.07 (0.53)
Median (minimum, maximum) 0 (0, 4) 0 (0, 7)
Missing (%) 159 (32.25) 147 (28.43)
Over the trial
n 268 304
Mean (SD) 0.12 (0.65) 0.11 (0.67)
Median (minimum, maximum) 0 (0, 7) 0 (0, 6)
Missing (%) 225 (45.64) 213 (41.20)
Podiatrist visits
Not intervention related
na 355 380
Mean (SD) 2.09 (3.84) 4.01 (2.63)
Median (minimum, maximum) 1 (0, 46) 3 (0, 20)
Missing (%) 138 (27.99) 137 (26.50)
Intervention related
n 413 N/A
Mean (SD) 2.52 (0.88) N/A
Median (minimum, maximum) 0 (0, 7) N/A
Missing (%) 0 (0%) N/A
N/A, not applicable.
a This includes only those podiatry visits received by participants in the intervention group that were not directly related to
the trial intervention itself.
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A total of 260 participants received a new pair of shoes. The price of the shoes ranged between £39 and
£89. There was insufficient information to determine the exact make and model of shoe received by the
participant; hence, an average shoe price of £64 was assumed for the analysis. As the NHS will not cover
the cost of the provision of new footwear, this was not considered for the base-case analysis. A sensitivity
analysis on the societal perspective looked at the impact of the shoe price on the cost-effectiveness results.
A total of 241 participants also received a pair of insoles: X-Line red (n = 23), X-Line blue (n = 209) or
Formthotics insoles (n = 9). They also received resistive therapy bands and therapy balls for the exercises.
The intervention cost on average was £155.79 (SD £55.02) for the 413 participants who received the
intervention when we include the price of the shoes (societal perspective) and £115.5 (SD £33.06) when
we exclude the price of the shoes.
Cost–utility analysis and uncertainty
The base-case analysis (Table 48) shows that the participants who were randomised to the intervention
experienced (marginally) improved health outcomes. At the end of the trial, the intervention group had
experienced 0.0129 (95% CI –0.0050 to 0.0314) more QALYs. However, the intervention is more costly
than usual care [on average £252.17 more per participant than usual care (95% CI –£69.48 to £589.38)]
when adjusted for all covariates (including baseline utility). ICERs ranged between £19,494 and £20,593
(societal perspective adjusted for all covariates) per additional QALY. For both the base-case and secondary
TABLE 47 Total mean costs based on all available cases, up to 12 months’ follow-up
Cost item
Total mean cost, £ (SD) Mean difference
(intervention – usual care)
(95% CI)Intervention (N= 493) Usual care (N= 517)
Hospital inpatient length of staya 1314.29 (3290.81) 1089.96 (2791.51) 224.3 (–181.0 to 629.6)
Hospital outpatient visits 37.57 (190.09) 26.66 (84.41) 10.91 (–13.24 to 35.06)
Hospital day case 85.22 (578.58) 90.31 (962.86) –5.08 (–143.31 to 133.13)
A&E visit 30.95 (103.97) 27.75 (82.85) 3.19 (–12.09 to 18.48)
Podiatry visits 73.35 (134.43) 140.64 (92.35) –67.29 (–83.90 to –50.68)
GP visit at GP practice 11.24 (64.47) 13.42 (42.01) –2.15 (–11.47 to 7.15)
Nurse visit at GP practice 9.43 (88.51) 8.88 (47.06) 0.55 (–11.31 to 12.42)
Occupational therapist 5.58 (28.71) 4.92 (29.71) 0.66 (–4.15 to 5.47)
Emergency service call 12.34 (67.62) 14.87 (74.05) –2.53 (–13.87 to 8.81)
Patient transportation 21.80 (116.51) 24.20 (132.79) –2.39 (–22.47 to 17.68)
Cost of interventionb 155.79 (55.02) N/A N/A
Podiatry visits 104.74 (32.14) N/A N/A
Shoes 40.29 (30.94) N/A N/A
Insoles 3.60 (3.33) N/A N/A
Exercise therabands 2.32 (1.17) N/A N/A
Exercise ball 1.00 (0.58) N/A N/A
Exercise DVD 3.82 (0) N/A N/A
N/A, not applicable.
a Length of stay.
b This is the average cost for the 413 participants in the intervention group who actually received the podiatry intervention.
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analysis (societal perspective), the probability of the intervention being the more cost-effective option is
> 0.60 for the incremental analysis adjusted for baseline EQ-5D, and > 0.65 when incremental QALYs are
adjusted for all covariates. The NMB associated with the intervention is positive, indicating that the
intervention is cost-effective, as the resources to be displaced would be less than the benefit to be gained
if the intervention was implemented in the NHS. However, these results were calculated from the point
estimate of the difference in QALYs; the lower-bound confidence limit for the 95% CI was negative,
and, therefore, there is the potential for a negative QALY gain.
The incremental cost-effectiveness plane (Figure 11) demonstrates the uncertainty associated with the
mean difference in costs and QALYs between both intervention groups by plotting the non-parametric
bootstrapping results. A total of 5000 bootstrapped replicates of differences in costs and QALYs are
shown. The majority of the replicates falls within the north-east quadrant, indicating that the intervention
is more effective but more costly.
TABLE 48 Summary for incremental analysis (ITT), cost-effectiveness results and uncertainty for the base-case
analysis (highlighted) and sensitivity analyses
Analysis
Difference in costsa
(95% CI)
Difference in QALYsa
(95% CI)
ICER for the
intervention
(£ per QALY)
Probability intervention
was cost-effective
£30,000/QALY (%)
Base case (MI),
NHS perspective
252.17 (–69.48 to 589.38) 0.0129 (–0.00 to 0.03) 19,494.35 65.58
Sensitivity 1
(complete case)
272.86 (–349.6 to 916.56) –0.0091 (–0.04 to 0.02) Intervention
dominated
17
Sensitivity 2 222.34 (–156.6 to 605.1) 0.0109 (–0.007 to 0.029) 20,385.75 61
Sensitivity 3 441.88 (–273.1 to 1052.4) 0.0150 (–0.002 to 0.033) 29,454.34 49
Sensitivity 4 327.17 (–65.17 to 451.09) 0.0140 (–0.003 to 0.032) 23,341.72 60
a Difference between groups (intervention – usual care) and 95% CIs were estimated from a bivariate model using SUR.
The covariates used to adjust for in the model were age, sex, treatment group, baseline utility and history of falling.
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FIGURE 11 Cost-effectiveness plane (ITT analysis) for the base-case analysis: base-case NHS perspective (MI adjusted
for baseline utility).
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The CEAC derived from the joint distribution of costs and effects is represented in Figure 12. The curve
was constructed by plotting the proportion of incremental cost–effect pairs that are cost-effective for a
range of thresholds. The horizontal interrupted line indicates a 50% probability of the intervention
representing value for money for the NHS. The probability of the intervention being cost-effective is > 60%
given the current NICE WTP threshold of £30,000 per additional QALY.
Cost-effectiveness analysis and uncertainty
A cost-effectiveness analysis, in which the outcome is expressed in terms of number of falls averted,
may be more intuitive to interpret for health-care professionals. However, there is no established WTP
threshold for an additional fall averted. Therefore, the cost per fall averted was assessed for comparison,
as allocation decisions can be made based only on cost per QALY estimates. In the base case, the podiatry
intervention was both more costly (mean incremental cost £241.64, 95% CI £–98.08 to £581.37) and
more effective (mean incremental effect 0.19 falls averted per person year, 95% CI –0.05 to 0.44 falls
averted per person year), with an incremental cost per fall averted of £1253.82 (ICER); however, for both
of these parameters the lower 95% confidence limit is negative, and so this does not exclude the
possibility of a negative result. Figure 13 shows the incremental costs and incremental effects on the form
of a cost-effectiveness plane. There is significant uncertainty in the effectiveness estimates, as the estimates
fall on both sides of the x-axis. Figure 14 shows the CEAC per fall averted.
Sensitivity analysis
Handling missing data
The complete-case analysis was tested as an alternative method to MI for handling missing data.
The complete-case scenario comprised 286 (28.3%) participants, of whom 129 (26.2%) were in the
intervention group and 157 (30.4%) were in the usual-care group. The complete-case analysis shows that
the intervention group accumulated greater costs and reported lower HRQoL than participants randomised
to usual care. The intervention costs were, on average, £272.86 more per participant than usual care
(95% CI –£349.63 to £916.56), although accumulated total QALYs are smaller than those for usual care
(mean difference –0.0091, 95% CI –0.0396 to 0.0196). Therefore, complete-case results indicate that the
0.0
0 5 10 15 20 25 30 35 40 45 50
Willingness to pay (£000)
55 60 65 70 75 80 85 90 95 100
0.2
0.4
0.6
Pr
o
b
ab
ili
ty
 o
f 
in
te
rv
en
ti
o
n
 b
ei
n
g
 c
o
st
-e
ff
ec
ti
ve
0.8
1.0
FIGURE 12 Cost-effectiveness acceptability curve (ITT analysis) for the base-case analysis: base-case NHS perspective
(MI adjusted for baseline utility).
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intervention is dominated by usual care (Figure 15). The NMB associated with the intervention indicates
that the resources to be displaced would be greater than the benefit to be gained if the intervention were
implemented in the NHS. Figure 16 represents the CEACs for the complete case when adjusted for all
covariates. The probability of the intervention being cost-effective is < 20% given the WTP for an
additional QALY up to £30,000; therefore, the intervention is unlikely to be cost-effective based on a
complete-case analysis.
Given the accumulative nature of costs and QALYs, these variables can be dealt with at different levels of
aggregation. The base-case analysis estimated QALYs by imputing missing utilities (e.g. disaggregated level).
A sensitivity analysis was conducted for the base case on the imputed data set in which we explored the
impact of imputing HRQoL at QALY level (e.g. aggregated level). Imputing HRQoL at an aggregated level
has no impact on the cost-effectiveness of the intervention).
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FIGURE 13 Cost-effectiveness plane (ITT analysis) per fall averted.
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FIGURE 14 Cost-effectiveness acceptability curve (ITT analysis) per fall averted.
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Resource use
A one-way sensitivity analysis was conducted to test the impact of including both fall- and non-fall-related
resource use. There is no major impact in the results when we investigate the impact of considering all resource
use in the assessment. The intervention is still cost-effective at the £30,000 per QALY gained threshold.
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FIGURE 15 Cost-effectiveness plane (ITT analysis) for the complete-case analysis (NHS perspective, adjusted
for covariates).
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FIGURE 16 Cost-effectiveness acceptability curve (ITT analysis) for the complete-case analysis (NHS perspective,
adjusted for covariates).
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Exploration of the need for a long-term model
The economic evaluation conducted alongside REFORM found that the podiatry intervention was likely to be
cost-effective over a 1-year time horizon. A sufficient condition for surgery to be definitely cost-effective over
a longer term is that in each year after 12 months, HRQoL is lower (and costs are the same or increasing
faster) in the usual-care group than in the intervention group. This section develops an exploratory model
to explore how the differences in QALYs evolve beyond the study. A straightforward way of projecting
QALYs beyond the trial is to assume that the difference in HRQoL observed at 1 year remains unchanged.
To compare the cost-effectiveness estimates, we defined two health states (alive and dead). The podiatry
intervention, when displacing usual care, is expected to bring gains of 0.0129 QALYs per patient (per year).
In addition, it was assumed that patients undergoing the podiatry intervention incur costs of £251 more per
year when alive. When looking at the first 5 years, the results of the model show that adopting the podiatry
intervention over usual care provides a higher HRQoL over a 5-year time horizon. Although the difference in
HRQoL between the intervention and usual-care groups decreases over time (e.g. 0.0126 at year 2 vs.
0.0117 at year 5), it remains higher for patients who received the intervention. The expected ICER related to
the adoption of the podiatry intervention ranged between £19,950 (year 2) and £21,460 (year 5) per QALY
gained. Nonetheless, the value for money of the intervention is decreasing with time. We consider that
this exploratory projection is likely to be conservative, as it excludes potential costs savings associated with
the intervention. Therefore, from this exploratory analysis we can conclude that this relatively low-cost
intervention appears to improve health outcomes within the short term. We are currently conducting a
long-term model to validate these preliminary results. The findings of this model will be published in a
peer-reviewed journal.
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Chapter 6 Qualitative results
Participants
Qualitative semistructured interviews were conducted with 15 podiatrists: 14 who delivered the REFORM
intervention and one PI from a site who was not involved in delivering the intervention but who assisted
with the day-to-day management of the study at the site. All trial podiatrists were invited to take part in
the qualitative interviews. The sample consisted of five men and 10 women, representing seven NHS
trusts and a university podiatry school in Ireland. Participating podiatrists had between 6 and 32 years’
experience. Various grades of podiatrist were represented: one at band 5, six at band 6, six at band 7 and
two at band 8. All podiatrists worked predominantly with patients from the community and were skilled in
providing footwear advice, exercises and insole therapy for the management of foot and ankle pathology
and biomechanical imbalance. The sample included podiatrists with postgraduate training at master’s
(three podiatrists) and doctoral (two podiatrists) level.
Further details of the REFORM podiatrists are provided in Table 49.
Twenty-one participants from the REFORM trial were interviewed. The sample comprised 10 men and
11 women aged between 65 and 87 years. Fifteen participants said that they lived with their spouse and/or
other family members and the remaining six lived alone. Further details of the REFORM trial participants are
provided in Table 50.
The qualitative interviews with trial participants and podiatrists discussed experiences of receiving and
delivering the REFORM podiatry intervention, respectively. The findings are reported according to the three
TABLE 49 Demographic characteristics of podiatrists in qualitative study
Podiatrist identifier Sex Years’ experience Qualification
1P Male 27 BSc and MSc
2P Male 10 BSc and MSc
3P Female 11 BSc
4P Male 10 BSc
5P Male 6 BSc
6P Female 8 BSc
7P Female 10 BSc
8P Female 32 MSc
9P Female 13 BSc
10P Female 22 BSc
11P Female 9 BSc
12P Male 28 DPodM
13P Female 18 BSc
14P Female 10 PhD and BSc
15P Female 9 PhD and BSc
BSc, bachelor of science; DpodM, diploma In podiatric medicine; MSc, master of science; PhD, doctor of philosophy.
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components of the REFORM trial intervention in turn: (1) footwear assessment, advice and provision,
(2) orthoses and (3) exercises. For each intervention component, three main themes are discussed:
(1) current usual practice, (2) acceptability and barriers to implementation among service providers and
(3) acceptability and adherence among service users. Within the adherence subsection, quantitative data
from the whole of the trial intervention group are included as appropriate.
Footwear assessment, advice and provision
Assessing and ordering footwear during usual practice
Podiatrists reported how patients frequently wore inappropriate footwear and cited common issues seen
during practice as narrow shoes, inappropriate heel height or shoe style and a lack of appropriate
fastening. Although some issues with men’s footwear were reported (e.g. fastening and inappropriate
slippers), it was the perception of the podiatrists that the majority of issues were with women’s footwear:
It tended to be the women that weren’t wearing the sort of shoes that would balance and that were
comfortable, they tended to wear, I don’t know, more fashionable shoes forgetting about what sort
of age they were and they hadn’t thought about the fact that the shoes were possibly causing
their instability.
Podiatrist 7
TABLE 50 Demographic characteristics of participants in qualitative study
Participant
Age at randomisation
(years) Sex
Reported fear of
falling at baseline
Fallen during the 12 months
after randomisation
1 70 Male Some of the time No
2 75 Male Some of the time No
3 77 Male A little of the time No
4 80 Female None of the time Yes
5 81 Female Most of the time Yes
6 77 Female A little of the time No
7 67 Female Some of the time No
8 65 Male A little of the time No
9 80 Female All of the time Yes
10 84 Male A little of the time No
11 80 Female A little of the time No
12 67 Female Some of the time Yes
13 87 Female None of the time Yes
14 79 Male All of the time No
15 79 Female A little of the time No
16 84 Male A little of the time Yes
17 69 Male A good bit of the time Yes
18 78 Male Some of the time Yes
19 86 Male None of the time Yes
20 79 Female Some of the time Yes
21 79 Female A good bit of the time No
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All podiatrists discussed how general footwear advice was provided as part of their usual practice, with a
small number of podiatrists basing this advice on falls prevention. Routinely, footwear advice involved
discussions around the types and styles of shoes and placed a particular emphasis on the importance of
indoor shoes. Central to these discussions was the need to enhance the patient’s understanding of ‘good
footwear’. To facilitate this, podiatrists described how they often directed patients to cheaper footwear
alternatives or specific companies, to demonstrate that a good shoe was not necessarily reflected by its
price. In addition, podiatrists spoke of using prompts such as shoe catalogues, leaflets and sample shoes
that were compared with patients’ current footwear, in order to further patients’ understanding.
Variation in the criteria to assess patients’ footwear was reported within routine practice; for instance,
some podiatrists described how they made assessments by glancing at the patients’ footwear or how the
assessment was ‘second nature’. The characteristics of footwear commonly assessed during routine
practice tended to include fastening, length, width, heel height, sole and fabric. Podiatrists confirmed that
there is currently no formal checklist used within routine practice for footwear assessment:
Yes it’s in your head and then you tick a box on SystmOne to say appropriate footwear worn . . .
it’s second nature.
Podiatrist 5
Podiatrists reported that footwear was not routinely provided, with only one podiatrist (podiatrist 5)
referring to fitting ‘stock hospital shoes’ when there was a clinical need.
Experiences of assessing and ordering footwear during the REFORM trial
For the purposes of the REFORM trial, participants were asked to bring samples of their indoor and
outdoor footwear to the clinic for assessment. As described in Chapter 2, podiatrists were asked to assess
participants’ footwear against a checklist provided by the research team of characteristics of suitable
footwear identified in the literature12 (see Appendix 21). If trial participants failed to bring samples of their
footwear, the assessment was based on a description. The majority of the podiatrists found the trial criteria
for assessing footwear straightforward to follow and described the checklist as clear and logical:
It [the checklist] was very similar to what I would normally do and it actually reiterated all the things
that I was doing before so it was, you know, clarified everything that I was doing and thinking yep
that it was [what] I would do anyway, so I mean that was quite useful because it took me back to
basics to actually think about it a bit more.
Podiatrist 7
However, a few podiatrists mentioned that the current electronic medical record did not have sufficient
data fields for the more detailed footwear checklist; therefore, alternative ways of capturing these data
would have to be found:
In our paperwork we have whether it’s a good fitting shoe, whether it was too big or too small,
whether it’s a slipper or bespoke orthopaedic aid and then we have an optional heel height and what
kind of fastening they have and we do have a comment box as well. So that’s our kind of footwear
assessment of what we can document.
Podiatrist 10
The REFORM trial also enabled podiatrists to order footwear for participants, which is something that is
not currently provided in usual podiatry care. Prior to ordering shoes, podiatrists were required to measure
participants’ feet. The measuring guide was a laminated picture of a foot, annotated with different shoe
sizes. Participants stood on the guide and their corresponding shoe size was read. The width of shoe
was determined by measuring the circumference of the foot using a tape measure and referring to a
chart to find the required width (www.dbshoes.co.uk/measuring_chart.php, accessed 2 October 2012;
www.hotter.com/gb/en/info/Hotter-Shoes-Fitting-Guide, accessed 2 October 2012). Although the majority
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of podiatrists described the measuring process as straightforward, a number of difficulties were reported,
especially among those who did not have training in shoe fitting outside the trial (the trial did not provide
additional training on this). Some podiatrists commented that the measuring guide on which participants
stood during the measuring process would sometimes slip unless it was taped to the floor. Challenges for
less mobile patients were also reported, as they found it hard to stand on the measure, which had to be
placed against a wall.
Despite some difficulties, the majority of podiatrists felt that footwear assessment and advice was generally
straightforward and a central element of their clinical role; however, some expressed concerns that in
routine practice there would be insufficient time to undertake a full footwear assessment:
It is time-consuming but we were given enough time to do it, so in an ordinary clinic if you had
20 minutes to do a routine treatment and educate them on footwear and have a discussion around it,
it would really eat into the time but for the study we had enough time to do that.
Podiatrist 1
Given these time pressures within usual practice, a number of the podiatrists did suggest that this element
of the intervention could potentially be conducted by a podiatry assistant or technician:
. . . probably our technicians or podiatry assistants are probably very, very competent at doing that
type of thing.
Podiatrist 7
In contrast, however, one podiatrist (podiatrist 4) felt very strongly that footwear measurement was
outside the role of podiatrist and should be conducted by an orthotist, working as part of a
multidisciplinary team.
Additional issues with the measuring process included the accuracy of the sizing guide, fitting slippers that
were available only in full sizes (not half sizes), the lack of footwear under size two and the time required
to fit footwear:
That was out of frustration because of the backwards and forwards process of ordering, fitting and
finding out that the shoe wasn’t right.
Podiatrist 3
A minority of podiatrists also found the shoe ordering process very time-consuming, something that was
attributed mainly to patients spending large amounts of time selecting footwear from what some
podiatrists considered an excessive number of options.
Experiences of and adherence to footwear advice/trial purchased shoes
As would be expected, adherence to footwear advice varied among participants. From the 12-month
follow-up questionnaire administered to the whole of the trial intervention group, we observed that nearly
two-thirds (n = 137, 63.7%) of the participants who reported that they had their shoes checked said that
their podiatrist gave them advice about their footwear or suggested that they should wear a different style of
shoe, of whom 104 (77.0%) reported that they followed this advice (80.8% of men and 74.7% of women).
It was the view of both podiatrists and trial participants that it can be difficult to action footwear advice
and change shoes/slippers, as high-street shops do not always stock footwear that is a suitable fit, and in
some areas there is a lack of stockists:
But you see they say what makes an everyday shoe unsafe . . . what they mean about secure
fastenings but they’re not easy to find either . . . That’s what I need, depth for my toes and they have
depth but you don’t get a great deal of choice and I believe there’s a shop down [name of street
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where shop is] that deals in, just a little shop and they deal in shoes, I haven’t been in. I’ve just looked
in the window as I’ve passed by.
Trial participant 8
Several podiatrists highlighted that, for many service users, the cost of the appropriate footwear
recommended could be prohibitive:
Obviously these brands that you recommended, you know, in the shops they can be 70 to 80 pounds,
so you know, unfortunately some people just can’t afford to get more specialised footwear.
Podiatrist 6
The availability of shoes through the trial had provided respondents with access to appropriate footwear by
overcoming these barriers. In addition, podiatrists were at pains to discuss with service users that, although
many shoes were expensive, ultimately the cost of the shoe did not always reflect whether or not it was
appropriate for them:
. . . so I think [the service providing shoes] is a great idea in theory but I think it’s probably quite costly
and maybe, you know, you can buy, you know, if you’ve got to buy a pair of shoes there’s a lot of
shoes you can buy that aren’t as expensive but still have those good qualities, you know, like a
cheaper pair of trainers really.
Podiatrist 12
The response to the footwear advice/footwear provided was mixed. Many participants reported that they
wore their ‘appropriate’ outdoor shoes all the time and were really satisfied with the fit and choice
of shoe:
I think I’ll always wear Hotter shoes now because they’re so good.
Trial participant 2
Other participants described how they stopped wearing the footwear, largely because the shoes did not fit
properly and were uncomfortable; in some cases, even the recommended shoe suppliers did not have
shoes that were a good comfortable fit for people who are older (some of whom had various foot
problems including arthritis, bunions or corns). In addition, there were also pragmatic reasons why
appropriate shoes were more difficult to identify for some service users, such as difficulty in putting shoes
on among this age group:
The age group of the patients in the REFORM trial were very elderly, or a lot of them were, and for
that reason they had difficulty getting down to their feet, so they tend to go for slip-on shoes for ease
of fitting them whereas a lace-up or Velcro-fastening shoe created additional problems.
Podiatrist 3
Despite participants demonstrating a good general understanding of ‘appropriate footwear’, there were
still a number of examples of inappropriate footwear being worn, reflecting the pragmatic solutions the
participants had found in order to incorporate the advice into their daily routines and practices:
I think if you wear sensible shoes, I think that’s the big thing. I mean I’m past all these stiletto heels
now. I used to wear them once but no, I do wear a little heel sometimes when I go out. I like these
flip-flops in the summer because they’ve got the heighted heel at the back and I find that very
comfortable. I’m not very keen on dead flat but because of my neck I don’t like a very flat shoe.
Yeah I think sensible shoes.
Trial participant 6
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Although not particularly supported by the quantitative data, podiatrists perceived that women were less
likely to action the footwear advice and that this needed to be taken into account when such advice was
being provided:
It’s about the complete loss of identity . . . you have to try and see if from the patient’s point of view
because it’s very cut and dry for us. This is what you need, this is what’s going to be really good for
you and that’s what you’re going to get and sometimes you have to work a little bit more around the
patient and I think, you know, going back to the original discussion about footwear, I think women
have an idea about how they want to present themselves to the world and if say that foot support or
orthotic is not going to fit in that shoe or the shoe is not going to support the function of the device,
it can be very difficult.
Podiatrist 4
Orthoses
Using orthoses during routine practice
The majority of podiatrists described how they had prescribed some form of orthosis in their usual practice,
predominantly for clinical conditions such as Achilles tendon problems or plantar fasciitis; however, one
podiatrist (podiatrist 1) reported that they had prescribed an orthosis for a participant who had fallen.
Of the podiatrists who had prescribed orthoses, the majority had prescribed the trial orthosis (X-Line) or a
similar orthosis. Issues encountered when routinely prescribing orthoses were reported and included
complaints that they were uncomfortable or too bulky to fit in participants’ shoes:
Sometimes they [the participants]find them a bit too bulky, so they can’t get their foot in as well as
the insole and just to be able to get them in the shoes themselves.
Podiatrist 2
Experiences of the X-Line orthosis during the REFORM trial
The majority of podiatrists and trial participants reported positive experiences of using the X-Line orthosis
and described the X-Line as a good, cost-effective orthosis. Podiatrists also explained how the X-Line was
good for participants who had arthritis or deformities, as the orthosis was slim and so could easily fit into
footwear. The arch support, control on the heel and met dome support were also cited along with the fact
that the X-Line was not overly corrective and so was not expected to cause problems such as lesions or
balance problems. Direct comparisons with other routinely prescribed orthoses were also made, with
podiatrists often stating a preference for the trial orthosis. Podiatrists’ positive experiences of the X-Line
orthosis were also demonstrated when one site reported that it may consider changing its routinely
prescribed orthosis to the X-Line, although this would ultimately depend on the cost of the device and
whether or not those who purchased equipment in the trust would agree to order this type of device:
These weren’t bad at all because they’re quite thin on the front as well, that’s another problem we
usually have of patients especially if they’ve got arthritis in their toes, claw toes that type of thing but
even the slight raise sort of lifts the foot up and then the shoes are pressing on the toes. But no I was
quite impressed with those.
Podiatrist 8
On a practical level, the majority of podiatrists found the X-Line insoles easy to fit into participants’
footwear. Trimming the insole was generally not found to be an issue, as this could mainly be done at
the clinic with scissors. If required, the insole could also be trimmed to three-quarter length, to aid fitting
into participants’ footwear. Attaching postings and additions was also not perceived to be a problem,
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as they were self-adhesive. This meant that they could be attached in the clinic and so did not require
special equipment or to be sent to the laboratory, as is sometimes the case:
The additions we just had the peel back, so like the sticky on the back and you just peel it off and away you
go whereas the ones we use at the minute, they have to go to the lab and like be glued on. So obviously
this is easy because you’ve got them in clinic and you can put them on there and then and off they go.
Podiatrist 2
However, although the majority of podiatrists related positive experiences, theere were some difficulties
reported with fitting and trimming the X-Line. For instance, one podiatrist (podiatrist 3) stated that trying
to fit the orthosis into a participant’s footwear made the shoes too tight and inappropriate:
The only difficulty came in with trying to fit an orthotic [insole] to what was an appropriate shoe and if
the shoe then became too tight then it was no longer an appropriate shoe.
Podiatrist 3
At study set-up, some sites raised concerns about the possibility of the trial identifying patients with an
unmet clinical need, who would require a full biomechanics assessment. Sites were apprehensive about
the impact that this would have on their clinics. These concerns were not represented within the
interviews; the majority of podiatrists were willing to prescribe the insole without a full assessment, as they
considered the device unlikely to cause participants any problems. However, three podiatrists reported
giving participants an assessment to check that it was clinically appropriate to prescribe the orthosis:
Yeah I mean it was a slight assessment with checking muscle strength and basic things but I wouldn’t
say it was a full complex biomechanical assessment.
Podiatrist 8
Experiences of and adherence to the orthosis prescribed during the REFORM trial
For those in the trial as a whole, Table 51 presents responses to the adherence questions for the
intervention participants who received an orthotic insole and responded to this question. At 12 months,
66.4% of participants reported wearing their orthosis most or all of the time, and 85.0% reported wearing
it at least a little of the time.
It is clear that wearing orthoses was generally acceptable; however, the podiatrists adapted their use to the
individual circumstances of the participant, for example by adapting the insole to accommodate foot
TABLE 51 Adherence to the orthoses for intervention participants who received the intervention
Time point (month)
3 6 12
Number of questionnaires received 457 427 408
Of which received intervention 393 372 357
Of which received an orthosis 237 224 215
In the past month, typically how often was foot orthosis (insole) worn in shoes, n (%)
All of the time 89 (38.5) 75 (33.9) 87 (40.7)
Most of the time 61 (26.4) 73 (33.0) 55 (25.7)
Some of the time 34 (14.7) 29 (13.1) 30 (14.0)
A little of the time 10 (4.3) 15 (6.8) 10 (4.7)
None of the time 37 (16.0) 29 (13.1) 32 (15.0)
DOI: 10.3310/hta21240 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 24
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Cockayne et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
87
deformities. As might be expected, how comfortable the participant found the insole was a significant
determinant in whether or not it was worn with any regularity:
They’re comfortable and that’s the main thing as well, if they weren’t comfortable they would have
been chucked out.
Trial participant 7
However, those who felt that the orthosis was likely to have a benefit, through either previous experiences
of using orthoses or anecdotes from family or friends, seemed to be prepared to endure some discomfort,
at least initially. Some participants were also willing to persevere with the orthotic, despite some initial
discomfort, because it had been recommended by the podiatrist and they felt that it was likely to be of
benefit. Several reported that they considered the insoles to be a good idea, especially as they had either
fallen several times or because they wanted to find something to help improve their walking, and
demonstrated a willingness to try:
Well it took several weeks to get accustomed to the insoles, it was quite painful but I was determined
to persevere.
Trial participant 4
Although in some cases the perseverance paid off, others ceased to wear the orthosis completely:
I used the orthotics, I had some from before, and they are not comfortable with my back. I mean
there’s nothing much the matter with my back but I ended up with a sore back, with wearing them.
Trial participant 13
A contributing factor in the resultant comfort was whether or not appropriate footwear was available.
Although the trial had attempted to accommodate the requirement for footwear when necessary, for
some participants, even with this option, the orthosis was still not a comfortable fit. This was especially the
case for individuals who had pre-existing problems with their feet, which made it difficult to cope with the
inserts, or who had to adapt the use of the inserts to make them tolerable:
Yes but on one foot I could wear them but not on the other because I’ve got very high arch, I broke
this foot when I was very, very young and it just made a difference. It made the shoe too tight.
Trial participant 3
However, for many the whole package of obtaining the appropriate footwear and orthosis worked well
and participants could feel the benefit from the increased support. Positive experiences were mainly
associated with comfort and support, for example improvement in posture or shoes fitting better and
being more comfortable to wear. This was in addition to the perceived effect it had on participants’
balance, the number of falls they had and their confidence:
. . . [the podiatrist] decided the shoes, although they were Clarks [C&J Clark Ltd, Somerset, UK] the
shoes I was wearing, they weren’t as good so she measured me for some shoe inserts and I got a pair
of Hotter shoes and a pair of Hotter slippers and these shoes and the inserts they’ve made a dramatic
difference, you know, to me walking and lifting; because I think my arches have probably fallen a bit,
so it gives me support in that way.
Trial participant 2
Those who were experiencing a noticeable benefit tended to wear the orthoses all the time:
I’ve got one set for these shoes and then another set I use if I go out anywhere or leisure, I just slip
them into whatever shoes I’m using.
Trial participant 2
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However, others, who did not feel such a palpable benefit or who did not have the expectation that
orthoses were likely to affect their risk of falls, tended to use the inserts in a more pragmatic way, and
adapted their use to what was practical and feasible:
I’ve got them in one of the pairs of shoes that I wear most of the time . . . [I wear them] probably four
times a week, because I can’t get them in, like I say, I’ve got a problem with my toe, so if I can’t put
them into any of my other shoes because there’s not enough room in there for my toes and that in
sole . . . I can’t say that I’ve really felt a difference, do you know what I mean – I’ve got used to
wearing them so they’re very comfortable.
Trial participant 7
Exercises
Prescribing exercises in routine practice
Some podiatrists reported prescribing exercises in their routine practice, largely for conditions such as
plantar fasciitis or Achilles tendon injuries. The podiatrists were not currently prescribing exercises for falls
prevention in routine care. They acknowledged issues associated with prescribing exercises, which included
the potential for the exercises to cause injury:
Yeah but with older people a lot of the exercises you’ve got to be really careful with that you don’t
cause further problems. Some of the exercises I think the patients go a bit too far with them and
would actually sort of damage tendons if they overstretch.
Podiatrist 8
Exercises prescribed during routine practice differed from those in the REFORM trial. Although podiatrists
reported having prescribed some, if not all, of the exercises provided during the trial, these exercises had
not been prescribed as a ‘package’ or in combination with each other. In terms of the individual exercises,
resistive bands and foot therapy balls were rarely provided but may have been prescribed in biomechanics
clinics. Some podiatrists raised the issue of professional domains, remarking that, in current practice,
prescribing exercises is the responsibility of physiotherapists rather than podiatrists:
Podiatrist 9: . . . but we’ve never had therabands within podiatry stock.
Interviewer: I think some of it is expensive, is that the reason?
Podiatrist 9: I think that would be, yeah the main reason I would think and it just seems to be for our
trust, it seems to be the role of the physiotherapist. So we maybe refer patients to physiotherapy for
that part of an exercise programme but we haven’t done it within the podiatry clinics.
To negate the need for specialist equipment in routine practice, podiatrists would suggest alternative ways
of conducting exercises; for example, they might advise patients to use a dressing gown cord instead of a
resistive band. In addition, over half of the podiatrists reported that they had prescribed exercises using
alternatives to a therapy ball that required patients to roll their feet over a can, or to pick up pencils or golf
or tennis balls.
Experiences of the exercises during the REFORM trial
Podiatrists mostly spoke positively of the trial exercises. Indeed, two podiatrists reported having changed
their routine practice to prescribe exercises when appropriate. However, some practical issues were
reported, including the difficulty with prescribing exercises for elderly and frail patients, especially given the
number of exercises that were included and the length of time it took to explain them. Podiatrists took a
DOI: 10.3310/hta21240 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 24
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Cockayne et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
89
pragmatic approach and modified the trial exercise package to adapt the regime for people with
comorbidities, to reduce the number of exercises or to suggest that particular exercises were
not undertaken:
Podiatrist 3: Yes when we were finding exercises for the very elderly patients, a lot of them struggled
to actually be able to go on tiptoe, stand on one foot because they were quite frail. Some patients
also had other health problems which made exercise a lot more difficult such as osteoarthritis of the
feet, so they would often phone up and say, I’ve tried very hard to do these exercises but they’re
causing me a lot of pain.
Interviewer: Right and so in those cases what was the advice you gave them?
Podiatrist 3: We asked them to modify their approach and to do as many of the exercises as they
could do but not feel too bad if they had to reduce the frequency of the exercise or maybe even miss
one exercise out, for instance, if they had osteoarthritis of the first MTP [metatarsophalangeal], big toe
joint, we would say to them, don’t worry about getting on tiptoe but do and try and do the
other ones.
To facilitate trial participants’ understanding of and adherence to the exercises, a booklet and a DVD were
provided. Podiatrists and trial participants spoke positively of the booklet, describing it as well written and
easy to follow, with clear instructions and a good combination of pictures and text. The booklet was
viewed as a useful resource that helped podiatrists to remind and explain to patients how to do the
exercises, something that was considered particularly important given the amount of information patients
received at their first appointment. During the trial, podiatrists used the booklet as a guide when delivering
the whole intervention and also worked through the booklet with patients, using the pictures to aid their
description of the exercises during clinic. Although one podiatrist (podiatrist 3) felt that some participants
viewed the information in the booklet as too simplistic, others saw its simplicity as a strength, stating that
it could have been issued without additional instructions. The positive feedback provided by podiatrists is
exemplified by the fact that a few sites asked if they could give out the booklet in their routine practice
prior to the end of the trial, with one podiatrist (podiatrist 10) also presenting the booklet at a staff
meeting:
I thought it was very good. It was very well written. It was very easy to follow and because it had the
pictures, the people could, you know, go back to it and have a look and it did make sense. It was
written well.
Podiatrist 7
In light of podiatrists’ initial concerns regarding the amount of information given to trial participants at the
start of the study, both the DVD and the booklet were considered helpful reminders. However, only a
small proportion of trial participants reported having watched the DVD. The podiatrists provided some
insight into this during their interviews, as they reported that patients had difficulty playing the DVD or, in
some cases, did not have a DVD player. In addition, one podiatrist (podiatrist 3) suggested that the DVD
may be more suitable for younger people and felt that those in the age group taking part in the trial
would prefer written information:
Some of the DVDs did not work and not every patient had access to a DVD player and the patients
tended to report back that while they found the booklet very helpful because that generation tends to
like to read things rather than play things, if you’re dealing with a younger generation the DVD would
have been more useful.
Podiatrist 3
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Podiatrists felt that a follow-up appointment was important to ensure that the exercises were being
conducted correctly:
. . . showing the patient how to do them correctly and getting them to do them correctly, because
occasionally when they came back to the clinic for their review appointment and you asked them to
demonstrate the exercises again, some of them hadn’t been doing them correctly, so it just needed a
bit of re-education really.
Podiatrist 1
Experiences of and adherence to the exercises prescribed during the REFORM trial
At 12 months, 28.9% of participants in the intervention group reported performing the exercises at least
three times per week and 74.5% reported performing them at least once per week (Table 52).
In the interviews, participants reported varying levels of adherence to the exercises, with some reporting
undertaking them every day, some reporting undertaking them three times a week and some reporting
that they did not do them at all. The length of time that participants complied for also varied, with some
reporting trying the exercises for a short time before stopping (e.g. 1 month), although others persevered
because of their desire to prevent falls.
In the main, the trial participants spoke positively about the trial exercises, although, in a similar vein to the
podiatrist interviews, the number and challenging nature of some exercises was discussed. Trial participants
and podiatrists expressed varying opinions regarding the resistive band and therapy ball exercises, which
are outlined in Table 53.
Although some participants reported that they had not noticed any differences since undertaking the
exercises, for many participants the exercises had led to perceived benefits, such as improvements in their
walking, balance, confidence and body awareness:
I didn’t do them every day to start with but I did them at least three times a week and within several
weeks I felt the benefit. I did feel the benefit from, you know. In my walking and in my balance and
the ability to get to stand up.
Trial participant 2
Whether or not participants perceived the exercises to be beneficial may have influenced their adherence.
For example, one participant commented that they had continued to undertake the exercises even when
they were tired, as their perception of improvements had given them an incentive to continue.
TABLE 52 Adherence to the exercises for intervention participants who received the intervention
Time point (month)
3 6 12
Number of questionnaires received 457 427 408
Of which received intervention 393 372 357
In the past month, typically how many times a week were foot and ankle exercises undertaken, n (%)
More than three times a week 51 (13.4) 43 (11.8) 45 (12.9)
Three times a week 90 (23.7) 66 (18.1) 56 (16.1)
Twice a week 89 (23.4) 86 (23.6) 71 (20.3)
Once a week 75 (19.7) 79 (21.7) 88 (25.2)
Not undertaken 75 (19.7) 90 (24.7) 89 (25.5)
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A number of participants also described strategies that they had adopted to make the exercises easier to fit
into their daily lives, for example goal-setting (e.g. wanting to stand up easily), splitting the exercises
throughout the day, and doing the exercises ‘first thing in the morning’ or while watching television,
which may have improved adherence:
I do them three times a week all at once, one after the other. Monday, Wednesday and Friday and I’ve
done them this morning before 7 o’clock. Well I make sure because I do it at a time that suits me that
doesn’t interfere with my life, you know, because I’m out of the house by quarter to nine every
morning, so you know, that’s the time it’s done.
Trial participant 1
For participants who did not regularly undertake the exercises, a range of reasons for non-adherence were
provided, including the length of time required to undertake them. Medical conditions such as heart
problems or arthritis also made performing the exercises difficult or painful for a number of participants:
. . . because I’ve got a bad heart, it doesn’t take me long to get out of breath, so I found them hard
work, very hard work.
Trial participant 7
TABLE 53 Trial participant and podiatrist opinions on resistive band and therapy ball exercises
Type of exercise Trial participant and podiatrist opinions
Resistive band exercises
Some podiatrists thought that the
exercises were good but expressed
concerns over whether or not the
participant could site the band properly
and undertake the exercises correctly
The place at where they put the theraband over the foot, so sometimes it
might have been more along the arches of the foot rather than across the
forefoot, so just where to place the theraband. Sometimes they were trying
to move their whole leg with the theraband
Podiatrist 13
Some trial participants reported
difficulties in siting the band and others
developed strategies to site the band
correctly
Mainly because I don’t think I have furniture that lends itself to it but it just
kept sliding off and we tried and tried
Trial participant 1
I used to put like the big elastic band around the table leg and move my leg
Trial participant 8
Therapy ball exercises
The majority of podiatrists liked the
exercise and found it easy to determine
which size of ball to prescribe, although
patients with foot deformities
encountered difficulties in performing
the exercises
It was quite useful idea, get the intrinsic muscles working a little bit, help
with the stability a good idea
Podiatrist 1
There were a few patients who couldn’t do it but just due to their foot
deformity they’ve got like arthritis of the toes or they couldn’t actually bend,
you know
Podiatrist 10
Most of the trial participants liked these
exercises. Not all could pick up the ball
but those who did often reported a
sense of achievement
I did find them very good and I felt very pleased with myself when I could
grip the ball. I used to say [name] come and see what I can do now, you
know, it’s an achievement because again you get to a certain age and you
don’t do, you know, generally you don’t do exercises really
Trial participant 9
I find the ones with the ball I find it very good to do that and I can more or
less, at first I couldn’t lift it, you know, but I am getting more flexibility in my
toes now with that
Trial participant 3
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Others had to adapt the exercise package to accommodate their own physical limitations:
One I couldn’t do. The one where you had to stand up with your back up against a wall. I couldn’t do
that because I couldn’t balance on one leg because this knee is so bad. There is no way I could stand
and put all my weight on one leg, so I tried that one once and thought wow.
Trial participant 7
For others, the exercises were not a priority either because they were not motivated to do them or because
they had other priorities such as being a full-time carer for a relative.
The REFORM package of care
Of the 211 participants who received an orthosis as part of the intervention and who provided a response
to both questions relating to adherence to the insole and to the exercises at 12 months, 68.7% (n = 145)
reported having worn their orthotic and preformed the exercises in the previous 4 weeks, 5.2% (n = 11)
reported no adherence to either aspect and the remaining 55 reported that they either only wore the
orthotic (n = 35) or only undertook the exercises (n = 20).
Given the multifaceted nature of the REFORM intervention, coupled with the often complex health issues
of the population group, the majority of participants were able to complete only some aspects of the care
package and had to adapt what was available to suit their own circumstances and perceptions of impact.
A similar pragmatic approach was taken by the podiatrists, who were able to see how they could
incorporate the basis of the intervention into routine practice:
I mean the majority I think I would probably give a few exercises and an insole to.
Podiatrist 7
Although podiatrists found the intervention acceptable and were, in principle, willing to administer all of
the elements, some did question how the intervention could be incorporated into routine care, given the
way that services were currently configured:
I think just, I suppose it just reminded me more of what I should be doing, what our roles should involve
because the way we work in [centre], we’re all quite fragmented I suppose. So I would not normally have a
patient in a clinic, in a routine clinic for a 20-minute appointment slot and so, if you’ve got a caseload of
patients and they’re coming in to see you every 4 months, if they’ve had a fall, you’re just not going to
start taking them through a falls exercise programme and there isn’t any other specialised clinic that you
book them into to have that time to do it. So we have falls, so you know if somebody has a fall, our service
accesses the falls clinic and the GP would refer onto the falls clinic and that’s nothing to do with podiatry.
Podiatrist 13
Some highlighted that, for the exercise element in particular, there may be more appropriate contexts in
which this could be delivered:
Yeah because we have got dedicated biomechanics clinics, so I think it would sort of fit in well within
that area of our service.
Podiatrist 9
Given the probable time restraints in routine care, some podiatrists suggested delivering certain elements
of the package of care in group sessions to save time and money; however, opinion was split on whether
or not this would be the best mode of delivery from the patients’ point of view:
Something that we could use later as maybe a group session and getting patients in to talk them
through as a group session and showing them the different exercises and the type of shoe that they
should be wearing.
Podiatrist 7
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I think on a one-to-one basis it is better. If you have them in a class, you’ll have people who are
self-conscious or not really willing to try things just out of fear and I think one-on-one situations they
feel comfortable, in a safe environment and it’s a better way to deliver it.
Podiatrist 1
Summary
Footwear
Podiatrists provide footwear advice in routine practice and are well versed in doing so. The trial footwear
checklist was detailed, provided a more formal evidence-based tool with which to assess footwear and was
acceptable to podiatrists. For the checklist to be used in routine practice, attention would have to be paid
to how the information on the checklist was recorded in the current electronic patient record systems.
Although most podiatrists found measuring for shoes straightforward, this could be time-consuming and
may be difficult within the constraints of normal clinic appointments. It was suggested that this aspect
could be conducted by technicians, podiatry assistant or orthotists rather than podiatrists as part of a
multidisciplinary team.
It is questionable whether appropriate footwear would be provided within current NHS budgets. Outside
the trial it may be more difficult to achieve adherence to footwear advice, given the financial constraints of
many of the service users. In addition, there is a subgroup of service users who will be unable to access
shoe retailers, who will not be able to achieve a good fit owing to existing foot problems, or who will be
resistant to wearing the footwear options available.
Orthotics
Podiatrists do not routinely prescribe orthotics for falls prevention. However, they were positive about
the trial orthotic and found it easy and acceptable to implement without the need for more complex
biometrics assessment. Appropriate footwear is required to achieve a good fit for the orthotic; this will be
less achievable for a wide range of service users outside the context of the trial if footwear is not being
provided. Service users will find a pragmatic solution to incorporating wearing an orthotic, if comfortable
to do so, into their everyday lives.
Exercises
Podiatrists do not currently prescribe exercise packages such as those in the REFORM intervention. They did
find it acceptable to do so, in particular with the aid of the trial booklet. However, explaining the exercises
properly was time-consuming and would be difficult to fit into a routine podiatry appointment. Podiatrists
also felt that a follow-up appointment would be necessary to check that the exercises were being
conducted appropriately to avoid injury.
The equipment necessary for the REFORM exercises was not always routinely available in podiatry clinics,
meaning that additional resources would be required or that alternatives to the formal equipment would
have to be suggested. Although podiatrists were happy to implement the exercise component of the
intervention, this was more commonly seen as being the domain of physiotherapy or biomechanics, and in
routine practice a way of incorporating the intervention into the current configuration of podiatry/falls
services would have to be developed. For example, it was suggested the exercises and footwear advice
could be explained in a group setting, perhaps in the context of a multidisciplinary falls clinic.
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Chapter 7 Discussion
Here we report the results of a large RCT assessing the clinical effectiveness and cost-effectiveness of amultifaceted podiatric intervention for the prevention of falls among podiatry patients within a NHS
setting and one international site in Ireland. Previous reviews, including the most recent Cochrane review,
have identified only one previous RCT of a similar intervention in an Australian setting.23 A meta-analysis of
eight RCTs using foot and ankle exercises noted improvements in surrogate measures of outcomes, such
as balance.19 In this discussion, we summarise our key findings, compare these with previous studies and
discuss the strengths and limitations of our study.
Key findings
The REFORM trial is the largest study of a podiatric programme that includes a foot and ankle exercise
programme to reduce the risk of falling. A total of 1010 participants were randomised. Our sample size
allowed for a 10% loss to follow-up. The actual overall loss to follow-up observed at 12 months was
12.4% [in total, a 12-month questionnaire was returned for 885/1010 (87.6%) randomised participants].
Although this loss was higher than expected, we still had sufficient numbers relative to the target sample
size of 890, as the trial over-recruited to 1010 participants. The primary clinical outcome for the trial was
the incidence rate of falls reported on monthly falls calendars in the 12 months following randomisation.
In practice, it is difficult to calculate the required sample size for a regression model, such as a Poisson or
negative binomial regression model, to analyse count data. This requires an estimate of the measure of
overdispersion and a justifiable treatment effect to detect. There were a limited number of data on which
to base these parameters and so the decision was made to power the trial to detect a difference in the
percentage of participants who reported at least one fall over the 12-month follow-up.
In total, 992 (98.2%) trial participants returned at least one falls calendar following randomisation, with
similar proportions across the two groups [484 (98.2%) participants in the intervention group and 508
(98.3%) participants in the usual-care group]. We found a reduction in the rate of falls per person-year
(IRR 0.88, 95% CI 0.73 to 1.05) and in the proportion of participants who had one or more falls over the
12 months from randomisation (OR 0.78, 95% CI 0.60 to 1.00). The difference was not statistically significant
in our prespecified primary outcome of rate of falls (p = 0.16); however, the difference in the proportion of
participants who had at least one fall (54.9% and 49.7% for usual care and intervention groups, respectively),
a key secondary outcome, was of borderline statistical significance (p = 0.05). In our sample size calculation,
we assumed that 50% of the usual-care group would fall during the 12-month follow-up, and we powered
to detect a fall to 40% in the intervention group. In fact, 55% of the usual-care group experienced a fall.
With the numbers recruited, we had 80% power to detect a fall to 46%, and approximately 36% power to
detect the difference of 5% observed. Although a 5% decrease in the number of participants falling is of
borderline statistical significance, it is difficult to say whether or not it is clinically meaningful. The estimated
number of participants to whom we would need to offer the intervention to prevent one person from
experiencing a fall is 20, which is relatively low.
A small, and similar, proportion of participants reported at baseline that they had been referred to a falls
clinic or service in the previous 12 months in the two groups. At the end of the 12-month follow-up, we
asked this question again: 30 out of 416 (7.2%) intervention participants and 22 out of 452 (4.9%) usual
care participants said that they had been referred to a falls clinic or service in the previous 12 months.
It is possible that participants in the intervention group interpreted this question as referring to their trial
appointments at the podiatry clinic. If participants in the usual-care group received some form of intervention
shortly before or during the trial follow-up, this could potentially have diluted the treatment effect. However,
with only small numbers reporting this, we do not believe that this could have significantly influenced the
results, and in any case we ran this as a pragmatic trial and so the results will reflect usual practice.
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Time to first fall was reduced in the intervention group but this was not statistically significantly (hazard
ratio 0.88, 95% CI 0.74 to 1.04; p = 0.14). No statistically significant differences between the two groups
were observed at 6 or 12 months in the fear of falling question, the Short Falls Efficacy Scale-International,
the FAI, the GDS or the CD-RISC2. The intervention group did, however, report higher levels of foot pain at
12 months on a 10-cm visual analogue scale from 0 (no pain) to 10 (worst pain possible). The mean pain in
the intervention group was 3.1, compared with 2.6 in the usual-care group (adjusted mean difference 0.43,
95% CI 0.06, 0.80; p = 0.02); however, although statistically significant, a difference of 4.3 mm may not be
clinically meaningful. It is unclear why participants in the intervention group reported higher pain scores.
Evidence from the qualitative study suggests that, in some cases, increased foot pain could have been a
result of insoles reducing the space in footwear. In other cases it may be that intervention participants were
simply more aware and more critical of (problems with) their feet, or they were using their feet more while
performing the exercises. Alternatively, this could be a chance finding.
Cost-effectiveness
The results of the economic evaluation conducted alongside the REFORM trial suggest that the
multifaceted intervention could be a cost-effective option for falls prevention in terms of QALYs gained
calculated using the EQ-5D. The ICER for the ITT approach in the imputed data set ranged between
£19,494 and £20,593 per additional QALY. The probability of being cost-effective for the base-case
analysis is > 60%. The results are robust to the sensitivity analyses testing the assumptions regarding
resource use, perspective of analysis and level of imputation regarding missing data on HRQoL. With the
one exception of when the missing data mechanism is tested, the complete-case analysis suggests that the
multifaceted podiatry intervention is expected to be more costly and slightly less beneficial than usual care.
However, the complete case in REFORM is not without limitations. In addition to the much reduced sample
size of the original data (28.3%), missing data patterns showed that incomplete data followed a non-
monotonic pattern, which suggests that the complete-case assessment would be inefficient, as it would
discard observed data from individuals who have some missing outcomes. A logistic regression analysis
showed that advancing age and lower EQ-5D at baseline are associated with missing QALY data. This
suggests that the data are unlikely to be MCAR; consequently, the results from the multiple imputed data
set are likely to be more accurate and more reliable than complete care results.
The main limitation of this economic evaluation, conducted alongside the REFORM trial, is that it does not
account for any differences in costs and QALYs that may be expected over the longer term (> 12 months
post randomisation). The HRQoL data showed that the reduction in the number of participants in perfect
health in the intervention group is lower than that in the usual-care group (17.7%); the increase in the
number of participants having problems is also lower in the intervention group. The effectiveness analysis
also indicated a reduction, albeit a non-statistically significant one, in fall rate in the intervention group
relative to usual care. Cost-effectiveness did not noticeably differ when we projected HRQoL beyond the
trial duration (up to 5 years). However, we consider this exploratory projection likely to be conservative,
and it would be important to explore the long-term impact of reducing the number of falls, as this might
also lead to a reduction in the number of fractures, which in turn will make it more likely that the
intervention yields long-term cost savings in the NHS.
Qualitative findings
The qualitative study explored issues of acceptability and implementation from the perspectives of both
patients and podiatrists. It found that most podiatrists could implement some elements of the programme,
such as the footwear advice and the provision of the orthotic, as part of their normal clinic practice, with
some podiatrists continuing to offer the intervention outside the trial. Some concerns were raised about
the ability of podiatrists to effectively deliver the exercise component within the time constraints of a
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routine clinical appointment. Although the podiatrists generally felt confident in doing so, time (and
equipment) would have to be allocated for this purpose, alongside any necessary follow-up appointments.
Given the way in which most falls prevention services are set up, some podiatrists felt that the intervention
may be well suited to a multidisciplinary falls service, which would include podiatry alongside
physiotherapy input for the exercise intervention, particularly in a group setting.
The trial participants were largely content with the intervention, and adherence was generally good.
Some trial participants, especially those with comorbidities, found some of the exercises challenging;
however, generally, both podiatrists and participants were able to adapt the exercises to suit individual
circumstances. Some participants noticed a benefit of the exercise training after several weeks and felt
more confident as a result. The trial participants found pragmatic ways to incorporate wearing an orthotic,
when it was comfortable to do so. Some participants, however, were not able to adhere to the footwear
advice/orthotic, as they were unable to achieve a good fit owing to existing foot problems or they were
resistant to wearing the footwear options available.
Comparison with other studies
Our results to some extent support the earlier findings by Spink et al.23 In this Australian trial, among 305
community-dwelling men and women (mean age 74 years) who were suffering from disabling foot pain
and who had an elevated risk of falling, a reduction in the incidence rate of falls was observed (IRR 0.64,
95% CI 0.45 to 0.91). The Australian population was similar to ours in that they were all receiving routine
podiatry care and were recruited from podiatry patient lists. However, participants had to be suffering from
disabling foot pain, which was not the case for our population; patients may have had foot pathology but
they did not necessarily have significant foot pain. Our population had a higher risk of falling; the usual-
care group sustained an average of 1.5 falls per year, compared with 1.06 for the Australian patient
group. Similarly, 55% of our usual care participants sustained one or more falls, compared with 49% in
the Spink et al.23 study.
The key elements of the interventions were similar, comprising foot and ankle exercises, an orthosis and an
assessment for poor footwear. Both studies were carried out among patients who were receiving ‘standard’
podiatry. However, there were some differences. We did not use exactly the same orthosis as that used in
the Australian study, and the foot and ankle exercises were modified partly in light of lessons learned from
the Australian study. In our study, when possible, new footwear was provided to participants in the
intervention group whose own current footwear was inappropriate. In the Spink et al.23 trial, participants
were provided with a subsidy for new footwear in the form of a voucher. Furthermore, the participants in
our study did not need to have ‘disabling foot pain’, as was the case in the Australian study. Forest plots to
compare the results of the two studies graphically are presented in Figures 17 and 18. An analysis of the
REFORM 2016
Spink et al.23 2011
Study ID
0.91 (0.75 to 1.09)
0.64 (0.45 to 0.91)
IRR (95% CI)
Favours intervention Favours usual care
10.449 2.22
FIGURE 17 Impact of multifaceted podiatry intervention on the incidence rate of falls over 12 months in older adults.
Reproduced from Spink et al.23 This is an open-access article distributed under the terms of the Creative Commons
Attribution Non-commercial License (CC BY-NC 2.0), which permits use, distribution, and reproduction in any medium,
provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license
(http://creativecommons.org/licenses/by-nc/2.0/ and http://creativecommons.org/licenses/by-nc/2.0/legalcode).
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REFORM data was repeated including only treatment groups in the models for comparability with the Spink
et al.23 trial. Individual patient data were provided by the authors of the Spink et al. trial, and so, whereas
results for the proportion of fallers are presented as a risk ratio in the publication, here we were able to
present these as an OR.
Strengths and limitations of the study
This was a large pragmatic trial, and we used a novel design, namely a cohort randomised trial, to evaluate
this podiatric intervention. The design had several strengths: the use of a run-in period with outcome data
collection could have reduced the incidence of post-randomisation attrition; those in the usual-care group
were unaware of the exact time at which they were randomised, and, in theory, this should have limited
resentful demoralisation. The design also allowed us to recruit participants who initially were ineligible
because they had not fallen but later became eligible because they had fallen while part of the
observational cohort. The initial engagement of participants with the intervention was high; 84% of
intervention participants attended a trial appointment. Compliance with the exercise component was
reasonable (at 12 months, 29% of intervention participants reported performing the exercises at least
three times per week and 75% reported doing them at least once per week). However, in the qualitative
interviews, some podiatrists stated that they felt that this could have been higher if they had had
additional contact with the participants. Another limitation of the study is that the sample size was based
on detecting a difference not in the primary outcome of incidence rate of falls but in the proportion of
participants reporting at least one fall in 12 months. This was because of the difficulty in calculating a
sample size for a count outcome, as discussed in Key findings. It is not possible, therefore, to confirm that
the trial was sufficiently powered for the primary outcome. In addition, participants were recruited from
podiatry clinics; therefore, the estimated impact of the intervention among people who do not regularly
see a NHS podiatrist or who receive care from a private podiatrist may be different. Using a run-in period
may also have biased the sample towards volunteers with a heightened interest and commitment to the
intervention. Furthermore, the intervention is a ‘complex’ one, and our design does not allow us to
estimate the different contributions of changes in footwear, the addition of an orthotic insole or the
undertaking of foot and ankle exercises to the observed effect. It may well be that one or more of
the interventions included in the ‘package of care’ is ineffective. There is also the possibility that some
participants in the usual-care group had enrolled in another falls prevention programme as part of their
NHS care, which could have diluted the treatment effect. This dilution effect is likely to be minimal,
however, given that only a small proportion of participants in the usual-care group reported being referred
to a falls clinic or service during the trial.
REFORM 2016
Spink et al. 23 2011
Study ID
0.81 (0.63 to 1.04)
0.74 (0.47 to 1.16)
OR (95% CI)
245/493
64/153
Events, intervention
284/517
75/152
Events, usual care
Favours intervention Favours usual care
10.47 2.13
FIGURE 18 Impact of multifaceted podiatry intervention on proportion of participants who fall at least once over
12 months. Reproduced from Spink et al.23 This is an open-access article distributed under the terms of the Creative
Commons Attribution Non-commercial License (CC BY-NC 2.0), which permits use, distribution, and reproduction in any
medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with
the license (http://creativecommons.org/licenses/by-nc/2.0/).
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Generalisability of the results
The REFORM intervention was a pragmatic RCT across nine sites in the UK and one site in Ireland. All
participants were recruited from podiatry clinic lists. This was to ensure that we could identify an additional
effect of the intervention not confounded by routine podiatric care. Consequently, the trial cannot answer
the question of whether or not the intervention is effective among patients who do not have routine
podiatry care. However, approximately one in six people aged > 65 years receives NHS podiatry care and,
therefore, our results are applicable to a significant proportion of the older population.
The trial results may also not be generalisable to patients who would not fulfil the eligibility criteria, that is,
those with lower limb amputations, neuropathy, dementia or other neurological conditions; those unable
to walk household distances without the help of a walking aid; those living in residential or nursing care
homes; and those aged < 65 years. The views of the podiatrists interviewed in the qualitative part of the
study were mixed on whether or not people with neuropathy or amputations could have benefited from
the intervention, and the majority agreed that a more intensive follow-up would have been required in
order to ensure patient safety.
Implications for health care
Our results suggest that there is a role for NHS podiatrists in reducing the risk of falling among their
patients. Although cost-effectiveness was demonstrated based on QALYs gained calculated via the EQ-5D
and not necessarily on reducing falls, falls could potentially have a negative effect of patients’ quality of life
and any intervention to improve this is valid. However, in terms of the current intervention, some of the
podiatrists felt that additional podiatry contact was required to maximise compliance with the individual
intervention components. There is the potential for the cost of the intervention to be further reduced if a
podiatry assistant rather than the podiatrist undertook the assessment of participants’ footwear and the
measuring, ordering and fitting of new footwear.
Implications for research
The impact of falls risk among these patients was relatively modest. As falls are a major source of
morbidity in an older population, research into combining different interventions to develop a more
effective overall strategy might be worth pursuing. Further research could also examine the risk and cost of
falls in other populations or settings (e.g. people with neuropathy or residential aged care facilities).
Additionally, the intervention could be tested in populations deemed to be at high risk of falling.
There is evidence to suggest that exercise is an effective falls prevention strategy, and it may be the case
that it is equally, or possibly more, effective when demonstrated to patients in group sessions, as opposed
to one on one. This would have the additional benefit of being cheaper to deliver and, therefore, being
more cost-effective. Further research could be undertaken to test the clinical effectiveness and cost-
effectiveness of a group exercise programme, which could also investigate whether or not the intervention
could be delivered equally effectively across the professional boundaries of podiatry and physiotherapy.
Alternatively, further research into the intensity of the exercise could be undertaken to see how much is
actually needed.
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Appendix 1 Regulatory approvals
Research site Date of research and development approval
Sheffield Teaching Hospitals NHS Foundation Trust 19 September 2012
Harrogate and District NHS Foundation Trust 2 July 2012
Leeds Community Healthcare NHS Trust 7 March 2013
National University of Ireland, Galway 26 April 2013
Humber NHS Foundation Trust 13 May 2013
Solent NHS Trust 29 October 2013
North Lincolnshire and Goole Hospitals NHS Foundation Trust 11 November 2013
Kent Community Health NHS Foundation Trust 11 February 2014
South Tyneside NHS Foundation Trust 1 April 2014
North Tees and Hartlepool Hospitals NHS Foundation Trust 9 May 2014
Approval was gained at two additional sites; neither was able to start recruitment.
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Appendix 2 REFORM invitation letter
Insert Trust logo  
Insert podiatry clinic details  
 
Date as postmarked  
 
Dear Patient  
           
An invitation to participate in a research project about the prevention of falls 
 
You may be aware that falls are a common problem, especially amongst older adults.  Our 
podiatry service is working with the University of York, to conduct a research study which 
aims to look at ways of reducing the number of falls people have.   
 
Our Podiatry service is sending this letter to all patients over the age of 65, to find out who 
would be willing and suitable to take part in the study.  Staff at the University of York do not 
have access to your name and address unless you fill in the enclosed consent form and 
questionnaire and return them to the University of York.  
 
Before you decide whether or not to take part in the study, it is important for you to 
understand why this research is being done and what it will involve.  The enclosed 
information leaflet explains the study in detail.  Please feel free to discuss the study with 
others.  Your participation in this study is voluntary.    
 
You do not need to attend the University of York to take part in this study. If you agree to 
take part, and are offered extra podiatry care, the additional two appointments will be 
arranged at your usual podiatry clinic. 
 
If you wish to take part, please complete the following enclosed forms and return them both 
to the research team at the University of York in the prepaid envelope provided (no stamp 
needed):   
 
• The yellow consent form 
• The  white questionnaire  
 
For study related questions please contact Mrs Sarah Cockayne at the University of York on 
XXXX or XXXX.  For questions in relation to your podiatry care and the 
our research podiatrist Miss Lorraine Loughrey on the same number. If 
leave a message and someone will contact you as soon as 
  
Thank you for taking the time to read this information.  
 
Yours faithfully  
 
(PI electronic signature) 
PI name  
Podiatrist and REFORM Principal Investigator  
Version 5 9.7.13 
study, please contact 
there is no-one available, 
please possible.
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Appendix 3 REFORM consent form
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Appendix 4 REFORM patient information sheet
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Appendix 5 REFORM background information
form
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Appendix 6 REFORM decline form
Trial ID number:
PARTICIPANT DECLINE FORM
We would find it really helpful to have a wide range of men and women over the age of
70 joining this study.
However, we quite understand if you do not wish to take part.  If this is the case, we
would be grateful if you could tell us the reason(s) why by placing a cross in as many
boxes as apply to you from the list below: -
I am not interested in taking part in this study.
I feel too unwell to take part in this study.
I do not have time to take part in this study.
Other reason
Please give more details here if you would like to: -
REFORM Patient decline form Version 1.0 12th August 2011
It would be very helpful if you would be willing to give us some brief details about
yourself. We will not be able to identify you from this form, and we will not contact
you again.  We will use the anonymous information that you provide to help us see if
there are any differences between those who agree to take part and those who decline.
If you wish, please complete the background information questions and return
these forms in the pre-paid envelope provided.  Thank you very much.
Centre number:
Admin code: 9809554066
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Appendix 7 REFORM baseline questionnaire
CONFIDENTIAL
REFORM Study
Reducing falls with ORthosis and a Multifaceted podiatry intervention
Participant Baseline Questionnaire
For office use only
Participant's trial ID number:
Date questionnaire sent:
Day Month Year
/ / 2 0
REFORM Participant baseline questionnaire version 4.0a 28 August 2013
Centre number:
1606458246
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PLEASE READ ALL THE INSTRUCTIONS BEFORE COMPLETING THE QUESTIONNAIRE
Thank you for agreeing to take part in this study. The responses you give in this
questionnaire will help us find out the best way to stop people who are over 65 years old from
having a fall.
Please answer ALL the questions. Although some of the questions may not seem
relevant to yourself or may appear similar, they do give us valuable information.
If you find it difficult to answer the question, please give the best answer you can.
Please follow the instructions for each section carefully.
For each section, if you are asked to put a cross in the box, please use a cross rather than a
tick, as if you were filling out a ballot paper.
For example in the following question, if your answer to the question is 'yes', you should place
a cross firmly in the box next to yes.
Do you drive a car? Yes
No
Please use a black or blue pen for all the questions.
Please do not use a pencil or any other coloured pen.
If you have any queries or problems completing this questionnaire please contact the
trial co-ordinator, Sarah Cockayne, telephone number XXXX, email XXXX.
If you are asked to write your answer, please do so by entering your answer in the box
provided, for example:
How old are you? years7 5
7268458246
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SECTION 1
This section asks about any falls you have had in the past 6 months and about some
general information about you.
Please enter the date you are completing this
questionnaire:
Day Month Year
/ / 2 0
1. Have you fallen in the past 6 months?
(Please cross one box only)
2. During the past 4 weeks have you worried about having a fall?
(Please cross one box only)
3a. Please tell us your height
All of
the time
Most of
the time
Some of
the time
A little of
the time
None of
the time
Yes No Don't know
1a. If 'Yes', how many falls did you have in the past 6 months?
A good bit
of the time
feet inches cm
stone lbs . kgs
or
orPlease tell us your weight3b.
4. Are you taking more than four medications prescribed by a doctor?
(Please cross one box only)
Yes No
5. Have you been referred to a falls clinic / falls service?
(Please cross one box only)
Yes No
0344458244
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Sa
mp
le
UK (English) © 1990 EuroQol Group EQ-5D™ is a trade mark of the EuroQol Group
Mobility
I have no problems in walking about
I have some problems in walking about
I am confined to bed
Self-Care
I have no problems with self-care
I have some problems washing or dressing myself
I am unable to wash or dress myself
Usual Activities (e.g. work, study, housework, family or leisure activities)
I have no problems with performing my usual activities
I have some problems with performing my usual activities
I am unable to perform my usual activities
Pain / Discomfort
I have no pain or discomfort
I have moderate pain or discomfort
I have extreme pain or discomfort
Anxiety / Depression
I am not anxious or depressed
I am moderately anxious or depressed
I am extremely anxious or depressed
SECTION 2
This section asks about your health in general.
By placing a cross in one box in each group below, please indicate which statements best
decribes your own health today.
APPENDIX 7
NIHR Journals Library www.journalslibrary.nihr.ac.uk
132
Sa
mp
le
UK (English) © 1990 EuroQol Group EQ-5D™ is a trade mark of the EuroQol Group
9 0
8 0
7 0
6 0
5 0
4 0
3 0
2 0
1 0
100
0
To help people say how good or bad a health state is, 
we have drawn a scale (rather like a thermometer) on 
which the best state you can imagine is marked 100 and 
the worst state you can imagine is marked 0.
We would like you to indicate on this scale how good or 
bad your own health is today, in your opinion. Please do 
this by drawing a line from the box below to whichever 
point on the scale indicates how good or bad your health 
state is today.
Best imaginable 
health state
Worst imaginable 
health state
Your own health 
state today
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SECTION 3
Now we would like to ask some questions about how concerned you are about the
possibility of falling.
Please reply thinking how you usually do the activity. If you currently do not do the activity,
please answer to show whether you think you would be concerned about falling IF you did
the activity.
For each of the following activities, please cross the box which is closest to you own opinion
to show how concerned you are that you might fall if you did the activity.
Getting dressed or undressed
Not at all
concerned
Somewhat
concerned
Fairly
concerned
Very
concerned
Taking a bath or shower
Getting in or out of a chair
Reaching for something above
your head or on the ground
Walking up or down a slope
Going out to a social event (eg,
religious service, family gathering
or club meeting)
SECTION 4
This section asks about how you've been feeling. Answer each question by placing a cross
in the box that best describes your answer.
1a. I tend to bounce back after illness or hardship
Not true
at all
Rarely
true
Sometimes
true
Often
true
True nearly all
of the time
Not true
at all
Rarely
true
Sometimes
true
Often
true
True nearly all
of the time
1b. I am able to adapt to change
6136458249
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SECTION 5
We are interested in finding out how often you carry out some activities. Please cross one
box for each question.
1. In the last 3 months, how often have you carried out these activities?
Preparing main meals
Washing up
Never
Less than once
per week
1 or 2 times
a week Most days
2. Over the last 3 months, how often have you carried out the following?
Washing clothes
Never
1-2 times in
3 months
3-12 times in
3 months
At least
weekly
Light housework
Heavy housework
Local shopping
Social outings
Walking outside for
over 15 minutes
Actively pursuing a
hobby
Driving a car/travel
on a bus
3. In the last 6 months, how often have you undertaken:
Travel outing / car ride
Never
1-2 times in
6 months
3-12 times in
6 months
At least
weekly
Gardening
Never Light Moderate
Heavy / All
necessary
Household maintenance
8567458249
DOI: 10.3310/hta21240 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 24
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Cockayne et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
135
SECTION 6
This section is about visits you have had to a NHS hospital as a patient for any reason.
Answer each question by placing a cross in the box that best describes your answer.
Attending hospital
1a. During the last six months have you stayed overnight in an NHS hospital?
Yes No (go to section 7)
1b. If 'Yes', on how many separate occasions did you stay overnight in hospital?
1c. For each stay please complete the information below:
3
Number of nights
in hospital
e.g.
Reason for admittance
ANGINA
In the last 6 months, how often have you undertaken:
Reading books
None
1 in 6
months
Less than 1
in 2 weeks
More than 1
every 2 weeks
Gainful work
None
Up to 10
hours/week
10 - 30
hours/week
Over 30
hours/week
2867458246
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SECTION 7
This section is about other services you have used in the past six months as a patient for any
reason. If the health care you received was related to a fall, record this in the 'about a fall'
column. If the health care was for any other reason, enter this in the 'other reason' column.
Please fill in all of the boxes even if you have not had any visits. This information is really
important for us.
0 3
1. Over the past six months, how many times have you:
Other visits to NHS hospital
a. Visited hospital for an out-patient appointment?
About a fall Other reason
b. Visited hospital for a day case / procedure (not
overnight)?
c. Attended Accident and Emergency?
Other care from the NHS
d. Seen your GP at the surgery or at home?
About a fall Other reason
e. Seen a nurse at your GP practice or the district
or community nurse?
f. Seen an occupational therapist and/or
physiotherapist at home?
Transportation
g. Used a '999' emergency ambulance?
About a fall Other reason
h. Used the Patient Transport Service?
(If None enter '00') (If None enter '00')
(If None enter '00')(If None enter '00')
(If None enter '00')(If None enter '00')
About a fall Other reason
0 0 0 0
For example, if you have not used a service for any reason
then put a '0' in both boxes:
If you have used a service three times about a fall and once
for another reason then you would write: 0 1
5367458244
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Support services
2a. Have you received any help or care (e.g. dressing, tasks around the home, providing
meals, shopping from a relative or a friend) in the last 6 months?
(Please cross one box only)
Yes No (go to 3a)
2b. If 'Yes', thinking about the last 6 months, typically how many hours per week did
someone help you?
3a. Does a paid care worker visit you at home?
(Please cross one box only)
Yes
3b. If 'Yes', thinking about the last 6 months, typically how many days per week did a
care worker visit?
No (go to 4a)
4a. Do you use meals on wheels?
(Please cross one box only)
Yes
4b. If 'Yes', thinking about the last 6 months, typically how many times a week did you
use meals on wheels?
No
0294458248
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SECTION 8
This section asks about any extra costs you have had in the past six months.
1a. In the last 6 months, have you had to buy any new equipment (e.g. a bed), or paid to
have any changes made to your house (e.g. installed a stairlift) due to ill health?
(Please cross one box only)
Yes No
1b. If 'Yes', please tell us the item and how much it cost.
(Please enter the cost to the nearest pound)
(go to section 9)
Item bought Cost
£
£
£
SECTION 9
This section asks about your living arrangements and some general information about you.
1. Do you?
(Please cross all that apply)
Live alone
Live with a partner or spouse?
Live with a friend or relative?
Live in sheltered accommodation?
2a. Did your education continue after the minimum school leaving age?
Do you have a degree or equivalent professional qualification?2b.
Yes No
NoYes
7045458249
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SECTION 10
This section asks about your mood. Choose the best answer for how you have felt this past
week by placing a cross in the appropriate box.
1. Are you basically satisfied with your life?
Yes No
2. Have you dropped many of your activities and interests?
3. Do you feel that your life is empty?
4. Do you often get bored?
5. Are you in good spirits most of the time?
6. Are you afraid that something bad is going to happen to you?
7. Do you feel happy most of the time?
8. Do you often feel helpless?
9. Do you prefer to stay at home, rather than going out and doing
new things?
10. Do you feel you have more problems with memory than most?
11. Do you think it is wonderful to be alive now?
12. Do you feel pretty worthless the way you are now?
13. Do you feel full of energy?
14. Do you feel that your situation is hopeless?
15. Do you think that most people are better off than you are?
For office use only: Insert total score
Thank you for taking the time to complete this questionnaire. Please return it to the York
Trials Unit at the University of York in the pre-paid envelope provided.
2131458240
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Appendix 8 REFORM sample falls calendar
September 2011        
 
REFORM Trial FALLS CALENDAR  
 
       Centre number                      Participant’s trial ID number  
 
If you have a fall, even if it was minor, place a cross (X) in the date box on the 
day it occurred and call us.  If you did not have a fall on any day this month, put a 
cross in the box next to the statement at the bottom. 
 
Monday Tuesday Wednesday Thursday Friday Saturday Sunday 
 
   1 
 
2 3 4 
5 6 7 8 
 
9 10 11 
12 13 14 15 
 
16 17 18 
19 20 21 22 
 
23 24 25 
26 27 28 29 
 
30 31  
 
If you didn’t have any falls at all this month please place a cross in this box.   
 
  Please call the researchers on 
XXXX if  
• You have a fall, even if it 
was minor 
• You have any queries  
 
    At the end of the month when this 
card is complete, please separate and post it 
back to us.  There is no need for you to add 
your name or any postage.  
 
 
Pre-paid post card with return postal address  
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Appendix 9 Falls telephone data collection sheet
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Appendix 10 REFORM 6-month follow-up
questionnaire
CONFIDENTIAL
REFORM Study
Reducing falls with ORthosis and a Multifaceted podiatry intervention
Participant Six Month Questionnaire
For office use only
Participant's trial ID number:
Date questionnaire sent:
Day Month Year
/ / 2 0
REFORM Participant six month questionnaire version 1.0a 12 August 2013
Centre number:
9009248079
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PLEASE READ ALL THE INSTRUCTIONS BEFORE COMPLETING THE QUESTIONNAIRE
Thank you for agreeing to take part in this study. The responses you give in this
questionnaire will help us find out the best way to stop people who are over 65 years old from
having a fall.
Please answer ALL the questions. Although some of the questions may not seem
relevant to yourself or may appear similar, they do give us valuable information.
If you find it difficult to answer the question, please give the best answer you can.
Please follow the instructions for each section carefully.
For each section, if you are asked to put a cross in the box, please use a cross rather than a
tick, as if you were filling out a ballot paper.
For example in the following question, if your answer to the question is 'yes', you should place
a cross firmly in the box next to yes.
Do you drive a car? Yes
No
Please use a black or blue pen for all the questions.
Please do not use a pencil or any other coloured pen.
If you have any queries or problems completing this questionnaire please contact the
trial co-ordinator, Sarah Cockayne, freephone XXXX or XXXX, email XXXX.
If you are asked to write your answer, please do so by entering your answer in the box
provided, for example:
How old are you? years7 5
7702248077
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SECTION 1
This section asks about any falls you have had in the past 6 months and about some
general information about you.
Please enter the date you are completing this
questionnaire:
Day Month Year
/ / 2 0
1. Have you fallen in the past 6 months?
(Please cross one box only)
2. During the past 4 weeks have you worried about having a fall?
(Please cross one box only)
3a. Please tell us your height
All of
the time
Most of
the time
Some of
the time
A little of
the time
None of
the time
Yes No Don't know
1a. If 'Yes', how many falls did you have in the past 6 months?
A good bit
of the time
feet inches cm
stone lbs . kgs
or
orPlease tell us your weight3b.
4. Are you taking more than four medications prescribed by a doctor?
(Please cross one box only)
Yes No
5. Have you been referred to a falls clinic / falls service?
(Please cross one box only)
Yes No
8235248079
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Sa
mp
le
UK (English) © 1990 EuroQol Group EQ-5D™ is a trade mark of the EuroQol Group
 
Mobility
I have no problems in walking about
I have some problems in walking about
I am confined to bed
Self-Care
I have no problems with self-care
I have some problems washing or dressing myself
I am unable to wash or dress myself
Usual Activities (e.g. work, study, housework, family or leisure activities)
I have no problems with performing my usual activities
I have some problems with performing my usual activities
I am unable to perform my usual activities
Pain / Discomfort
I have no pain or discomfort
I have moderate pain or discomfort
I have extreme pain or discomfort
Anxiety / Depression
I am not anxious or depressed
I am moderately anxious or depressed
I am extremely anxious or depressed
SECTION 2
This section asks about your health in general.
By placing a cross in one box in each group below, please indicate which statements best
decribes your own health today.
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Sa
mp
le
UK (English) © 1990 EuroQol Group EQ-5D™ is a trade mark of the EuroQol Group
9 0
8 0
7 0
6 0
5 0
4 0
3 0
2 0
1 0
100
0
To help people say how good or bad a health state is, 
we have drawn a scale (rather like a thermometer) on 
which the best state you can imagine is marked 100 and 
the worst state you can imagine is marked 0.
We would like you to indicate on this scale how good or 
bad your own health is today, in your opinion. Please do 
this by drawing a line from the box below to whichever 
point on the scale indicates how good or bad your health 
state is today.
Best imaginable 
health state
Worst imaginable 
health state
Your own health 
state today
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SECTION 3
Now we would like to ask some questions about how concerned you are about the
possibility of falling.
Please reply thinking how you usually do the activity. If you currently do not do the activity,
please answer to show whether you think you would be concerned about falling IF you did
the activity.
For each of the following activities, please cross the box which is closest to you own opinion
to show how concerned you are that you might fall if you did the activity.
Getting dressed or undressed
Not at all
concerned
Somewhat
concerned
Fairly
concerned
Very
concerned
Taking a bath or shower
Getting in or out of a chair
Reaching for something above
your head or on the ground
Walking up or down a slope
Going out to a social event (eg,
religious service, family gathering
or club meeting)
SECTION 4
This section asks about how you've been feeling. Answer each question by placing a cross
in the box that best describes your answer.
1a. I tend to bounce back after illness or hardship
Not true
at all
Rarely
true
Sometimes
true
Often
true
True nearly all
of the time
Not true
at all
Rarely
true
Sometimes
true
Often
true
True nearly all
of the time
1b. I am able to adapt to change
Going up or down stairs
9505248070
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SECTION 5
We are interested in finding out how often you carry out some activities. Please cross one
box for each question.
1. In the last 3 months, how often have you carried out these activities?
Preparing main meals
Washing up
Never
Less than once
per week
1 or 2 times
a week Most days
2. Over the last 3 months, how often have you carried out the following?
Washing clothes
Never
1-2 times in
3 months
3-12 times in
3 months
At least
weekly
Light housework
Heavy housework
Local shopping
Social outings
Walking outside for
over 15 minutes
Actively pursuing a
hobby
Driving a car/travel
on a bus
3. In the last 6 months, how often have you undertaken:
Travel outing / car ride
Never
1-2 times in
6 months
3-12 times in
6 months
At least
weekly
Gardening
Never Light Moderate
Heavy / All
necessary
Household maintenance
9230248075
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SECTION 6
This section is about visits you have had to a NHS hospital as a patient for any reason.
Answer each question by placing a cross in the box that best describes your answer.
Attending hospital
1a. During the last six months have you stayed overnight in an NHS hospital?
Yes No (go to section 7)
1b. If 'Yes', on how many separate occasions did you stay overnight in hospital?
1c. For each stay please complete the information below:
3
Number of nights
in hospital
e.g.
Reason for admittance
ANGINA
In the last 6 months, how often have you undertaken:
Reading books
None
1 in 6
months
Less than 1
in 2 weeks
More than 1
every 2 weeks
Gainful work
None
Up to 10
hours/week
10 - 30
hours/week
Over 30
hours/week
6698248070
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SECTION 7
This section is about other services you have used in the past six months as a patient for any
reason. If the health care you received was related to a fall, record this in the 'about a fall'
column. If the health care was for any other reason, enter this in the 'other reason' column.
Please fill in all of the boxes even if you have not had any visits. This information is really
important for us.
0 3
1. Over the past six months, how many times have you:
Other visits to NHS hospital
a. Visited hospital for an out-patient appointment?
About a fall Other reason
b. Visited hospital for a day case / procedure (not
overnight)?
c. Attended Accident and Emergency?
Other care from the NHS
d. Seen your GP at the surgery or at home?
About a fall Other reason
e. Seen a nurse at your GP practice or the district
or community nurse?
f. Seen an occupational therapist and/or
physiotherapist at home?
Transportation
g. Used a '999' emergency ambulance?
About a fall Other reason
h. Used the Patient Transport Service?
(If None enter '00') (If None enter '00')
(If None enter '00')(If None enter '00')
(If None enter '00')(If None enter '00')
About a fall Other reason
0 0 0 0
For example, if you have not used a service for any reason
then put a '0' in both boxes:
If you have used a service three times about a fall and once
for another reason then you would write: 0 1
2301248077
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Support services
2a. Have you received any help or care (e.g. dressing, tasks around the home, providing
meals, shopping from a relative or a friend) in the last 6 months?
(Please cross one box only)
Yes No (go to 3a)
2b. If 'Yes', thinking about the last 6 months, typically how many hours per week did
someone help you?
3a. Does a paid care worker visit you at home?
(Please cross one box only)
Yes
3b. If 'Yes', thinking about the last 6 months, typically how many days per week did a
care worker visit?
No (go to 4a)
4a. Do you use meals on wheels?
(Please cross one box only)
Yes
4b. If 'Yes', thinking about the last 6 months, typically how many times a week did you
use meals on wheels?
No
9136248070
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SECTION 8
This section asks about any extra costs you have had in the past six months.
1a. In the last 6 months, have you had to buy any new equipment (e.g. a bed), or paid to
have any changes made to your house (e.g. installed a stairlift) due to ill health?
(Please cross one box only)
Yes No
1b. If 'Yes', please tell us the item and how much it cost.
(Please enter the cost to the nearest pound)
(go to section 9)
Item bought Cost
£
£
£
SECTION 9
This section asks about your living arrangements and some general information about you.
1. Do you?
(Please cross all that apply)
Live alone
Live with a partner or spouse?
Live with a friend or relative?
Live in sheltered accommodation?
2a. Did your education continue after the minimum school leaving age?
Do you have a degree or equivalent professional qualification?2b.
Yes No
NoYes
1266248076
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SECTION 10
This section asks about your mood. Choose the best answer for how you have felt this past
week by placing a cross in the appropriate box.
1. Are you basically satisfied with your life?
Yes No
2. Have you dropped many of your activities and interests?
3. Do you feel that your life is empty?
4. Do you often get bored?
5. Are you in good spirits most of the time?
6. Are you afraid that something bad is going to happen to you?
7. Do you feel happy most of the time?
8. Do you often feel helpless?
9. Do you prefer to stay at home, rather than going out and doing
new things?
10. Do you feel you have more problems with memory than most?
11. Do you think it is wonderful to be alive now?
12. Do you feel pretty worthless the way you are now?
13. Do you feel full of energy?
14. Do you feel that your situation is hopeless?
15. Do you think that most people are better off than you are?
For office use only: Insert total score
6043248074
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Thank you for taking the time to complete this questionnaire. Please return it to
the York Trials Unit at the University of York in the pre-paid envelope provided.
SECTION 11
If you have any general comments about the study, or this questionnaire, please write
them below.
6279248075
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Appendix 11 REFORM 12-month follow-up
questionnaire
CONFIDENTIAL
REFORM Study
Reducing falls with ORthosis and a Multifaceted podiatry intervention
Participant 12 Month Questionnaire
For office use only
Participant's trial ID number:
Date questionnaire sent:
Day Month Year
/ / 2 0
REFORM Participant 12 month questionnaire version 2.0 16 June 2014
Centre number:
2365625650
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PLEASE READ ALL THE INSTRUCTIONS BEFORE COMPLETING THE QUESTIONNAIRE
Thank you for agreeing to take part in this study. The responses you give in this
questionnaire will help us find out the best way to stop people who are over 65 years old from
having a fall.
Please answer ALL the questions. Although some of the questions may not seem
relevant to yourself or may appear similar, they do give us valuable information.
If you find it difficult to answer the question, please give the best answer you can.
Please follow the instructions for each section carefully.
For each section, if you are asked to put a cross in the box, please use a cross rather than a
tick, as if you were filling out a ballot paper.
For example in the following question, if your answer to the question is 'yes', you should place
a cross firmly in the box next to yes.
Do you drive a car? Yes
No
Please use a black or blue pen for all the questions.
Please do not use a pencil or any other coloured pen.
If you have any queries or problems completing this questionnaire please contact the
trial co-ordinator, Sarah Cockayne, telephone number XXXX, email XXXX.
If you are asked to write your answer, please do so by entering your answer in the box
provided, for example:
How old are you? years7 5
4992625658
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SECTION 1
This section asks about any falls you have had in the past 6 months and about some
general information about you.
Please enter the date you are completing this
questionnaire:
Day Month Year
/ / 2 0
1. Have you fallen in the past 6 months?
(Please cross one box only)
2. During the past 4 weeks have you worried about having a fall?
(Please cross one box only)
All of
the time
Most of
the time
Some of
the time
A little of
the time
None of
the time
Yes No Don't know
1a. If 'Yes', how many falls did you have in the past 6 months?
A good bit
of the time
3. Are you taking more than four medications prescribed by a doctor?
(Please cross one box only)
Yes No
4. Have you been referred to a falls clinic / falls service in the past 12 months?
(Please cross one box only)
Yes No
4947625658
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mp
le
UK (English) © 1990 EuroQol Group EQ-5D™ is a trade mark of the EuroQol Group
Mobility
I have no problems in walking about
I have some problems in walking about
I am confined to bed
Self-Care
I have no problems with self-care
I have some problems washing or dressing myself
I am unable to wash or dress myself
Usual Activities (e.g. work, study, housework, family or leisure activities)
I have no problems with performing my usual activities
I have some problems with performing my usual activities
I am unable to perform my usual activities
Pain / Discomfort
I have no pain or discomfort
I have moderate pain or discomfort
I have extreme pain or discomfort
Anxiety / Depression
I am not anxious or depressed
I am moderately anxious or depressed
I am extremely anxious or depressed
SECTION 2
This section asks about your health in general.
By placing a cross in one box in each group below, please indicate which statements best
decribes your own health today.
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Sa
mp
le
UK (English) © 1990 EuroQol Group EQ-5D™ is a trade mark of the EuroQol Group
9 0
8 0
7 0
6 0
5 0
4 0
3 0
2 0
1 0
100
0
To help people say how good or bad a health state is, 
we have drawn a scale (rather like a thermometer) on 
which the best state you can imagine is marked 100 and 
the worst state you can imagine is marked 0.
We would like you to indicate on this scale how good or 
bad your own health is today, in your opinion. Please do 
this by drawing a line from the box below to whichever 
point on the scale indicates how good or bad your health 
state is today.
Best imaginable 
health state
Worst imaginable 
health state
Your own health 
state today
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SECTION 3
Now we would like to ask some questions about how concerned you are about the
possibility of falling.
Please reply thinking how you usually do the activity. If you currently do not do the activity,
please answer to show whether you think you would be concerned about falling IF you did
the activity.
For each of the following activities, please cross the box which is closest to you own opinion
to show how concerned you are that you might fall if you did the activity.
Getting dressed or undressed
Not at all
concerned
Somewhat
concerned
Fairly
concerned
Very
concerned
Taking a bath or shower
Getting in or out of a chair
Reaching for something above
your head or on the ground
Walking up or down a slope
Going out to a social event (eg,
religious service, family gathering
or club meeting)
Going up or down stairs
9805625656
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SECTION 4
We are interested in finding out how often you carry out some activities. Please cross one
box for each question.
1. In the last 3 months, how often have you carried out these activities?
Preparing main meals
Washing up
Never
Less than once
per week
1 or 2 times
a week Most days
2. Over the last 3 months, how often have you carried out the following?
Washing clothes
Never
1-2 times in
3 months
3-12 times in
3 months
At least
weekly
Light housework
Heavy housework
Local shopping
Social outings
Walking outside for
over 15 minutes
Actively pursuing a
hobby
Driving a car/travel
on a bus
3. In the last 6 months, how often have you undertaken:
Travel outing / car ride
Never
1-2 times in
6 months
3-12 times in
6 months
At least
weekly
Gardening
Never Light Moderate
Heavy / All
necessary
Household maintenance
1975625656
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SECTION 5
This section is about visits you have had to a NHS hospital as a patient for any reason.
Answer each question by placing a cross in the box that best describes your answer.
Attending hospital
1a. During the last six months have you stayed overnight in an NHS hospital?
Yes No (go to section 6)
1b. If 'Yes', on how many separate occasions did you stay overnight in hospital?
1c. For each stay please complete the information below:
3
Number of nights
in hospital
e.g.
Reason for admittance
ANGINA
In the last 6 months, how often have you undertaken:
Reading books
None
1 in 6
months
Less than 1
in 2 weeks
More than 1
every 2 weeks
Gainful work
None
Up to 10
hours/week
10 - 30
hours/week
Over 30
hours/week
0040625658
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SECTION 6
This section is about other services you have used in the past six months as a patient for any
reason. If the health care you received was related to a fall, record this in the 'about a fall'
column. If the health care was for any other reason, enter this in the 'other reason' column.
Please fill in all of the boxes even if you have not had any visits. This information is really
important for us.
0 3
1. Over the past six months, how many times have you:
Other visits to NHS hospital
a. Visited hospital for an out-patient appointment?
About a fall Other reason
b. Visited hospital for a day case / procedure (not
overnight)?
c. Attended Accident and Emergency?
Other care from the NHS
d. Seen your GP at the surgery or at home?
About a fall Other reason
e. Seen a nurse at your GP practice or the district
or community nurse?
f. Seen an occupational therapist and/or
physiotherapist at home?
Transportation
g. Used a '999' emergency ambulance?
About a fall Other reason
h. Used the Patient Transport Service?
(If None enter '00') (If None enter '00')
(If None enter '00')(If None enter '00')
(If None enter '00')(If None enter '00')
About a fall Other reason
0 0 0 0
For example, if you have not used a service for any reason
then put a '0' in both boxes:
If you have used a service three times about a fall and once
for another reason then you would write: 0 1
9739625652
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Support services
2a. Have you received any help or care (e.g. dressing, tasks around the home, providing
meals, shopping from a relative or a friend) in the last 6 months?
(Please cross one box only)
Yes No (go to 3a)
2b. If 'Yes', thinking about the last 6 months, typically how many hours per week did
someone help you?
3a. Does a paid care worker visit you at home?
(Please cross one box only)
Yes
3b. If 'Yes', thinking about the last 6 months, typically how many days per week did a
care worker visit?
No (go to 4a)
4a. Do you use meals on wheels?
(Please cross one box only)
Yes
4b. If 'Yes', thinking about the last 6 months, typically how many times a week did you
use meals on wheels?
No
6335625651
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SECTION 7
This section asks about any extra costs you have had in the past six months.
1a. In the last 6 months, have you had to buy any new equipment (e.g. a bed), or paid to
have any changes made to your house (e.g. installed a stairlift) due to ill health?
(Please cross one box only)
Yes No
1b. If 'Yes', please tell us the item and how much it cost.
(Please enter the cost to the nearest pound)
(go to section 9)
Item bought Cost
£
£
£
SECTION 8
This section asks about your living arrangements and some general information about you.
1. Do you?
(Please cross all that apply)
Live alone
Live with a partner or spouse?
Live with a friend or relative?
Live in sheltered accommodation?
9706625656
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SECTION 9
This section asks about your mood. Choose the best answer for how you have felt this past
week by placing a cross in the appropriate box.
1. Are you basically satisfied with your life?
Yes No
2. Have you dropped many of your activities and interests?
3. Do you feel that your life is empty?
4. Do you often get bored?
5. Are you in good spirits most of the time?
6. Are you afraid that something bad is going to happen to you?
7. Do you feel happy most of the time?
8. Do you often feel helpless?
9. Do you prefer to stay at home, rather than going out and doing
new things?
10. Do you feel you have more problems with memory than most?
11. Do you think it is wonderful to be alive now?
12. Do you feel pretty worthless the way you are now?
13. Do you feel full of energy?
14. Do you feel that your situation is hopeless?
15. Do you think that most people are better off than you are?
For office use only: Insert total score
9794625653
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SECTION 10
This section asks about the advice you have received from the podiatry clinic over the past
12 months. We are also interested in finding out if you’ve been wearing insoles or orthotics
in your shoes and doing any foot or ankle exercises.
These questions ask about your NHS podiatry care.
1a. Have you attended an NHS podiatry clinic in the past 12 months?
(Please cross one box only)
Yes No
1b. If 'Yes', how many times have you attended the podiatry clinic in the past 12 months?
These questions ask about your footwear
2a. Has your NHS podiatrist checked your everyday shoes in the past 12 months?
(Please cross one box only)
Yes No Don't know
2b. If ‘Yes’ did your podiatrist give you advice about your footwear or suggest you should
wear a different style of shoe? (Please cross one box only)
Yes No Don't know
2c. If ‘Yes’ did you follow the footwear advice the podiatrist gave you?
(Please cross one box only)
Yes No Partly
3a. In the past 12 months, has an NHS podiatrist given or made you an insole or orthotic
to wear in your shoe? (Please cross one box only)
Yes No
These questions ask if you’re wearing an insole or orthotic
3b. If you were given an insole or orthotic, typically over the past 12 months how often
have you worn them for? (Please cross one box only)
All of
the time
Most of
the time
Some of
the time
A little of
the time
None of
the time
5201625652
DOI: 10.3310/hta21240 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 24
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Cockayne et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
171
4a. Has your NHS podiatrist given you any foot or ankle exercises in the past 12 months?
(Please cross one box only)
Yes No
These questions ask about what exercise you do
4b. If ‘Yes’ thinking about the past 12 months, typically how many times a week did you
undertake the foot and ankle exercises? (Please cross one box only)
None, I did
not do any
Less than
once a week
Once a
week
Twice a
week
Three times
a week
More than three
times a week
4c. Has another healthcare professional (other than your podiatrist) given you any foot or
ankle exercises to do in the past 12 months? (Please cross one box only)
Yes No
4d. If ‘Yes’ thinking about the past 12 months, typically how many times a week did you
undertake these exercises? (Please cross one box only)
None, I did
not do any
Less than
once a week
Once a
week
Twice a
week
Three times
a week
More than three
times a week
5. Have you been involved in any other exercise activities over the past 12 months?
(Please cross one box only)
Yes No
If ‘Yes’ please give futher details:
6. We would like to know if you have any pain or discomfort in your feet today. Please
do this by drawing a vertical mark on the line below to indicate how much pain or
discomfort you have today.
No pain Worse possible pain
For office use only mm
100
0601625651
APPENDIX 11
NIHR Journals Library www.journalslibrary.nihr.ac.uk
172
If you have any general comments about the study, or this questionnaire, please write
them below:
Thank you for taking the time to complete this questionnaire. Please return it to the
York Trials Unit at the University of York in the pre-paid envelope provided.
7250625658
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Appendix 12 REFORM participant 6-month
exercise and orthosis diary
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XXXX or XXXX, email XXXX.
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Appendix 13 REFORM change of circumstance
form
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Appendix 14 REFORM adverse event form
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Appendix 15 REFORM participant information
sheet (qualitative)
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Appendix 16 REFORM participant interview
consent form
XXXX XXXX XXXX
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Appendix 17 REFORM qualitative podiatrist
information sheet
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Appendix 18 REFORM podiatrist interview
consent form
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Appendix 19 REFORM participant qualitative
topic guide
DOI: 10.3310/hta21240 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 24
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Cockayne et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
191
APPENDIX 19
NIHR Journals Library www.journalslibrary.nihr.ac.uk
192
DOI: 10.3310/hta21240 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 24
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Cockayne et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
193

Appendix 20 REFORM podiatrist qualitative
topic guide
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Appendix 21 REFORM footwear assessment
checklist
Outdoor Yes No
Appropriate heel height?
Appropriate heed width?
Appropriate fixation/fastening?
Appropriate heel counter?
Suitable sole?
Correct size?
Indoor
Appropriate heel height?
Appropriate heed width?
Appropriate fixation/fastening?
Appropriate heel counter?
Suitable sole?
Correct size?
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